2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)

Developed with the special contribution of the Heart Failure Association (HFA) of the ESC

Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chairperson) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK), Volkmar Falk (Germany), José Ramón González-Juanatey (Spain), Veli-Pekka Harjola (Finland), Ewa A. Jankowska (Poland), Mariell Jessup (USA), Cecilia Linde (Sweden), Petros Nihoyannopoulos (UK), John T. Parissis (Greece), Burkert Pieske (Germany), Jillian P. Riley (UK), Giuseppe M. C. Rosano (UK/Italy), Luis M. Ruilope (Spain), Frank Ruschitzka (Switzerland), Frans H. Rutten (The Netherlands), Peter van der Meer (The Netherlands)

Document Reviewers: Gerasimos Filippatos (CPG Review Coordinator) (Greece), John J. V. McMurray (CPG Review Coordinator) (UK), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Nawwar Al-Attar (UK), John James Atherton (Australia), Johann Bauersachs (Germany), A. John Camm (UK), Scipione Carerj (Italy), Claudio Ceconi (Italy), Antonio Coca (Spain), Perry Elliott (UK), Çetin Erol (Turkey), Petros Nihoyannopoulos (UK), John T. Parissis (Greece), Burkert Pieske (Germany), Jillian P. Riley (UK), Giuseppe M. C. Rosano (UK/Italy), Luis M. Ruilope (Spain), Frank Ruschitzka (Switzerland), Frans H. Rutten (The Netherlands), Peter van der Meer (The Netherlands)

ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix.

ESC entities having participated in the development of this document:

Associations: Acute Cardiovascular Care Association (ACCA), European Association for Cardiovascular Prevention and Rehabilitation (EACPR), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

Councils: Council on Cardiovascular Nursing and Allied Professions, Council for Cardiology Practice, Council on Cardiovascular Primary Care, Council on Hypertension.

Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases, Myocardial Function, Pulmonary Circulation and Right Ventricular Function, Valvular Heart Disease.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).

Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

The article has been co-published with permission in European Heart Journal and European Journal of Heart Failure. All rights reserved in respect of European Heart Journal.
Table of Contents

Abbreviations and acronyms..................................................2131
1. Preamble.................................................................2134
2. Introduction...........................................................2136
3. Definition, epidemiology and prognosis..........................2136
   3.1 Definition of heart failure........................................2136
   3.2 Terminology.....................................................2137
      3.2.1 Heart failure with preserved, mid-range and reduced
            ejection fraction............................................2137
      3.2.2 Terminology related to the time course of heart
            failure.........................................................2137
      3.2.3 Terminology related to the symptomatic severity
            of heart failure..............................................2138
   3.3 Epidemiology, aetiology and natural history of heart failure2138
   3.4 Prognosis........................................................2138
4. Diagnosis..............................................................2138
   4.1 Symptoms and signs..............................................2138
   4.2 Essential initial investigations: natriuretic peptides,
       electrocardiogram, and echocardiography...................2139
   4.3 Algorithm for the diagnosis of heart failure.................2140
      4.3.1 Algorithm for the diagnosis of heart failure in the
            non-acute setting............................................2140
      4.3.2 Diagnosis of heart failure with preserved ejection
            fraction.........................................................2140
5. Cardiac imaging and other diagnostic tests.....................2142
   5.1 Chest X-ray.....................................................2142
   5.2 Transthoracic echocardiography................................2142
      5.2.1 Assessment of left ventricular systolic function......2142
      5.2.2 Assessment of left ventricular diastolic function....2143
      5.2.3 Assessment of right ventricular function and
            pulmonary arterial pressure................................2143
   5.3 Transoesophageal echocardiography............................2143
   5.4 Stress echocardiography........................................2143
   5.5 Cardiac magnetic resonance....................................2143
   5.6 Single-photon emission computed tomography and
       radionuclide ventriculography................................2143
   5.7 Positron emission tomography...................................2143
   5.8 Coronary angiography............................................2144
5.9 Cardiac computed tomography....................................2144
5.10 Other diagnostic tests............................................2145
   5.10.1 Genetic testing in heart failure............................2145
6. Delaying or preventing the development of overt heart
   failure or preventing death before the onset of symptoms......2146
7. Pharmacological treatment of heart failure with reduced
   ejection fraction....................................................2147
   7.1 Objectives in the management of heart failure..............2147
   7.2 Treatments recommended in all symptomatic patients
       with heart failure with reduced ejection fraction.........2148
      7.2.1 Angiotensin-converting enzyme inhibitors.............2148
      7.2.2 Beta-blockers.............................................2148
      7.2.3 Mineralocorticoid/aldosterone receptor antagonists...2148
   7.3 Other treatments recommended in selected symptomatic
       patients with heart failure with reduced ejection fraction2148
      7.3.1 Diuretics................................................2148
      7.3.2 Angiotensin receptor neprilsin inhibitor..............2151
      7.3.3 \(I_f\)-channel inhibitor................................2152
      7.3.4 Angiotensin II type I receptor blockers...............2152
      7.3.5 Combination of hydralazine and isosorbide
            dinitrate.....................................................2152
   7.4 Other treatments with less certain benefits in
       symptomatic patients with heart failure with reduced ejection
       fraction........................................................2152
      7.4.1 Digoxin and other digitalis glycosides...............2152
      7.4.2 \(n\)-3 polyunsaturated fatty acids......................2153
   7.5 Treatments not recommended (unproven benefit) in
       symptomatic patients with heart failure with reduced ejection
       fraction........................................................2153
      7.5.1 3-Hydroxy-3-methylglutaryl coenzyme A reductase
            inhibitors (‘statins’........................................2153
      7.5.2 Oral anticoagulants and antiplatelet therapy..........2153
      7.5.3 Renin inhibitors..........................................2153
   7.6 Treatments not recommended (believed to cause harm)
       in symptomatic patients with heart failure with reduced
       ejection fraction................................................2154
      7.6.1 Calcium-channel blockers................................2154
8. Non-surgical device treatment of heart failure with reduced ejection fraction ........................................ 2154
8.1 Implantable cardioverter-defibrillator .......... 2154
8.1.1 Secondary prevention of sudden cardiac death .... 2154
8.1.2 Primary prevention of sudden cardiac death .... 2155
8.2 Cardiac resynchronization therapy .......... 2156
8.3 Other implantable electrical devices ......... 2157
9. Treatment of heart failure with preserved ejection fraction .... 2157
9.1 Effect of treatment on symptoms in heart failure with preserved ejection fraction .......... 2158
9.2 Effect of treatment on hospitalization for heart failure in heart failure with preserved ejection fraction .......... 2158
9.3 Effect of treatment on mortality in heart failure with preserved ejection fraction .......... 2158
9.4 Other considerations .................. 2158
10. Arrhythmias and conductance disturbances .......... 2158
10.1 Atrial fibrillation .................. 2159
10.1.1 Prevention of atrial fibrillation in patients with heart failure .......... 2159
10.1.2 Management of new-onset, rapid atrial fibrillation in patients with heart failure .......... 2159
10.1.3 Rate control .......... 2159
10.1.4 Rhythm control .......... 2160
10.1.5 Thromboembolism prophylaxis .......... 2161
10.2 Ventricular arrhythmias .......... 2161
10.3 Symptomatic bradycardia, pauses and atrio-ventricular block .......... 2162
11. Co-morbidities ........................................ 2163
11.1 Heart failure and co-morbidities .......... 2163
11.2 Angina and coronary artery disease .......... 2163
11.2.1 Pharmacological management .......... 2163
11.2.2 Myocardial revascularization .......... 2163
11.3 Cachexia and sarcopenia (for frailty, please refer to Section 14) .......... 2164
11.4 Cancer .......... 2164
11.5 Central nervous system (including depression, stroke and autonomic dysfunction) .......... 2165
11.6 Diabetes .......... 2165
11.7 Erectile dysfunction .......... 2166
11.8 Gout and arthritis .......... 2166
11.9 Hypokalaemia and hyperkalaemia .......... 2166
11.10 Hyperlipidaemia .......... 2166
11.11 Hypertension .......... 2166
11.12 Iron deficiency and anaemia .......... 2167
11.13 Kidney dysfunction (including chronic kidney disease, acute kidney injury, cardio-renal syndrome, and prostatic obstruction) .......... 2168
11.14 Lung disease (including asthma and chronic obstructive pulmonary disease) .......... 2169
11.15 Obesity .......... 2169
11.16 Sleep disturbance and sleep-disordered breathing .......... 2169
11.17 Valvular heart disease .......... 2170
11.17.1 Aortic stenosis .......... 2170
11.17.2 Aortic regurgitation .......... 2170
11.17.3 Mitral regurgitation .......... 2170
11.17.4 Tricuspid regurgitation .......... 2170
12. Acute heart failure .................................... 2171
12.1 Definition and classification .......... 2171
12.2 Diagnosis and initial prognostic evaluation .......... 2172
12.3 Management .................................... 2176
12.3.1 Identification of precipitants/causes leading to decompensation that needs urgent management .......... 2176
12.3.2 Criteria for hospitalization in ward vs intensive care/coronary care unit .......... 2177
12.3.3 Management of the early phase .......... 2177
12.3.4 Management of patients with cardiogenic shock .......... 2182
12.4 Management of evidence-based oral therapies .......... 2182
12.5 Monitoring of clinical status of patients hospitalized due to acute heart failure .......... 2183
12.6 Criteria for discharge from hospital and follow-up in high-risk period .......... 2183
12.7 Goals of treatment during the different stages of management of acute heart failure .......... 2183
13. Mechanical circulatory support and heart transplantation .......... 2184
13.1 Mechanical circulatory support .......... 2184
13.1.1 Mechanical circulatory support in acute heart failure .......... 2184
13.1.2 Mechanical circulatory support in end-stage chronic heart failure .......... 2184
13.2 Heart transplantation .......... 2186
14. Multidisciplinary team management .......... 2187
14.1 Organization of care .......... 2187
14.2 Discharge planning .......... 2189
14.3 Lifestyle advice .......... 2189
14.4 Exercise training .......... 2189
14.5 Follow-up and monitoring .......... 2189
14.6 The older adult, frailty and cognitive impairment .......... 2190
14.7 Palliative and end-of-life care .......... 2190
15. Gaps in evidence .......... 2191
16. To do and not to messages from the Guidelines .......... 2192
17. Web Addenda .......... 2193
18. Appendix .......... 2194
19. References .......... 2194

Abbreviations and acronyms

ACC/AHA American College of Cardiology/American Heart Association
ACCF/AHA American College of Cardiology Foundation/American Heart Association
ACE angiotensin-converting enzyme
ACEI angiotensin-converting enzyme inhibitor
ACS acute coronary syndrome
AF atrial fibrillation
AHF acute heart failure
AHI apnoea/hypopnoea index
AIDS acquired immunodeficiency syndrome
AKI acute kidney injury
Aldo-DHF aldosterone receptor blockade in diastolic heart failure
AL amyloid light chain
ALT alanine aminotransferase
AMI acute myocardial infarction
AMICA Atrial fibrillation Management In Congestive heart failure with Ablation
ANP A-type natriuretic peptide
ANS autonomic nervous system
ARB angiotensin receptor blocker
ARNI angiotensin receptor neprilysin inhibitor
ARVC arrhythmogenic right ventricular cardiomyopathy
AST aspartate aminotransferase
ASV assisted servo-ventilation
ATLAS Assessment of Treatment with Lisinopril And Survival
AV atrio-ventricular
AVP arginine vasopressin
b.i.d. bis in die (twice daily)
BioPACE Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization
BiPAP bilevel positive airway pressure
BiVAD biventricular assist device
BLOCK-HF Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrio-ventricular Block
BMI body mass index
BNP B-type natriuretic peptide
BP blood pressure
bpm beats per minute
BSA body surface area
BTB bridge to bridge
BTD bridge to decision
BTR bridge to recovery
BTT bridge to transplantation
BUN blood urea nitrogen
CABANA Catheter ABlation versus ANtiarrhythmic drug therapy for Atrial fibrillation
CABG coronary artery bypass grafting
CAD coronary artery disease
CARE-HF CArdiac REsynchronization in Heart Failure
CASTLE-AF Catheter Ablation versus Standard conventional Treatment in patients with Left ventricular dysfunction and Atrial Fibrillation
CCB calcium-channel blocker
CCM cardiac contractility modulation
CCS Canadian Cardiovascular Society
CCU coronary care unit
CHA2DS2-VASc Congestive heart failure or left ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
CHARM-Alternative Candesartan in heart failure assessment of reduction in mortality and morbidity
CHARM-Added Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity
CHARM-Preserved Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity
CI cardiac index
CI-AKI contrast-induced acute kidney injury
CIBIS II Cardiac Insufficiency Bisoprolol Study II
CK creatine kinase
CKD chronic kidney disease
CK-MB creatine kinase MB
CMP cardiomyopathy
CMR cardiac magnetic resonance
COMPANION Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure
CONFIRM-HF Ferric CarboxymaltOse evaluation on performance in patients with IRon deficiency in coMbination with chronic Heart Failure
CONSENSUS Cooperative North Scandinavian Enalapril Survival Study
COPD chronic obstructive pulmonary disease
COPERNICUS Carvedilol Prospective Randomized Cumulative Survival
COX-2 inhibitor cyclooxygenase-2 inhibitor
CPAP continuous positive airway pressure
CPG Committee for Practice Guidelines
CRT cardiac resynchronization therapy
cRT-D defibrillator with cardiac resynchronization therapy
cRT-P pacemaker with cardiac resynchronization therapy
CSA central sleep apnoea
CSR Cheyne-Stokes respiration
CT computed tomography
CYP3A4 cytochrome P450 3A4
DCM dilated cardiomyopathy
DES desmin
dHA docosahexaenoic acid
DIG-PEF ancillary Digitalis Investigation Group trial
dNA deoxynucleobonic acid
DOSE Diuretic Optimization Strategies Evaluation
DPD 3,3-diphosphono-1,2-propanodicarboxylic acid
DPP4i dipeptidyl peptidase-4 inhibitor
dT destination therapy
de′ early diastolic tissue velocity
ECG electrocardiogram
ECHO-CRT Echocardiography Guided Cardiac Resynchronization Therapy
ECLS extracorporeal life support
ECMO extracorporeal membrane oxygenation
ED emergency department
eF ejection fraction
eGFR estimated glomerular filtration rate
EHRA European Heart Rhythm Association
EMA European Medicines Agency
EMD endomyocardial biopsy
EMF endomyocardial fibrosis
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMPHASIS-HF</td>
<td>Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure</td>
</tr>
<tr>
<td>EPA</td>
<td>eicosapentaenoic acid</td>
</tr>
<tr>
<td>EPHEUS</td>
<td>Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study</td>
</tr>
<tr>
<td>ESC</td>
<td>European Society of Cardiology</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EULAR</td>
<td>European League Against Rheumatism</td>
</tr>
<tr>
<td>Ex-DHF</td>
<td>Exercise training in Diastolic Heart Failure</td>
</tr>
<tr>
<td>FACIT-Pal</td>
<td>Functional Assessment of Chronic Illness Therapy - Palliative Care</td>
</tr>
<tr>
<td>FAIR-HF</td>
<td>Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure</td>
</tr>
<tr>
<td>FCM</td>
<td>ferric carboxymaltose</td>
</tr>
<tr>
<td>FiO₂</td>
<td>fraction of inspired oxygen</td>
</tr>
<tr>
<td>GGTP</td>
<td>gamma-glutamyl transpeptidase</td>
</tr>
<tr>
<td>GH</td>
<td>growth hormone</td>
</tr>
<tr>
<td>GLS</td>
<td>global longitudinal strain</td>
</tr>
<tr>
<td>GLP-1</td>
<td>glucagon-like peptide 1</td>
</tr>
<tr>
<td>HAS-BLED</td>
<td>Hypertension, Abnormal renal/liver function (1 point each), Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (&gt; 65 years), Drugs/alcohol concomitantly (1 point each)</td>
</tr>
<tr>
<td>HbA1c</td>
<td>glycated haemoglobin</td>
</tr>
<tr>
<td>HCM</td>
<td>hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>HES</td>
<td>hypertensive ischemic stroke</td>
</tr>
<tr>
<td>HF</td>
<td>heart failure</td>
</tr>
<tr>
<td>HFA</td>
<td>Heart Failure Association</td>
</tr>
<tr>
<td>HFrEF</td>
<td>heart failure with mid-range ejection fraction</td>
</tr>
<tr>
<td>HFrEF</td>
<td>heart failure with preserved ejection fraction</td>
</tr>
<tr>
<td>H-IWARN</td>
<td>h-index of research articles</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>human immunodeficiency virus/acquired immune deficiency syndrome</td>
</tr>
<tr>
<td>HR</td>
<td>heart rate</td>
</tr>
<tr>
<td>Hs troponin</td>
<td>high sensitivity troponin</td>
</tr>
<tr>
<td>IABP</td>
<td>intra-aortic balloon pump</td>
</tr>
<tr>
<td>IABP-SHOCK</td>
<td>IntraAortic Balloon Pump in Cardiogenic Shock</td>
</tr>
<tr>
<td>IABP-SHOCK II</td>
<td>IntraAortic Balloon Pump in Cardiogenic Shock II</td>
</tr>
<tr>
<td>ICD</td>
<td>implantable cardioverter-defibrillator</td>
</tr>
<tr>
<td>ICU</td>
<td>intensive care unit</td>
</tr>
<tr>
<td>IHD</td>
<td>ischaemic heart disease</td>
</tr>
<tr>
<td>IL</td>
<td>interleukin</td>
</tr>
<tr>
<td>INH</td>
<td>Interdisciplinary Network for Heart Failure</td>
</tr>
<tr>
<td>INTERMACS</td>
<td>Interagency Registry for Mechanically Assisted Circulatory Support</td>
</tr>
<tr>
<td>IN-TIME</td>
<td>Implant-based multiparameter telemonitoring of patients with heart failure</td>
</tr>
<tr>
<td>IPD</td>
<td>individual patient data</td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td>Irbesartan in Heart Failure with Preserved Ejection Fraction Study</td>
</tr>
<tr>
<td>I.V.</td>
<td>intravenous</td>
</tr>
<tr>
<td>IVC</td>
<td>inferior vena cava</td>
</tr>
<tr>
<td>IVRT</td>
<td>isovolumetric relaxation time</td>
</tr>
<tr>
<td>KCCQ</td>
<td>Kansas City Cardiomyopathy Questionnaire</td>
</tr>
<tr>
<td>LA</td>
<td>left atrial/left atrium</td>
</tr>
<tr>
<td>LAE</td>
<td>left atrial enlargement</td>
</tr>
<tr>
<td>LAVI</td>
<td>left atrial volume index</td>
</tr>
<tr>
<td>LBBD</td>
<td>left bundle branch block</td>
</tr>
<tr>
<td>LGE</td>
<td>late gadolinium enhancement</td>
</tr>
<tr>
<td>LMNA</td>
<td>lamin A/C</td>
</tr>
<tr>
<td>LMWH</td>
<td>low-molecular-weight heparin</td>
</tr>
<tr>
<td>LV</td>
<td>left ventricular/left ventricle</td>
</tr>
<tr>
<td>LVAD</td>
<td>left ventricular assist device</td>
</tr>
<tr>
<td>LVEDP</td>
<td>left ventricular end diastolic pressure</td>
</tr>
<tr>
<td>LVEDV</td>
<td>left ventricular end diastolic volume</td>
</tr>
<tr>
<td>LVEF</td>
<td>left ventricular ejection fraction</td>
</tr>
<tr>
<td>LVESV</td>
<td>left ventricular end systolic volume</td>
</tr>
<tr>
<td>LVID</td>
<td>left ventricular internal dimension</td>
</tr>
<tr>
<td>LVMi</td>
<td>left ventricular mass index</td>
</tr>
<tr>
<td>LVSD</td>
<td>left ventricular systolic dysfunction</td>
</tr>
<tr>
<td>MADIT-CRT</td>
<td>Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy</td>
</tr>
<tr>
<td>MCS</td>
<td>mechanical circulatory support</td>
</tr>
<tr>
<td>MERIT-HF</td>
<td>Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure</td>
</tr>
<tr>
<td>MR</td>
<td>mineralocorticoid receptor/magnetic resonance</td>
</tr>
<tr>
<td>MRA</td>
<td>mineralocorticoid receptor antagonist</td>
</tr>
<tr>
<td>MR-proANP</td>
<td>mid-regional pro A-type natriuretic peptide</td>
</tr>
<tr>
<td>MV</td>
<td>mitral valve</td>
</tr>
<tr>
<td>MV A-Wave</td>
<td>mitral valve late diastolic flow</td>
</tr>
<tr>
<td>MV E-Wave</td>
<td>mitral valve early diastolic flow</td>
</tr>
<tr>
<td>MYBPC3</td>
<td>cardiac myosin binding protein C</td>
</tr>
<tr>
<td>MYH7</td>
<td>cardiac β-myosin heavy chain</td>
</tr>
<tr>
<td>n-3 PUFA</td>
<td>n-3 polyunsaturated fatty acid</td>
</tr>
<tr>
<td>NEP</td>
<td>neprolysin</td>
</tr>
<tr>
<td>NOAC</td>
<td>non-vitamin K antagonist oral anticoagulant</td>
</tr>
<tr>
<td>NP</td>
<td>natriuretic peptide</td>
</tr>
<tr>
<td>NPPV</td>
<td>non-invasive positive pressure ventilation</td>
</tr>
<tr>
<td>NSAID</td>
<td>non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>NSTE-ACS</td>
<td>non-ST elevation acute coronary syndrome</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>N-terminal pro-B type natriuretic peptide</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York Heart Association</td>
</tr>
<tr>
<td>o.d.</td>
<td>omne in die (once daily)</td>
</tr>
<tr>
<td>OMT</td>
<td>optimal medical therapy</td>
</tr>
<tr>
<td>OSA</td>
<td>obstructive sleep apnoea</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>partial pressure of carbon dioxide in arterial blood</td>
</tr>
<tr>
<td>PAH</td>
<td>pulmonary arterial hypertension</td>
</tr>
<tr>
<td>PaO₂</td>
<td>partial pressure of oxygen in arterial blood</td>
</tr>
<tr>
<td>PARADIGM-HF</td>
<td>Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial</td>
</tr>
<tr>
<td>PARAMOUNT</td>
<td>LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction</td>
</tr>
<tr>
<td>PCI</td>
<td>percutaneous coronary intervention</td>
</tr>
</tbody>
</table>
1. Preamble

Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk-benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk-benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined in Tables 1.1 and 1.2.

The experts of the writing and reviewing panels provided declarations of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (http://www.escardio.org/guidelines). Any changes in declarations of interest that arise during the writing period must be notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.

The ESC CPG supervises and coordinates the preparation of new Guidelines produced by task forces, expert groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task Force. The finalized document is approved by the CPG for publication in the European Heart Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The task of developing ESC Guidelines covers not only integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. To implement the guidelines, condensed pocket guidelines versions, summary slides, booklets with essential messages, summary cards for non-specialists, and an electronic version for digital applications (smartphones, etc.) are produced. These versions are abridged and thus, if needed, one should always refer to the full text version, which is freely available on the ESC website. The National Cardiac Societies of the ESC are encouraged to endorse, translate and implement all ESC Guidelines. Implementation programmes are needed because

<table>
<thead>
<tr>
<th>Table 1.1 Classes of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Classes of recommendations</strong></td>
</tr>
<tr>
<td>Class I</td>
</tr>
<tr>
<td>Class II</td>
</tr>
<tr>
<td>Class IIa</td>
</tr>
<tr>
<td>Class IIb</td>
</tr>
<tr>
<td>Class III</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 1.2 Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Level of evidence A</strong></td>
</tr>
<tr>
<td><strong>Level of evidence B</strong></td>
</tr>
<tr>
<td><strong>Level of evidence C</strong></td>
</tr>
</tbody>
</table>
it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations. Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them and implementing them into clinical practice.

Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

2. Introduction

The aim of all the ESC Guidelines is to help health professionals to make decisions in their everyday life based on the best available evidence. We will soon be celebrating the 30th anniversary of clinical trials that for the first time incontrovertibly demonstrated that the miserable outcome of patients with heart failure (HF) can be markedly improved. Since then, in the area of HF management we have witnessed and celebrated numerous highs, which have definitely outnumbered several lows, all of which have allowed us to unravel the pathophysiology of this clinical syndrome, but more importantly has led to better care of our patients. In the year 2016, no one would any longer dispute that, by applying all evidence-based discoveries, HF is now becoming a preventable and treatable disease.

The aim of this document is to provide practical, evidence-based guidelines for the diagnosis and treatment of HF. The principal changes from the 2012 guidelines relate to:

(i) a new term for patients with HF and a left ventricular ejection fraction (LVEF) that ranges from 40 to 49% — ‘HF with mid-range EF (HFrEF)’; we believe that identifying HFrEF as a separate group will stimulate research into the underlying characteristics, pathophysiology and treatment of this population;
(ii) clear recommendations on the diagnostic criteria for HF with reduced EF (HFrEF), HFrEF and HF with preserved EF (HFrEF);
(iii) a new algorithm for the diagnosis of HF in the non-acute setting based on the evaluation of HF probability;
(iv) recommendations aimed at prevention or delay of the development of overt HF or the prevention of death before the onset of symptoms;
(v) indications for the use of the new compound sacubitril/valsartan, the first in the class of angiotensin receptor neprilysin inhibitors (ARNIs);
(vi) modified indications for cardiac resynchronization therapy (CRT);
(vii) the concept of an early initiation of appropriate therapy going along with relevant investigations in acute HF that follows the ‘time to therapy’ approach already well established in acute coronary syndrome (ACS);
(viii) a new algorithm for a combined diagnosis and treatment approach of acute HF based on the presence/absence of congestion/hypoperfusion.

We followed the format of the previous ESC 2012 HF Guidelines. Therapeutic recommendations state the treatment effect supported by the class and level of recommendation in tabular format; in the case of chronic HF due to left ventricular systolic dysfunction (LVSD) the recommendations focus on mortality and morbidity outcomes. Detailed summaries of the key evidence supporting generally recommended treatments have been provided. For diagnostic recommendations a level of evidence C has been typically decided upon, because for the majority of diagnostic tests there are no data from randomized controlled trials (RCTs) showing that they will lead to reductions in morbidity and/or mortality. Practical guidance is provided for the use of the important disease-modifying drugs and diuretics. When possible, other relevant guidelines, consensus statements and position papers have been cited to avoid unduly lengthy text. All tables should be read in conjunction with their accompanying text and not read in isolation.

This document is the result of extensive interactions between the Task Force, the review team and the ESC Committee for Practice Guidelines. It represents a consensus of opinion of all of the experts involved in its development. Concurrently to the development of the 2016 ESC Guidelines on HF, the group writing the “2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure” independently developed its recommendations on new pharmacotherapy for Heart Failure. Both working groups/Task Force independently surveyed the evidence, arrived at similar conclusions, and constructed similar, but not identical, recommendations. Given the concordance, the respective organizations simultaneously issued aligned recommendations on the use of these new treatments to minimize confusion and improve the care of patients with HF.

3. Definition, epidemiology and prognosis

3.1 Definition of heart failure

HF is a clinical syndrome characterized by typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress.

The current definition of HF restricts itself to stages at which clinical symptoms are apparent. Before clinical symptoms become apparent, patients can present with asymptomatic structural or functional cardiac abnormalities [systolic or diastolic left ventricular (LV) dysfunction], which are precursors of HF. Recognition of these precursors is important because they are related to poor outcomes, and starting treatment at the precursor stage may reduce mortality in patients with asymptomatic systolic LV dysfunction (for details see Section 6).

Demonstration of an underlying cardiac cause is central to the diagnosis of HF. This is usually a myocardial abnormality causing systolic and/or diastolic ventricular dysfunction. However, abnormalities of the valves, pericardium, endocardium, heart rhythm and...
conduction can also cause HF (and more than one abnormality is often present). Identification of the underlying cardiac problem is crucial for therapeutic reasons, as the precise pathology determines the specific treatment used (e.g., valve repair or replacement for valvular disease, specific pharmacological therapy for HF with reduced EF, reduction of heart rate in tachycardiomyopathy, etc).

### 3.2 Terminology

#### 3.2.1 Heart failure with preserved, mid-range and reduced ejection fraction

The main terminology used to describe HF is historical and is based on measurement of the LVEF. HF comprises a wide range of patients, from those with normal LVEF [typically considered as $\geq 50\%$; HF with preserved EF (HfPEf)] to those with reduced LVEF [typically considered as $<40\%$; HF with reduced EF (HFrEF)] (Table 3.1). Patients with an LVEF in the range of 40–49% represent a ‘grey area’, which we now define as HFmrEF (Table 3.1). Differentiation of patients with HF based on LVEF is important due to different underlying aetiologies, demographics, co-morbidities and response to therapies. Most clinical trials published after 1990 selected patients based on LVEF [usually measured using echocardiography, a radionuclide technique or cardiac magnetic resonance (CMR)], and it is only in patients with HFrEF that therapies have been shown to reduce both morbidity and mortality.

The diagnosis of HFrEF is more challenging than the diagnosis of HFrEF. Patients with HfPEf generally do not have a dilated LV, but instead often have an increase in LV wall thickness and/or increased left atrial (LA) size as a sign of increased filling pressures. Most have additional ‘evidence’ of impaired LV filling or suction capacity, also classified as diastolic dysfunction, which is generally accepted as the likely cause of HF in these patients (hence the term ‘diastolic HF’). However, most patients with HFrEF (previously referred to as ‘systolic HF’) also have diastolic dysfunction, and subtle abnormalities of systolic function have been shown in patients with HFrEF. Hence the preference for stating preserved or reduced LVEF over preserved or reduced ‘systolic function’.

In previous guidelines it was acknowledged that a grey area exists between HFrEF and HfPEf. These patients have an LVEF that ranges from 40 to 49%, hence the term HFrEF. Identifying HFrEF as a separate group will stimulate research into the underlying characteristics, pathophysiology and treatment of this group of patients. Patients with HFmrEF most probably have primarily mild systolic dysfunction, but with features of diastolic dysfunction (Table 3.1).

Patients without detectable LV myocardial disease may have other cardiovascular causes for HF (e.g., pulmonary hypertension, valvular heart disease, etc.). Patients with non-cardiovascular pathologies (e.g., anaemia, pulmonary, renal or hepatic disease) may have symptoms similar or identical to those of HF and each may complicate or exacerbate the HF syndrome.

#### 3.2.2 Terminology related to the time course of heart failure

In these guidelines, the term HF is used to describe the symptomatic syndrome, graded according to the New York Heart Association (NYHA) functional classification (see Section 3.2.3 and Web Table 3.2), although a patient can be rendered asymptomatic by treatment. In these guidelines, a patient who has never exhibited the typical symptoms and/or signs of HF and with a reduced LVEF is described as having asymptomatic LV systolic dysfunction. Patients who have had HF for some time are often said to have ‘chronic HF’.

A treated patient with symptoms and signs that have remained generally unchanged for at least 1 month is said to be ‘stable’. If chronic stable HF deteriorates, the patient may be described as ‘decompensated’ and this may happen suddenly or slowly, often leading to hospital admission, an event of considerable prognostic importance. New-onsen (‘de novo’) HF may also present acutely, for example, as a consequence of acute myocardial infarction (AMI), or in a subacute (gradual) fashion, for example, in patients with a dilated cardiomyopathy (DCM), who often have symptoms for weeks or months before the diagnosis becomes clear. Although symptoms and signs of HF may resolve, the underlying cardiac dysfunction may not, and patients remain at the risk of recurrent ‘decompensation’.

Occasionally, however, a patient may have HF due to a problem that resolves completely (e.g. acute viral myocarditis, takotsubo cardiomyopathy or tachycardiomyopathy). Other patients, particularly those with ‘idiopathic’ DCM, may also show substantial or even complete recovery of LV systolic function with modern disease-modifying therapy (including angiotensin-converting enzyme inhibitor (ACEI), beta-blocker, mineralocorticoid receptor antagonist

---

### Table 3.1 Definition of heart failure with preserved (HfPEf), mid-range (HFrEF) and reduced ejection fraction (HFrEF)

<table>
<thead>
<tr>
<th>Type of HF</th>
<th>HfPEf</th>
<th>HFrEF</th>
<th>HFrEF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CRITERIA</strong></td>
<td>Symptoms ± Signs*</td>
<td>Symptoms ± Signs*</td>
<td>Symptoms ± Signs*</td>
</tr>
<tr>
<td>1</td>
<td>LV EF &lt; 40%</td>
<td>LVEF 40–49%</td>
<td>LVEF ≥ 50%</td>
</tr>
<tr>
<td>2</td>
<td>1. Elevated levels of natriuretic peptides*; 2. At least one additional criterion: a. relevant structural heart disease (LVH and/or LAE); b. diastolic dysfunction (for details see Section 4.3.2).</td>
<td>1. Elevated levels of natriuretic peptides*; 2. At least one additional criterion: a. relevant structural heart disease (LVH and/or LAE); b. diastolic dysfunction (for details see Section 4.3.2).</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*BNP = B-type natriuretic peptide; HF = heart failure; HFmrEF = heart failure with mid-range ejection fraction; HFrEF = heart failure with preserved ejection fraction; HfPEf = heart failure with reduced ejection fraction; LAE = left atrial enlargement; LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; NT-proBNP = N-terminal pro-B-type natriuretic peptide.  
*Signs may not be present in the early stages of HF (especially in HfPEf) and in patients treated with diuretics.  
*BNP > 35 pg/mL and/or NT-proBNP > 125 pg/mL.
(MRA), ivabradine and/or CRT]. ‘Congestive HF’ is a term that is sometimes used, and may describe acute or chronic HF with evidence of volume overload. Many or all of these terms may be accurately applied to the same patient at different times, depending upon their stage of illness.

3.2.3 Terminology related to the symptomatic severity of heart failure
The NYHA functional classification (Web Table 3.2) has been used to describe the severity of symptoms and exercise intolerance. However, symptom severity correlates poorly with many measures of LV function; although there is a clear relationship between the severity of symptoms and survival, patients with mild symptoms may still have an increased risk of hospitalization and death.8–10

Sometimes the term ‘advanced HF’ is used to characterize patients with severe symptoms, recurrent decompensation and severe cardiac dysfunction.11 The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) classification describes stages of HF development based on structural changes and symptoms (Web Table 3.3).12 The Killip classification may be used to describe the severity of the patient’s condition in the acute setting after myocardial infarction (see Section 12).13

3.3 Epidemiology, aetiology and natural history of heart failure
The prevalence of HF depends on the definition applied, but is approximately 1–2% of the adult population in developed countries, rising to ≥10% among people >70 years of age.14–17 Among people >65 years of age presenting to primary care with breathlessness on exertion, one in six will have unrecognized HF (mainly HfPfEF).18,19 The lifetime risk of HF at age 55 years is 33% for men and 28% for women.16 The proportion of patients with HfPfEF ranges from 22 to 73%, depending on the definition applied, the clinical setting (primary care, hospital clinic, hospital admission), age and sex of the studied population, previous myocardial infarction and the year of publication.17,18,20–30

Data on temporal trends based on hospitalized patients suggest that the incidence of HF may be decreasing, more for HFrEF than for HfPfEF.31,32 HfPfEF and HFrEF seem to have different epidemiological and aetiological profiles. Compared with HFrEF, patients with HfPfEF are older, more often women and more commonly have a history of hypertension and atrial fibrillation (AF), while a history of myocardial infarction is less common.32,33 The characteristics of patients with HfPmrEF are between those with HFrEF and HfPfEF,34 but further studies are needed to better characterize this population.

The aetiology of HF is diverse within and among world regions. There is no agreed single classification system for the causes of HF, with much overlap between potential categories (Table 3.4). Many patients will have several different pathologies—cardiovascular and non-cardiovascular—that conspire to cause HF. Identification of these diverse pathologies should be part of the diagnostic workup, as they may offer specific therapeutic opportunities.

Many patients with HF and ischaemic heart disease (IHD) have a history of myocardial infarction or revascularization. However, a normal coronary angiogram does not exclude myocardial scar (e.g. by CMR imaging) or impaired coronary microcirculation as alternative evidence for IHD.

In clinical practice, a clear distinction between acquired and inherited cardiomyopathies remains challenging. In most patients with a definite clinical diagnosis of HF, there is no confirmatory role for routine genetic testing, but genetic counselling is recommended in patients with hypertrophic cardiomyopathy (HCM), ‘idiopathic’ DCM or arrhythmogenic right ventricular cardiomyopathy (ARVC) (see Section 5.10.1), since the outcomes of these tests may have clinical implications.

Over the last 30 years, improvements in treatments and their implementation have improved survival and reduced the hospitalization rate in patients with HFrEF, although the outcome often remains unsatisfactory. The most recent European data (ESC-HF pilot study) demonstrate that 12-month all-cause mortality rates for hospitalized and stable/ambulatory HF patients were 17% and 7%, respectively, and the 12-month hospitalization rates were 44% and 32%, respectively.35 In patients with HF (both hospitalized and ambulatory), most deaths are due to cardiovascular causes, mainly sudden death and worsening HF. All-cause mortality is generally higher in HFrEF than HfPfEF.35,36 Hospitalizations are often due to non-cardiovascular causes, particularly in patients with HfPfEF. Hospitalization for cardiovascular causes did not change from 2000 to 2010, whereas those with non-cardiovascular causes increased.31

3.4 Prognosis
Estimation of prognosis for morbidity, disability and death helps patients, their families and clinicians decide on the appropriate type and timing of therapies (in particular, decisions about a rapid transition to advanced therapies) and assists with planning of health and social services and resources.

Numerous prognostic markers of death and/or HF hospitalization have been identified in patients with HF (Web Table 3.5). However, their clinical applicability is limited and precise risk stratification in HF remains challenging.

In recent decades, several multivariable prognostic risk scores have been developed for different populations of patients with HF,36–41 and some are available as interactive online applications. Multivariable risk scores may help predict death in patients with HF, but remain less useful for the prediction of subsequent HF hospitalizations.37,38 A systematic review examining 64 prognostic models37 along with a meta-analysis and meta-regression study of 117 prognostic models38 revealed only a moderate accuracy of models predicting mortality, whereas models designed to predict the combined endpoint of death or hospitalization, or only hospitalization, had an even poorer discriminative ability.

4. Diagnosis
4.1 Symptoms and signs
Symptoms are often non-specific and do not, therefore, help discriminate between HF and other problems (Table 4.1).42–46 Symptoms and signs of HF due to fluid retention may resolve quickly with diuretic therapy. Signs, such as elevated jugular venous pressure and displacement of the apical impulse, may be more specific, but are harder to detect and have poor reproducibility.46,47 Symptoms and signs may be particularly difficult to identify and interpret in obese individuals, in the elderly and in patients with chronic lung disease.48–50 Younger patients with HF often have a different aetiology, clinical presentation and outcome compared with older patients.51,52
A detailed history should always be obtained. HF is unusual in an individual with no relevant medical history (e.g. a potential cause of cardiac damage), whereas certain features, particularly previous myocardial infarction, greatly increase the likelihood of HF in a patient with appropriate symptoms and signs.

At each visit, symptoms and signs of HF need to be assessed, with particular attention to evidence of congestion. Symptoms and signs are important in monitoring a patient’s response to treatment and stability over time. Persistence of symptoms despite treatment usually indicates the need for additional therapy, and worsening of symptoms is a serious development (placing the patient at risk of urgent hospital admission and death) and merits prompt medical attention.

### Table 3.4 Aetiologies of heart failure

<table>
<thead>
<tr>
<th>DISEASED MYOCARDIUM</th>
<th>Aetiologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischaemic heart disease</td>
<td>Myocardial scar</td>
</tr>
<tr>
<td></td>
<td>Myocardial stunning/hibernation</td>
</tr>
<tr>
<td></td>
<td>Epicardial coronary artery disease</td>
</tr>
<tr>
<td></td>
<td>Abnormal coronary microcirculation</td>
</tr>
<tr>
<td></td>
<td>Endothelial dysfunction</td>
</tr>
<tr>
<td>Toxic damage</td>
<td>Recreational substance abuse</td>
</tr>
<tr>
<td></td>
<td>Heavy metals</td>
</tr>
<tr>
<td></td>
<td>Medications (e.g. anthracyclines), immunomodulating drugs (e.g. interferons monoclonal antibodies such as trastuzumab, cetuximab), antidepressant drugs, antiarrhythmics, non-steroidal anti-inflammatory drugs, anaesthetics.</td>
</tr>
<tr>
<td></td>
<td>Radiation</td>
</tr>
<tr>
<td>Immune-mediated and inflammatory damage</td>
<td>Related to infection Bacteria, spirochaetes, fungi, protozoa, parasites (Chagas disease), rickettsiae, viruses (HIV/AIDS).</td>
</tr>
<tr>
<td></td>
<td>Not related to infection Lymphocytic/giant cell myocarditis, autoimmune diseases (e.g. Graves’ disease, rheumatoid arthritis, connective tissue disorders, mainly systemic lupus erythematosus), hypersensitivity and eosinophilic myocarditis (Churg–Strauss).</td>
</tr>
<tr>
<td>Infiltration</td>
<td>Related to malignancy Direct infiltrations and metastases.</td>
</tr>
<tr>
<td></td>
<td>Not related to malignancy Amyloidosis, sarcoidosis, haemochromatosis (iron), glycogen storage diseases (e.g. Pompe disease), lysosomal storage diseases (e.g. Fabry disease).</td>
</tr>
<tr>
<td>Metabolic derangements</td>
<td>Hormonal Thyroid disease, parathyroid disease, acromegaly, GH deficiency, hypercortisolism, Cushing’s disease, Addison disease, diabetes, metabolic syndrome, phaeochromocytoma, pathologies related to pregnancy and peripartum.</td>
</tr>
<tr>
<td></td>
<td>Nutritional Deficiencies in thiamine, L-carnitine, selenium, iron, phosphates, calcium, complex malnutrition (e.g. malignancy, AIDS, anorexia nervosa), obesity.</td>
</tr>
<tr>
<td>Genetic abnormalities</td>
<td>Diverse forms HCM, DCM, LV non-compaction, ARVC, restrictive cardiomyopathy (for details see respective expert documents), muscular dystrophies and laminopathies.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABNORMAL LOADING CONDITIONS</th>
<th>Aetiologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>Acquired Mitral, aortic, tricuspid and pulmonary valve diseases.</td>
</tr>
<tr>
<td></td>
<td>Congenital Atrial and ventricular septum defects and others (for details see a respective expert document).</td>
</tr>
<tr>
<td>Pericardial and endomyocardial pathologies</td>
<td>Pericardial Constrictive pericarditis</td>
</tr>
<tr>
<td></td>
<td>Pericardial effusion</td>
</tr>
<tr>
<td>Endomyocardial</td>
<td>HES, EMF, endocardial fibroelastosis.</td>
</tr>
<tr>
<td>High output states</td>
<td>Severe anaemia, sepsis, thyrotoxicosis, Paget’s disease, arteriovenous fistula, pregnancy.</td>
</tr>
<tr>
<td>Volume overload</td>
<td>Renal failure, iatrogenic fluid overload.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ARRHYTHMIAS</th>
<th>Aetiologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tachyarrhythmias</td>
<td>Atrial, ventricular arrhythmias.</td>
</tr>
<tr>
<td>Bradyarrhythmias</td>
<td>Sinus node dysfunction, conduction disorders.</td>
</tr>
</tbody>
</table>

ARVC = arrhythmogenic right ventricular cardiomyopathy; DCM = dilated cardiomyopathy; EMF = endomyocardial fibrosis; GH = growth hormone; HCM = hypertrophic cardiomyopathy; HES = hypereosinophilic syndrome; HIV/AIDS = human immunodeficiency virus/acquired immune deficiency syndrome; LV = left ventricular.

### 4.2 Essential initial investigations: natriuretic peptides, electrocardiogram and echocardiography

The plasma concentration of natriuretic peptides (NPs) can be used as an initial diagnostic test, especially in the non-acute setting when echocardiography is not immediately available. Elevated NPs help establish an initial working diagnosis, identifying those who require further cardiac investigation; patients with values below the cut-point for the exclusion of important cardiac dysfunction do not require echocardiography (see also Section 4.3 and Section 12). Patients with normal plasma NP concentrations are unlikely to have HF. The upper limit of normal in the non-acute setting for
HFpEF; on average, values are lower for HFpEF than for HFrEF.54,55


tation underlying HF (for details, see below)22 (see also Section 12.2 and Table 12.3).

An abnormal electrocardiogram (ECG) increases the likelihood of the diagnosis of HF, but has low specificity.18,46,63,64 Some abnormalities on the ECG provide information on aetiology (e.g. myocardial infarction), and findings on the ECG might provide indications for therapy (e.g. anticoagulation for AF, pacing for bradycardia, CRT if broadened QRS complex) (see Sections 8 and 10). HF is unlikely in patients presenting with a completely normal ECG (sensitivity 89%).43 Therefore, the routine use of an ECG is mainly recommended to rule out HF.

### 4.3 Algorithm for the diagnosis of heart failure

#### 4.3.1 Algorithm for the diagnosis of heart failure in the non-acute setting

An algorithm for the diagnosis of HF in the non-acute setting is shown in Figure 4.1. The diagnosis of HF in the acute setting is discussed in Section 12.

For patients presenting with symptoms or signs for the first time, non-urgently in primary care or in a hospital outpatient clinic (Table 4.1), the probability of HF should first be evaluated based on the patient’s prior clinical history [e.g. coronary artery disease (CAD), arterial hypertension, diuretic use], presenting symptoms (e.g. orthopnoea), physical examination (e.g. bilateral oedema, increased jugular venous pressure, displaced apical beat) and resting ECG. If all elements are normal, HF is highly unlikely and other diagnoses need to be considered. If at least one element is abnormal, plasma NPs should be measured, if available, to identify those who need echocardiography (an echocardiogram is indicated if the NP level is above the exclusion threshold or if circulating NP levels cannot be assessed).53–60,65–78

#### 4.3.2 Diagnosis of heart failure with preserved ejection fraction

The diagnosis of HFpEF remains challenging. LVEF is normal and signs and symptoms for HF (Table 4.1) are often non-specific and do not discriminate well between HF and other clinical conditions. This section summarizes practical recommendations necessary for proper diagnosis of this clinical entity in clinical practice.

The diagnosis of chronic HFpEF, especially in the typical elderly patient with co-morbidities and no obvious signs of central fluid overload, is cumbersome and a validated gold standard is missing. To improve the specificity of diagnosing HFpEF, the clinical diagnosis needs to be supported by objective measures of cardiac dysfunction at rest or during exercise. The diagnosis of HFpEF requires the following conditions to be fulfilled (see Table 3.1):

- **The presence of symptoms and/or signs of HF (see Table 4.1)**
- **A ‘preserved’ EF (defined as LVEF ≥50% or 40–49% for HFrEF)**
- **Elevated levels of NPs (BNP >35 pg/mL and/or NT-proBNP >125 pg/mL)**
- **Objective evidence of other cardiac functional and structural alterations underlying HF** (for details, see below)

---

**Table 4.1 Symptoms and signs typical of heart failure**

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Typical</strong></td>
<td><strong>More specific</strong></td>
</tr>
<tr>
<td>Breathlessness</td>
<td>Elevated jugular venous pressure</td>
</tr>
<tr>
<td>Orthopnoea</td>
<td>Hepatoglandular reflux</td>
</tr>
<tr>
<td>Paroxysmal nocturnal dyspnoea</td>
<td>Third heart sound (gallop rhythm)</td>
</tr>
<tr>
<td>Reduced exercise tolerance</td>
<td>Laterally displaced apical impulse</td>
</tr>
<tr>
<td>Fatigue, tiredness, increased time to recover after exercise</td>
<td></td>
</tr>
<tr>
<td>Ankle swelling</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Less typical</th>
<th>Less specific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nocturnal cough</td>
<td>Weight gain (&gt;2 kg/week)</td>
</tr>
<tr>
<td>Wheezing</td>
<td>Weight loss (in advanced HF)</td>
</tr>
<tr>
<td>Blasted feeling</td>
<td>Tissue wasting (cachexia)</td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>Cardiac murmur</td>
</tr>
<tr>
<td>Confusion (especially in the elderly)</td>
<td>Peripheral oedema (ankle, sacral, scrotal)</td>
</tr>
<tr>
<td>Depression</td>
<td>Pulmonary crepitations</td>
</tr>
<tr>
<td>Palpitations</td>
<td>Reduced air entry and dullness to percussion at lung bases (pleural effusion)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>Tachycardia</td>
</tr>
<tr>
<td>Syncope</td>
<td>Irregular pulse</td>
</tr>
<tr>
<td>Bendopnea</td>
<td>Tachypnoea</td>
</tr>
</tbody>
</table>

**HF** = heart failure.

B-type natriuretic peptide (BNP) is 35 pg/mL and for N-terminal pro-BNP (NT-proBNP) it is 125 pg/mL in the acute setting, higher values should be used [BNP < 100 pg/mL, NT-proBNP < 300 pg/mL and mid-regional pro-A-type natriuretic peptide (MR-proANP) < 120 pmol/L]. Diagnostic values apply similarly to HFrEF and HFpEF; on average, values are lower for HFpEF than for HFrEF.54,55 At the mentioned exclusionary cut-points, the negative predictive values are very similar and high (0.94–0.98) in both the non-acute and acute setting, but the positive predictive values are lower both in the non-acute setting (0.44–0.57) and in the acute setting (0.66–0.67).54,56–61 Therefore, the use of NPs is recommended for ruling-out HF, but not to establish the diagnosis.

There are numerous cardiovascular and non-cardiovascular causes of elevated NPs that may weaken their diagnostic utility in HF. Among them, AF, age and renal failure are the most important factors impeding the interpretation of NP measurements.55 On the other hand, NP levels may be disproportionately low in obese patients22 (see also Section 12.2 and Table 12.3).

An abnormal electrocardiogram (ECG) increases the likelihood of the diagnosis of HF, but has low specificity.18,46,63,64 Some abnormalities on the ECG provide information on aetiology (e.g. myocardial infarction), and findings on the ECG might provide indications for therapy (e.g. anticoagulation for AF, pacing for bradycardia, CRT if broadened QRS complex) (see Sections 8 and 10). HF is unlikely in patients presenting with a completely normal ECG (sensitivity 89%).43 Therefore, the routine use of an ECG is mainly recommended to rule out HF.

Echocardiography is the most useful, widely available test in patients with suspected HF to establish the diagnosis. It provides immediate information on chamber volumes, ventricular systolic and diastolic function, wall thickness, valve function and pulmonary hypertension.65–74 This information is crucial in establishing the diagnosis and in determining appropriate treatment (see Sections 5.2–5.4 for details on echocardiography).

The information provided by careful clinical evaluation and the above mentioned tests will permit an initial working diagnosis and treatment plan in most patients. Other tests are generally required only if the diagnosis remains uncertain (e.g. if echocardiographic images are suboptimal or an unusual cause of HF is suspected) (for details see Sections 5.5–5.10).
Figure 4.1 Diagnostic algorithm for a diagnosis of heart failure of non-acute onset

BNP = B-type natriuretic peptide; CAD = coronary artery disease; HF = heart failure; MI = myocardial infarction; NT-proBNP = N-terminal pro-B type natriuretic peptide.

Patient reporting symptoms typical of HF (see Table 4.1).

Normal ventricular and atrial volumes and function.

Consider other causes of elevated natriuretic peptides (Table 12.3).
In case of uncertainty, a stress test or invasively measured elevated LV filling pressure may be needed to confirm the diagnosis (for details, see below).

The initial assessment consists of a clinical diagnosis compatible with the algorithm presented above and the assessment of LVEF by echocardiography. The cut-off of 50% for a diagnosis of HFrEF is arbitrary; patients with an LVEF between 40 and 49% are often classified as HfP EF in clinical trials.79 However, in the present guidelines, we define HfP EF as an LVEF ≥50% and consider patients with an LVEF between 40 and 49% as a grey area, which could be indicated as HfM EF. Clinical signs and symptoms are similar for patients with HFrEF, HfM EF and HfP EF. Typical demographics and co-morbidities are provided in Web Table 4.2. The resting ECG may reveal abnormalities such as AF, LV hypertrophy and repolarisation abnormalities. A normal ECG and/or plasma concentrations of BNP <35 pg/mL and/or NT-proBNP <125 pg/mL make a diagnosis of HfP EF, HfM EF or HFrEF unlikely.

The next step comprises an advanced workup in case of initial evidence of HfP EF/HfM EF and consists of objective demonstration of structural and/or functional alterations of the heart as the underlying cause for the clinical presentation. Key structural alterations are a left atrial volume index (LAVI) >34 mL/m² or a left ventricular mass index (LVMI) ≥115 g/m² for males and ≥95 g/m² for females.65,72 Key functional alterations are an E/e′ >13 and a mean e′ septal and lateral wall <9 cm/s.65,67,70,72,80–84 Other (indirect) echocardiographically derived measurements are longitudinal strain or tricuspid regurgitation velocity (TRV).72,81 An overview of normal and abnormal values for echocardiographic parameters related to diastolic function is presented in Web Table 4.3. Not all of the recommended values are identical to those published in previous guidelines, because of the inclusion of new data published in recent reports, in particular by Cabarello et al.70

A diastolic stress test can be performed with echocardiography, typically using a semi-supine bicycle ergometer exercise protocol with assessment of LV (E/e′) and pulmonary artery pressures (TRV), systolic dysfunction (longitudinal strain), stroke volume and cardiac output changes with exercise.85,86 Different dynamic exercise protocols are available, with semi-supine bicycle ergometry and echocardiography at rest and submaximal exercise being used most often.85 Exercise-induced increases in E/e′ beyond diastolic cut-offs (i.e. >13), but also other indirect measures of systolic and diastolic function, such as longitudinal strain or TRV, are used. Alternatively, invasive haemodynamics at rest with assessment of filling pressures [pulmonary capillary wedge pressure (PCWP) ≥15 mmHg or left ventricular end diastolic pressure (LVEDP) ≥16 mmHg] followed by exercise haemodynamics if below these thresholds, with assessment of changes in filling pressures, pulmonary artery systolic pressure, stroke volume and cardiac output, can be performed.87

The diagnosis of HfP EF in patients with AF is difficult. Since AF is associated with higher NP levels, the use of NT-proBNP or BNP for diagnosing HfP EF probably needs to be stratified by the presence of sinus rhythm (with lower cut-offs) vs. AF (higher cut-offs). LAVI is increased by AF, and functional parameters of diastolic dysfunction are less well established in AF, and other cut-off values probably apply. On the other hand, AF might be a sign of the presence of HfP EF, and patients with AF and HfP EF often have similar patient characteristics. In addition, patients with HfP EF and AF might have more advanced HF compared with patients with HfP EF and sinus rhythm.

Patients with HfP EF are a heterogeneous group with various underlying aetiologies and pathophysiological abnormalities. Based on specific suspected causes, additional tests can be performed (Web Table 4.4).71,88–94 However, they can only be recommended if the results might affect management.

5. Cardiac imaging and other diagnostic tests

Cardiac imaging plays a central role in the diagnosis of HF and in guiding treatment. Of several imaging modalities available, echocardiography is the method of choice in patients with suspected HF, for reasons of accuracy, availability (including portability), safety and cost.48,69,72 Echocardiography may be complemented by other modalities, chosen according to their ability to answer specific clinical questions and taking account of contraindications to and risks of specific tests.71,73

In general, imaging tests should only be performed when they have a meaningful clinical consequence. The reliability of the outcomes is highly dependent on the imaging modality, the operator and centre experience and imaging quality. Normal values may vary with age, sex and imaging modality.

5.1 Chest X-ray

A chest X-ray is of limited use in the diagnostic work-up of patients with suspected HF. It is probably most useful in identifying an alternative, pulmonary explanation for a patient’s symptoms and signs, i.e. pulmonary malignancy and interstitial pulmonary disease, although computed tomodography (CT) of the chest is currently the standard of care. For the diagnosis of asthma or chronic obstructive pulmonary disease (COPD), pulmonary function testing with spirometry is needed. The chest X-ray may, however, show pulmonary venous congestion or oedema in a patient with HF, and is more helpful in the acute setting than in the non-acute setting.49,64 It is important to note that significant LV dysfunction may be present without cardiomegaly on the chest X-ray.49,64

5.2 Transthoracic echocardiography

Echocardiography is a term used here to refer to all cardiac ultrasound imaging techniques, including two-dimensional/three-dimensional echocardiography, pulsed and continuous wave Doppler, colour flow Doppler, tissue Doppler imaging (TDI) contrast echocardiography and deformation imaging (strain and strain rate).

Transthoracic echocardiography (TTE) is the method of choice for assessment of myocardial systolic and diastolic function of both left and right ventricles.

5.2.1 Assessment of left ventricular systolic function

For measurement of LVEF, the modified biplane Simpson’s rule is recommended. LV end diastolic volume (LVEDV) and LV end systolic volume (LVESV) are obtained from apical four- and two-chamber views. This method relies on accurate tracing of endocardial borders. In case of poor image quality, contrast agents should be used to improve endocardial delineation.72,91 Measurement of regional wall motion abnormalities might be particularly relevant for patients suspected of CAD or myocarditis.

The Teichholz and Quinones methods of calculating LVEF from linear dimensions, as well as a measurement of fractional shortening, are not recommended, as they may result in inaccuracies,
particularly in patients with regional LV dysfunction and/or LV re-modelling. Three-dimensional echocardiography of adequate quality improves the quantification of LV volumes and LVEF and has the best accuracy compared with values obtained through CMR.\textsuperscript{95}

Doppler techniques allow the calculation of haemodynamic variables, such as stroke volume index and cardiac output, based on the velocity time integral at the LV outflow tract area.

In recent years, tissue Doppler parameters (S wave) and deformation imaging techniques (strain and strain rate) have been shown to be reproducible and feasible for clinical use, especially in detecting subtle abnormalities in systolic function in the preclinical stage; however, measurements may vary among vendors and software versions.\textsuperscript{94}

5.2.2 Assessment of left ventricular diastolic function
LV diastolic dysfunction is thought to be the underlying pathophysiological abnormality in patients with HFpEF and perhaps HFmrEF, and thus its assessment plays an important role in diagnosis. Although echocardiography is at present the only imaging technique that can allow for the diagnosis of diastolic dysfunction, no single echocardiography variable is sufficiently accurate to be used in isolation to make a diagnosis of LV diastolic dysfunction. Therefore, a comprehensive echocardiography examination incorporating all relevant two-dimensional and Doppler data is recommended (see Section 4.3.2).

5.2.3 Assessment of right ventricular function and pulmonary arterial pressure
An obligatory element of echocardiography examination is the assessment of right ventricle (RV) structure and function, including RV and right atrial (RA) dimensions, an estimation of RV systolic function and pulmonary arterial pressure. Among parameters reflecting RV systolic function, the following measures are of particular importance: tricuspid annular plane systolic excursion (TAPSE; abnormal TAPSE <17 mm indicates RV systolic dysfunction) and tissue Doppler-derived tricuspid lateral annular systolic velocity (s’) (s’ velocity <9.5 cm/s indicates RV systolic dysfunction).\textsuperscript{72,96} Systolic pulmonary artery pressure is derived from an optimal recording of maximal tricuspid regurgitant jet and the tricuspid systolic gradient, together with an estimate of RA pressure on the basis of inferior vena cava (IVC) size and its breathing-related collapse.\textsuperscript{97} RV size should be routinely assessed by conventional two-dimensional echocardiography using multiple acoustic windows, and the report should include both qualitative and quantitative parameters. In laboratories with experience in three-dimensional echocardiography, when knowledge of RV volumes may be clinically important, three-dimensional measurement of RV volumes is recommended.\textsuperscript{95} Three-dimensional speckle tracking echocardiography may be an additional quantitative method to assess RV function in specialised centres.\textsuperscript{98}

5.3 Transoesophageal echocardiography
Transoesophageal echocardiography (TOE) is not needed in the routine diagnostic assessment of HF; however, it may be valuable in some clinical scenarios of patients with valve disease, suspected aortic dissection, suspected endocarditis or congenital heart disease and for ruling out intracavitary thrombi in AF patients requiring cardioversion. When the severity of mitral or aortic valve disease does not match the patient’s symptoms using TTE alone, a TOE examination should be performed.

5.4 Stress echocardiography
Exercise or pharmacological stress echocardiography may be used for the assessment of inducible ischaemia and/or myocardium viability\textsuperscript{99} and in some clinical scenarios of patients with valve disease (e.g. dynamic mitral regurgitation, low-flow–low-gradient aortic stenosis).\textsuperscript{99,100} There are also suggestions that stress echocardiography may allow the detection of diastolic dysfunction related to exercise exposure in patients with exertional dyspnoea, preserved LVEF and inconclusive diastolic parameters at rest.\textsuperscript{85,86}

5.5 Cardiac magnetic resonance
CMR is acknowledged as the gold standard for the measurements of volumes, mass and EF of both the left and right ventricles. It is the best alternative cardiac imaging modality for patients with non-diagnostic echocardiographic studies (particularly for imaging of the right heart) and is the method of choice in patients with complex congenital heart diseases.\textsuperscript{91,101,102} CMR is the preferred imaging method to assess myocardial fibrosis using late gadolinium enhancement (LGE) along with T1 mapping and can be useful for establishing HF aetiology.\textsuperscript{91,103} For example, CMR with LGE allows differentiation between ischaemic and non-ischaemic origins of HF and myocardial fibrosis/scars can be visualized. In addition, CMR allows the characterization of myocardial tissue of myocarditis, amyloidosis, sarcoidosis, Chagas disease, Fabry disease non-compaction cardiomyopathy and haemochromatosis.\textsuperscript{91,101,103,104} CMR may also be used for the assessment of myocardial ischaemia and viability in patients with HF and CAD (considered suitable for coronary revascularization). However, limited evidence from RCTs has failed to show that viability assessed by CMR or other means identified patients who obtained clinical benefit from revascularization.\textsuperscript{105–107}

Clinical limitations of CMR include local expertise, lower availability and higher costs compared with echocardiography, uncertainty about safety in patients with metallic implants (including cardiac devices) and less reliable measurements in patients with tachyarrhythmias. Claustrophobia is an important limitation for CMR. Linear gadolinium-based contrast agents are contraindicated in individuals with a glomerular filtration rate (GFR) <30 mL/min/1.73m², because they may trigger nephrogenic systemic fibrosis (this may be less of a concern with newer cyclic gadolinium-based contrast agents).\textsuperscript{108}

5.6 Single-photon emission computed tomography and radionuclide ventriculography
Single-photon emission CT (SPECT) may be useful in assessing ischaemia and myocardial viability.\textsuperscript{109} Gated SPECT can also yield information on ventricular volumes and function, but exposes the patient to ionizing radiation. 3.3-diphosphono-1,2-propanodioxoacetic acid (DPD) scintigraphy may be useful for the detection of transthyretin cardiac amyloidosis.\textsuperscript{110}

5.7 Positron emission tomography
Positron emission tomography (PET) (alone or with CT) may be used to assess ischaemia and viability, but the flow tracers (N-13 ammonia or O-15 water) require an on-site cyclotron.\textsuperscript{92,111} Rubidium is an alternative tracer for ischaemia testing with PET, which can be produced locally at relatively low cost. Limited availability, radiation exposure and cost are the main limitations.
5.8 Coronary angiography

Indications for coronary angiography in patients with HF are in concordance with the recommendations of other relevant ESC guidelines. Coronary angiography is recommended in patients with HF who suffer from angina pectoris recalcitrant to medical therapy, provided the patient is otherwise suitable for coronary revascularization. Coronary angiography is also recommended in patients with a history of symptomatic ventricular arrhythmia or aborted cardiac arrest. Coronary angiography should be considered in patients with HF and intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests in order to establish the ischaemic aetiology and CAD severity.

5.9 Cardiac computed tomography

The main use of cardiac CT in patients with HF is as a non-invasive means to visualize the coronary anatomy in patients with HF with low intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to exclude the diagnosis of CAD, in the absence of relative contraindications. However, the test is only required when its results might affect a therapeutic decision.

The most important clinical indications for the applicability of certain imaging methods in patients with suspected or confirmed HF are shown in the recommendations table.

### Recommendations for cardiac imaging in patients with suspected or established heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTE is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish a diagnosis of either HFrEF, HFmrEF or HFpEF.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>TTE is recommended to assess LVEF in order to identify patients with HF who would be suitable for evidence-based pharmacological and device (ICD, CRT) treatment recommended for HFrEF.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>TTE is recommended for the assessment of valve disease, right ventricular function and pulmonary arterial pressure in patients with an already established diagnosis of either HFrEF, HFmrEF or HFpEF in order to identify those suitable for correction of valve disease.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>TTE is recommended for the assessment of myocardial structure and function in subjects to be exposed to treatment which potentially can damage myocardium (e.g. chemotherapy).</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Other techniques (including systolic tissue Doppler velocities and deformation indices, i.e. strain and strain rate), should be considered in a TTE protocol in subjects at risk of developing HF in order to identify myocardial dysfunction at the preclinical stage.</td>
<td>IIa</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>CMR is recommended for the assessment of myocardial structure and function (including right heart) in subjects with poor acoustic window and patients with complex congenital heart diseases (taking account of cautions/contra-indications to CMR).</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>CMR with LGE should be considered in patients with dilated cardiomyopathy in order to distinguish between ischaemic and non-ischaemic myocardial damage in case of equivocal clinical and other imaging data (taking account of cautions/contra-indications to CMR).</td>
<td>IIa</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>CMR is recommended for the characterization of myocardial tissue in case of suspected myocarditis, amyloidosis, sarcoidosis, Chagas disease, Fabry disease non-compaction cardiomyopathy, and haemochromatosis (taking account of cautions/contra-indications to CMR).</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Non-invasive stress imaging (CMR, stress echocardiography, SPECT, PET) may be considered for the assessment of myocardial ischaemia and viability in patients with HF and CAD (considered suitable for coronary revascularization) before the decision on revascularization.</td>
<td>IIb</td>
<td>B</td>
<td>116–118</td>
</tr>
<tr>
<td>Invasive coronary angiography is recommended in patients with HF and angina pectoris recalcitrant to pharmacological therapy or symptomatic ventricular arrhythmia or aborted cardiac arrest (who are considered suitable for potential coronary revascularization) in order to establish the diagnosis of CAD and its severity.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Invasive coronary angiography should be considered in patients with HF and intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests (who are considered suitable for potential coronary revascularization) in order to establish the diagnosis of CAD and its severity.</td>
<td>IIa</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Cardiac CT may be considered in patients with HF and low to intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.</td>
<td>IIb</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Reassessment of myocardial structure and function is recommended using non-invasive imaging: in patients presenting with worsening HF symptoms (including episodes of AHF) or experiencing any other important cardiovascular event; in patients with HF who have received evidence-based pharmacotherapy in maximal tolerated doses, before the decision on device implantation (ICD, CRT); in patients exposed to therapies which may damage the myocardium (e.g. chemotherapy) (serial assessments).</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

AHF = acute heart failure; CAD = coronary artery disease; CMR = cardiac magnetic resonance; CRT = cardiac resynchronization therapy; CT = computed tomography; HF = heart failure; HFrEF = heart failure with preserved ejection fraction; HFmrEF = heart failure with mid-range ejection fraction; HFpEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-defibrillator; LGE = late gadolinium enhancement; LVEF = left ventricular ejection fraction; PET = positron emission tomography; SPECT = single-photon emission computed tomography; TTE = transthoracic echocardiography.

*aClass of recommendation.

*bLevel of evidence.

*cReference(s) supporting recommendations.
5.10 Other diagnostic tests

Comprehensive assessment of patients with HF comprises, besides medical history and physical examination, including adequate imaging techniques, a set of additional diagnostic tests, i.e. laboratory variables, ECG, chest X-ray, exercise testing, invasive haemodynamic assessments and endomyocardial biopsy. The major typical indications are summarized in the recommendations table for diagnostic tests in patients with HF. Although there is extensive research on biomarkers in HF (e.g. ST2, galectin 3, copeptin, adrenomedullin), there is no definite evidence to recommend them for clinical practice.

### Recommendations for diagnostic tests in patients with heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The following diagnostic tests are recommended/should be considered for initial assessment of a patient with newly diagnosed HF in order to evaluate the patient’s suitability for particular therapies, to detect reversible/treatable causes of HF and comorbidities interfering with HF:</strong>&lt;br&gt;- haemoglobin and WBC&lt;br&gt;- sodium, potassium, urea, creatinine (with estimated GFR)&lt;br&gt;- liver function tests (bilirubin, AST, ALT, GGTP)&lt;br&gt;- glucose, HbA1c&lt;br&gt;- lipid profile&lt;br&gt;- TSH&lt;br&gt;- ferritin, TSAT = TIBC&lt;br&gt;- natriuretic peptides</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td><strong>Additional diagnostic tests aiming to identify other HF aetiologies and comorbidities should be considered in individual patients with HF when there is a clinical suspicion of a particular pathology (see Table 3.4 on HF aetiologies).</strong></td>
<td>Ia</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>A 12-lead ECG is recommended in all patients with HF in order to determine heart rhythm, heart rate, QRS morphology, and QRS duration, and to detect other relevant abnormalities. This information is needed to plan and monitor treatment.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td><strong>Exercise testing in patients with HF:</strong>&lt;br&gt;- is recommended as a part of the evaluation for heart transplantation and/or mechanical circulatory support (cardiopulmonary exercise testing);&lt;br&gt;- should be considered to optimize prescription of exercise training (preferably cardiopulmonary exercise testing);&lt;br&gt;- should be considered to identify the cause of unexplained dyspnoea (cardiopulmonary exercise testing);&lt;br&gt;- may be considered to detect reversible myocardial ischaemia.</td>
<td>I</td>
<td>C</td>
<td>119, 120</td>
</tr>
<tr>
<td><strong>Chest radiography (X-ray) is recommended in patients with HF to detect/exclude alternative pulmonary or other diseases, which may contribute to dyspnoea. It may also identify pulmonary congestion/oedema and is more useful in patients with suspected HF in the acute setting.</strong></td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td><strong>Right heart catheterization with a pulmonary artery catheter:</strong>&lt;br&gt;- is recommended in patients with severe HF being evaluated for heart transplantation or mechanical circulatory support;&lt;br&gt;- should be considered in patients with probable pulmonary hypertension assessed by echocardiography in order to confirm pulmonary hypertension and its reversibility before the correction of valve/structural heart disease;&lt;br&gt;- may be considered in order to adjust therapy in patients with HF who remain severely symptomatic despite initial standard therapies and whose haemodynamic status is unclear.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td><strong>EMB should be considered in patients with rapidly progressive HF despite standard therapy when there is a probability of a specific diagnosis which can be confirmed only in myocardial samples and specific therapy is available and effective.</strong></td>
<td>Ia</td>
<td>C</td>
<td>93</td>
</tr>
<tr>
<td>Thoracic ultrasound may be considered for the confirmation of pulmonary congestion and pleural effusion in patients with AHF.</td>
<td>Ib</td>
<td>C</td>
<td>121</td>
</tr>
<tr>
<td>Ultrasonography measurement of inferior vena cava diameter may be considered for the assessment of volume status in patients with HF.</td>
<td>Ib</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

AHF = acute heart failure; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BNP = B-type natriuretic peptide; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; EMB = endomyocardial biopsy; GFR = glomerular filtration rate; GGTP = gamma-glutamyl transpeptidase; Hba1c = glycated haemoglobin; HF = heart failure; HFpEF = heart failure with reduced ejection fraction; QRS = Q, R, and S waves (combination of three of the graphical deflections); TIBC = total iron-binding capacity; TSAT = transferrin saturation; TSH = thyroid-stimulating hormone; WBC = white blood cell.

*Class of recommendation.
*Level of evidence.
*Reference(s) supporting recommendations.

5.10.1 Genetic testing in heart failure

Molecular genetic analysis in patients with cardiomyopathies is recommended when the prevalence of detectable mutations is sufficiently high and consistent to justify routine targeted genetic screening. Recommendations for genetic testing in patients with HF are based on the position statement of the European Society
of Cardiology Working Group on Myocardial and Pericardial Diseases. In most patients with a definite clinical diagnosis of HF, there is no confirmatory role for routine genetic testing to establish the diagnosis. Genetic counselling is recommended in patients with HCM, idiopathic DCM and ARVC. Restrictive cardiomyopathy and isolated non-compaction cardiomyopathies are of a possible genetic origin and should also be considered for genetic testing.

HCM is mostly inherited as an autosomal dominant disease with variable expressivity and age-related penetrance. Currently, more than 20 genes and 1400 mutations have been identified, most of which are located in the sarcomere genes encoding cardiac β-myosin heavy chain (MYH7) and cardiac myosin binding protein C (MYBPC3).

DCM is idiopathic in 50% of cases, about one-third of which are hereditary. There are already more than 50 genes identified that are associated with DCM. Many genes are related to the cytoskeleton. The most frequent ones are titin (TTN), lamin (LMNA) and desmin (DES).

ARVC is hereditary in most cases and is caused by gene mutations that encode elements of the desmosome. Desmosomal gene mutations explain 50% of cases and 10 genes are currently associated with the disease.

Counselling should be performed by someone with sufficient knowledge of the specific psychological, social and medical implications of a diagnosis. Determination of the genotype is important, since some forms (e.g. mutations in LMNA and phospholamban (PLN)) are related to a poorer prognosis. DNA analysis could also be of help to establish the diagnosis of rare forms, such as mitochondrial cardiomyopathies. Screening of first-degree relatives for early detection is recommended from early adolescence onwards, although earlier screening may be considered depending on the age of disease onset in other family members.

Recently, the MOGE(S) classification of inherited cardiomyopathies has been proposed, which includes the morphofunctional phenotype (M), organ(s) involvement (O), genetic inheritance pattern (G), aetiological annotation (E), including genetic defect or underlying disease/substrate, and the functional status (S) of the disease.

6. Delaying or preventing the development of overt heart failure or preventing death before the onset of symptoms

There is considerable evidence that the onset of HF may be delayed or prevented through interventions aimed at modifying risk factors for HF or treating asymptomatic LV systolic dysfunction (see recommendations table). Many trials show that control of hypertension will delay the onset of HF and some also show that it will prolong life.

Different antihypertensive drugs [diuretics, ACEIs, angiotensin receptor blockers (ARBs), beta-blockers] have been shown to be effective, especially in older people, both in patients with and without a history of myocardial infarction.

Along with the ongoing discussion on optimal target blood pressure values in hypertensive non-diabetic subjects, the recent SPRINT study has already demonstrated that treating hypertension to a lower goal [systolic blood pressure (SBP) <120 mmHg vs. <140 mmHg] in older hypertensive subjects (≥75 years of age) or high-risk hypertensive patients reduces the risk of cardiovascular disease, death and hospitalization for HF.

Recently, empagliflozin (an inhibitor of sodium-glucose cotransporter 2), has been shown to improve outcomes (including the reduction of mortality and HF hospitalizations) in patients with type 2 diabetes. Other hypoglycaemic agents have not been shown convincingly to reduce the risk of cardiovascular events and may increase the risk of HF. Intensification of hypoglycaemic therapy to drive down glycated haemoglobin (HbA1c) with agents other than empagliflozin does not reduce the risk of developing HF (for details see Section 11.6 on diabetes).

Although smoking cessation has not been shown to reduce the risk of developing HF, the epidemiological associations with the development of cardiovascular disease suggest that such advice, if followed, would be beneficial.

The association between alcohol intake and the risk of developing de novo HF is U-shaped, with the lowest risk with modest alcohol consumption (up to 7 drinks/week). Greater alcohol intake may trigger the development of toxic cardiomyopathy, and when present, complete abstinence from alcohol is recommended.

An inverse relationship between physical activity and the risk of HF has been reported. A recent meta-analysis found that doses of physical activity in excess of the guideline recommended minimal levels may be required for more substantial reductions in HF risk.

It has been shown that among subjects ≥40 years of age with either cardiovascular risk factors or cardiovascular disease (but neither asymptomatic LV dysfunction nor overt HF), BNP-driven collaborative care between the primary care physician and the specialist cardiovascular centre may reduce the combined rates of LV systolic dysfunction and overt HF.

Statins reduce the rate of cardiovascular events and mortality; there is also reasonable evidence that they prevent or delay the onset of HF. Neither aspirin nor other antiplatelet agents, nor revascularization, have been shown to reduce the risk of developing HF or mortality in patients with stable CAD. Obesity is also a risk factor for HF, but the impact of treatments of obesity on the development of HF is unknown.

In patients with CAD, without LV systolic dysfunction or HF, ACEIs prevent or delay the onset of HF and reduce cardiovascular and all-cause mortality, although the benefit may be small in the contemporary setting, especially in patients receiving aspirin.

Up-titration of renin–angiotensin system antagonists and beta-blockers to maximum tolerated dosages may improve outcomes, including HF, in patients with increased plasma concentrations of NPs.

A primary percutaneous coronary intervention (PCI) at the earliest phase of an ST segment elevation myocardial infarction (STEMI) to reduce infarct size decreases the risk of developing a substantial reduction in LVEF and subsequent development of HFpEF. Initiation of an ACEI, a beta-blocker and an MRA immediately after a myocardial infarction, especially when it is associated with LV systolic dysfunction, reduces the rate of hospitalization for HF and mortality, as do statins.

In asymptomatic patients with chronically reduced LVEF, regardless of their aetiology, an ACEI can reduce the risk of HF requiring hospitalization. This has not yet been shown for beta-blockers or MRAs.
In patients with asymptomatic LV systolic dysfunction (LVEF <30%) of ischaemic origin who are ≥40 days after an AMI, an implantable cardioverter-defibrillator (ICD) is recommended to prolong life.149

7. Pharmacological treatment of heart failure with reduced ejection fraction

7.1 Objectives in the management of heart failure

The goals of treatment in patients with HF are to improve their clinical status, functional capacity and quality of life, prevent hospital admission and reduce mortality. The fact that several drugs for HF have shown detrimental effects on long-term outcomes, despite showing beneficial effects on shorter-term surrogate markers, has led regulatory bodies and clinical practice guidelines to seek mortality/morbidity data for approving/recommending therapeutic interventions for HF. However, it is now recognized that preventing HF hospitalization and improving functional capacity are important benefits to be considered if a mortality excess is ruled out.159–161

Figure 7.1 shows a treatment strategy for the use of drugs (and devices) in patients with HFrEF. The recommendations for each treatment are summarized below.

Neuro-hormonal antagonists (ACEIs, MRAs and beta-blockers) have been shown to improve survival in patients with HFrEF and are recommended for the treatment of every patient with HFrEF, unless contraindicated or not tolerated. A new compound (LCZ696) that combines the moieties of an ARB (valsartan) and a neprilysin (NEP) inhibitor (sacubitril) has recently been shown to be superior to an ACEI (enalapril) in reducing the risk of death and of hospitalization for HF in a single trial with strict inclusion/exclusion criteria.162 Sacubitril/valsartan is therefore recommended to replace ACEIs in ambulatory HFrEF patients who remain symptomatic despite optimal therapy and who fit these trial criteria. ARBs have not been consistently proven to reduce mortality in patients with HFrEF and their use should be restricted to patients intolerant of an ACEI or those who take an ACEI but are unable to tolerate an ACEI = angiotensin-converting enzyme inhibitor; CAD = coronary artery disease; HF = heart failure; ICD = implantable cardioverter-defibrillator; LV = left ventricular; LVEF = left ventricular ejection fraction; OMT = optimal medical therapy

Class of recommendation.

Level of evidence.

Reference(s) supporting recommendations.
MRA. Ivabradine reduces the elevated heart rate often seen in HFrEF and has also been shown to improve outcomes, and should be considered when appropriate.

The above medications should be used in conjunction with diuretics in patients with symptoms and/or signs of congestion. The use of diuretics should be modulated according to the patient’s clinical status.

The key evidence supporting the recommendations in this section is given in Web Table 7.1. The recommended doses of these disease-modifying medications are given in Table 7.2. The recommendations given in Sections 7.5 and 7.6 summarize drugs that should be avoided or used with caution in patients with HFrEF.

7.2 Treatments recommended in all symptomatic patients with heart failure with reduced ejection fraction

7.2.1 Angiotensin-converting enzyme inhibitors

ACEIs have been shown to reduce mortality and morbidity in patients with HFrEF and are recommended unless contraindicated or not tolerated in all symptomatic patients. ACEIs should be up-titrated to the maximum tolerated dose in order to achieve adequate inhibition of the renin–angiotensin–aldosterone system (RAAS). There is evidence that in clinical practice the majority of patients receive suboptimal doses of ACEI. ACEIs are also recommended in patients with asymptomatic LV systolic dysfunction to reduce the risk of HF development, HF hospitalization and death (see Section 6).

Pharmacological treatments indicated in patients with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Level*</th>
<th>Ref†</th>
</tr>
</thead>
<tbody>
<tr>
<td>An ACE-I is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death.</td>
<td>I</td>
<td>A</td>
<td>2, 163–165</td>
</tr>
<tr>
<td>A beta-blocker is recommended, in addition an ACE-I, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death.</td>
<td>I</td>
<td>A</td>
<td>167–173</td>
</tr>
<tr>
<td>An MRA is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE-I and a beta-blocker, to reduce the risk of HF hospitalization and death.</td>
<td>I</td>
<td>A</td>
<td>174, 175</td>
</tr>
</tbody>
</table>

ACEI = angiotensin-converting enzyme inhibitor; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association.

*Class of recommendation.

†Level of evidence.

Reference(s) supporting recommendations.

7.2.2 Beta-blockers

Beta-blockers reduce mortality and morbidity in symptomatic patients with HFrEF, despite treatment with an ACEI and, in most cases, a diuretic, but have not been tested in congested or decompensated patients. There is consensus that beta-blockers and ACEIs are complementary, and can be started together as soon as the diagnosis of HFrEF is made. There is no evidence favouring the initiation of treatment with a beta-blocker before an ACEI has been started. Beta-blockers should be initiated in clinically stable patients at a low dose and gradually up-titrated to the maximum tolerated dose. In patients admitted due to acute HF (AHF) beta-blockers should be cautiously initiated in hospital, once the patient is stabilized.

An individual patient data meta-analysis of all the major beta-blocker trials in HFrEF has shown no benefit on hospital admissions and mortality in the subgroup of patients with HFrEF who are in AF. However, since this is a retrospective subgroup analysis, and because beta-blockers did not increase the risk, the guideline committee decided not to make a separate recommendation according to heart rhythm. Beta-blockers should be considered for rate control in patients with HFrEF and AF, especially in those with high heart rate (see Section 10.1 for details).

Beta-blockers are recommended in patients with a history of myocardial infarction and asymptomatic LV systolic dysfunction to reduce the risk of death (see Section 6).

Practical guidance on how to use beta-blockers is given in Web Table 7.5.

7.2.3 Mineralocorticoid/aldosterone receptor antagonists

MRAs (spironolactone and eplerenone) block receptors that bind aldosterone and, with different degrees of affinity, other steroid hormone (e.g. corticosteroids, androgens) receptors. Spironolactone or eplerenone are recommended in all symptomatic patients (despite treatment with an ACEI and a beta-blocker) with HFrEF and LVEF ≤35%, to reduce mortality and HF hospitalization. Caution should be exercised when MRAs are used in patients with impaired renal function and in those with serum potassium levels >5.0 mmol/L. Regular checks of serum potassium levels and renal function should be performed according to clinical status.

Practical guidance on how to use MRAs is given in Web Table 7.6.

7.3 Other treatments recommended in selected symptomatic patients with heart failure with reduced ejection fraction

7.3.1 Diuretics

Diuretics are recommended to reduce the signs and symptoms of congestion in patients with HFrEF, but their effects on
Figure 7.1 Therapeutic algorithm for a patient with symptomatic heart failure with reduced ejection fraction. Green indicates a class I recommendation; yellow indicates a class IIa recommendation. ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; BNP = B-type natriuretic peptide; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; H-ISDN = hydralazine and isosorbide dinitrate; HR = heart rate; ICD = implantable cardioverter defibrillator; LBBB = left bundle branch block; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; MR = mineralocorticoid receptor; NT-proBNP = N-terminal pro-B type natriuretic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; VF = ventricular fibrillation; VT = ventricular tachycardia. *Symptomatic = NYHA Class II-IV. **HFrEF = LVEF < 40%. ***If ACE inhibitor not tolerated/contra-indicated, use ARB. ****If MR antagonist not tolerated/contra-indicated, use ARB. *****With a hospital admission for HF within the last 6 months or with elevated natriuretic peptides (BNP > 250 pg/ml or NT-proBNP > 500 pg/ml in men and 750 pg/ml in women). ******With an elevated plasma natriuretic peptide level (BNP > 150 pg/mL or plasma NT-proBNP > 600 pg/mL, or if HF hospitalization within recent 12 months plasma BNP > 100 pg/mL or plasma NT-proBNP > 400 pg/mL). *****In doses equivalent to enalapril 10 mg b.i.d. ******With a hospital admission for HF within the previous year. *******CRT is recommended if QRS > 130 msec and LBBB (in sinus rhythm). ********CRT should/may be considered if QRS > 130 msec with non-LBBB (in a sinus rhythm) or for patients in AF provided a strategy to ensure bi-ventricular capture in place (individualized decision). For further details, see Sections 7 and 8 and corresponding web pages.
mortality and morbidity have not been studied in RCTs. A Cochrane meta-analysis has shown that in patients with chronic HF, loop and thiazide diuretics appear to reduce the risk of death and worsening HF compared with placebo, and compared with an active control, diuretics appear to improve exercise capacity.178,179

Loop diuretics produce a more intense and shorter diuresis than thiazides, although they act synergistically and the combination may be used to treat resistant oedema. However, adverse effects are more likely and these combinations should only be used with care. The aim of diuretic therapy is to achieve and maintain euvalaemia with the lowest achievable dose. The dose of the diuretic must be adjusted according to the individual needs over time. In selected asymptomatic euvalaemic/hypovolaemic patients, the use of a diuretic drug might be (temporarily) discontinued. Patients can be trained to self-adjust their diuretic dose based on monitoring of symptoms/signs of congestion and daily weight measurements.

Doses of diuretics commonly used to treat HF are provided in Table 7.3. Practical guidance on how to use diuretics is given in Web Table 7.7.

### Table 7.2 Evidence-based doses of disease-modifying drugs in key randomized trials in heart failure with reduced ejection fraction (or after myocardial infarction)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Starting dose (mg)</th>
<th>Target dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE-I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Captopril</td>
<td>6.25 t.i.d.</td>
<td>50 t.i.d.</td>
</tr>
<tr>
<td>Enalapril</td>
<td>2.5 b.i.d.</td>
<td>10–20 b.i.d.</td>
</tr>
<tr>
<td>Lisinopril†</td>
<td>2.5–5.0 a.d.</td>
<td>20–35 a.d.</td>
</tr>
<tr>
<td>Ramipril</td>
<td>2.5 a.d.</td>
<td>10 a.d.</td>
</tr>
<tr>
<td>Trandolapril‡</td>
<td>0.5 a.d.</td>
<td>4 a.d.</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisoprolol</td>
<td>1.25 a.d.</td>
<td>10 a.d.</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>3.125/25 b.i.d.</td>
<td>25/50 b.i.d.</td>
</tr>
<tr>
<td>Nebivolol§</td>
<td>1.25 a.d.</td>
<td>10 a.d.</td>
</tr>
<tr>
<td>ARBs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candesartan</td>
<td>4–8 a.d.</td>
<td>32 a.d.</td>
</tr>
<tr>
<td>Valsartan</td>
<td>40 b.i.d.</td>
<td>160 b.i.d.</td>
</tr>
<tr>
<td>Losartan†‡</td>
<td>50 a.d.</td>
<td>150 a.d.</td>
</tr>
<tr>
<td>MRAs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eplerenone</td>
<td>25 a.d.</td>
<td>50 a.d.</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>25 a.d.</td>
<td>50 a.d.</td>
</tr>
<tr>
<td>ARNI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacubitril/valsartan</td>
<td>49/51 b.i.d.</td>
<td>97/103 b.i.d.</td>
</tr>
<tr>
<td>If-channel blocker</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ivrabradine</td>
<td>5 b.i.d.</td>
<td>7.5 b.i.d.</td>
</tr>
</tbody>
</table>

ACE-I = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; b.i.d. = bis in die (twice daily); MRA = mineralocorticoid receptor antagonist; o.d. = omne in die (once daily); t.i.d. = ter in die (three times a day).

†Indicates an ACE-I where the dosing target is derived from post-myocardial infarction trials.

‡Indicates drugs where a higher dose has been shown to reduce morbidity/mortality compared with a lower dose of the same drug, but there is no substantive randomized, placebo-controlled trial and the optimum dose is uncertain.

†Indicates a treatment not shown to reduce cardiovascular or all-cause mortality in patients with heart failure (or shown to be non-inferior to a treatment that does).

‡A maximum dose of 50 mg twice daily can be administered to patients weighing over 85 kg.

### Table 7.3 Doses of diuretics commonly used in patients with heart failure

<table>
<thead>
<tr>
<th>Diuretics</th>
<th>Initial dose (mg)</th>
<th>Usual daily dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loop diuretics*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide</td>
<td>20–40</td>
<td>40–240</td>
</tr>
<tr>
<td>Bumetanide</td>
<td>0.5–1.0</td>
<td>1–5</td>
</tr>
<tr>
<td>Torasemide</td>
<td>5–10</td>
<td>10–20</td>
</tr>
<tr>
<td>Thiazides†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendroflumethiazide</td>
<td>2.5</td>
<td>2.5–10</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>25</td>
<td>12.5–100</td>
</tr>
<tr>
<td>Metolazone</td>
<td>2.5</td>
<td>2.5–10</td>
</tr>
<tr>
<td>Indapamide§</td>
<td>2.5</td>
<td>2.5–5</td>
</tr>
<tr>
<td>Potassium-sparing diuretics*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spironolactone/eplerenone</td>
<td>12.5–25</td>
<td>50–100</td>
</tr>
<tr>
<td>Amiloride</td>
<td>2.5</td>
<td>5–10</td>
</tr>
<tr>
<td>Triamterene</td>
<td>25</td>
<td>50–100</td>
</tr>
</tbody>
</table>

ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.

*Oral or intravenous; dose might need to be adjusted according to volume status/weight; excessive doses may cause renal impairment and ototoxicity.

†Do not use thiazides if estimated glomerular filtration rate <30 mL/min/1.73 m², except when prescribed synergistically with loop diuretics.

§Indapamide is a non-thiazide sulfonylurea.

‡A mineralocorticoid antagonist (MRA) i.e. spironolactone/eplerenone is always preferred. Amiloride and triamterene should not be combined with an MRA.
7.3.2 Angiotensin receptor neprilysin inhibitor

A new therapeutic class of agents acting on the RAAS and the neutral endopeptidase system has been developed [angiotensin receptor neprilysin inhibitor (ARNI)]. The first in class is LCZ696, which is a molecule that combines the moieties of valsartan and sacubitril (neprilysin inhibitor) in a single substance. By inhibiting neprilysin, the degradation of NPs, bradykinin and other peptides is slowed. High circulating A-type natriuretic peptide (ANP) and BNP exert physiologic effects through binding to NP receptors and the augmented generation of cGMP, thereby enhancing diuresis, natriuresis and myocardial relaxation and anti-remodelling. ANP and BNP also inhibit renin and aldosterone secretion. Selective AT1-receptor blockade reduces vasoconstriction, sodium and water retention and myocardial hypertrophy.

A recent trial investigated the long-term effects of sacubitril/valsartan compared with an ACEI (enalapril) on morbidity...

---

**Table: Other pharmacological treatments recommended in selected patients with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diuretics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion.</td>
<td>I</td>
<td>B</td>
<td>178, 179</td>
</tr>
<tr>
<td>Diuretics should be considered to reduce the risk of HF hospitalization in patients with signs and/or symptoms of congestion.</td>
<td>Ila</td>
<td>B</td>
<td>178, 179</td>
</tr>
<tr>
<td><strong>Angiotensin receptor neprilysin inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacubitril/valsartan is recommended as a replacement for an ACE-I to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE-I, a beta-blocker and an MRA</td>
<td>I</td>
<td>B</td>
<td>162</td>
</tr>
<tr>
<td><strong>If-channel inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ivabradine should be considered to reduce the risk of HF hospitalization or cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm despite treatment with an evidence-based dose of beta-blocker (or maximum tolerated dose below that), ACE-I (or ARB), and an MRA (or ARB).</td>
<td>Ila</td>
<td>B</td>
<td>180</td>
</tr>
<tr>
<td>Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm who are unable to tolerate or have contra-indications for a beta-blocker. Patients should also receive an ACE-I (or ARB) and an MRA (or ARB).</td>
<td>Ila</td>
<td>C</td>
<td>181</td>
</tr>
<tr>
<td><strong>ARB</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>An ARB is recommended to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients unable to tolerate an ACE-I (patients should also receive a beta-blocker and an MRA).</td>
<td>I</td>
<td>B</td>
<td>182</td>
</tr>
<tr>
<td>An ARB may be considered to reduce the risk of HF hospitalization and death in patients who are symptomatic despite treatment with a beta-blocker who are unable to tolerate an MRA.</td>
<td>Ila</td>
<td>C</td>
<td>-</td>
</tr>
<tr>
<td><strong>Hydralazine and isosorbide dinitrate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with LVEF ≤35% or with an LVEF &lt;45% combined with a dilated LV in NYHA Class III–IV despite treatment with an ACE-I a beta-blocker and an MRA to reduce the risk of HF hospitalization and death.</td>
<td>Ila</td>
<td>B</td>
<td>183</td>
</tr>
<tr>
<td>Hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither an ACE-I nor an ARB (or they are contra-indicated) to reduce the risk of death.</td>
<td>Ila</td>
<td>B</td>
<td>184</td>
</tr>
<tr>
<td><strong>Other treatments with less-certain benefits</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Digoxin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin may be considered in symptomatic patients in sinus rhythm despite treatment with an ACE-I (or ARB), a beta-blocker and an MRA, to reduce the risk of hospitalization (both all-cause and HF-hospitalizations).</td>
<td>Ila</td>
<td>B</td>
<td>185</td>
</tr>
<tr>
<td><strong>N-3 PUFA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>An n-3 PUFA* preparation may be considered in symptomatic HF patients to reduce the risk of cardiovascular hospitalization and cardiovascular death.</td>
<td>Ila</td>
<td>B</td>
<td>186</td>
</tr>
</tbody>
</table>

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BNP = B-type natriuretic peptide; bpm = beats per minute; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NT-proBNP = N-terminal pro-B type natriuretic peptide; NYHA = New York Heart Association; PUFA = polyunsaturated fatty acid; OMT = optimal medical therapy (for HFrEF this mostly comprises an ACEI or sacubitril/valsartan, a beta-blocker and an MRA).

aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dPatient should have elevated natriuretic peptides (plasma BNP ≥150 pg/mL or plasma NT-proBNP ≥600 pg/mL, or if HF hospitalization within the last 12 months, plasma BNP ≥100 pg/mL or plasma NT-proBNP ≥400 pg/mL) and able to tolerate enalapril 10 mg b.i.d.

eApplies only to preparation studied in cited trial.
and mortality in patients with ambulatory, symptomatic HFrEF with LVEF ≤40% (this was changed to ≤35% during the study), elevated plasma NP levels (BNP ≥150 pg/mL or NT-proBNP ≥600 pg/mL or, if they had been hospitalized for HF within the previous 12 months, BNP ≥100 pg/mL or NT-proBNP ≥400 pg/mL), and an estimated GFR (eGFR) ≥ 30 mL/min/1.73 m² of body surface area, who were able to tolerate separate treatments periods with enalapril (10 mg b.i.d.) and sacubitril/valsartan (97/103 mg b.i.d.) during a run-in period.162 In this population, sacubitril/valsartan (97/103 mg b.i.d.) was superior to ACEI (enalapril 10 mg b.i.d.) in reducing hospitalizations for worsening HF, cardiovascular mortality and overall mortality.162 Sacubitril/valsartan is therefore recommended in patients with HFrEF who fit this profile.

Despite the superiority of sacubitril/valsartan over enalapril in the PARADIGM-HF trial, some relevant safety issues remain when initiating therapy with this drug in clinical practice. Symptomatic hypotension was more often present in the sacubitril/valsartan group (in those ≥75 years of age, it affected 18% in the sacubitril/valsartan group vs. 12% in the enalapril group), although there was no increase in the rate of discontinuation.162 The risk of angioedema in the trial was reduced by recruiting only those who tolerated therapy with enalapril 10 mg b.i.d. and an sacubitril/valsartan during an active run-in phase of 5–9 weeks (it resulted in a 0.4% rate of angioedema in sacubitril/valsartan group vs. 0.2% in an enalapril group). Also, the number of African American patients, who are at a higher risk of angioedema, was relatively small in this study. To minimize the risk of angioedema caused by overlapping ACE and nephrilysin inhibition, the ACEI should be withheld for at least 36 h before initiating sacubitril/valsartan. Combined treatment with an ACEI (or ARB) and sacubitril/valsartan is contraindicated. There are additional concerns about its effects on the degradation of beta-amyloid peptide in the brain, which could theoretically accelerate amyloid deposition.189–191 However, a recent small 14-day study with healthy subjects showed elevation of the beta-amyloid protein in the soluble rather than the aggregate form, which if confirmed over longer time periods in patients with HFrEF may indicate the cerebral safety of sacubitril/valsartan.192 Long-term safety needs to be addressed.

7.3.3 I1-channel inhibitor
Ivabradine slows the heart rate through inhibition of the I1 channel in the sinus node and therefore should only be used for patients in sinus rhythm. Ivabradine reduced the combined endpoint of mortality or hospitalization for HF in patients with symptomatic HFrEF or LVEF ≤35%, in sinus rhythm and with a heart rate ≥70 beats per minute (bpm) who had been hospitalized for HF within the previous 12 months, receiving treatment with an evidence-based dose of beta-blocker (or maximum tolerated dose), an ACEI (or ARB) and an MRA.180 The European Medicines Agency (EMA) approved ivabradine for use in Europe in patients with HFrEF with LVEF ≤35% and in sinus rhythm with a resting heart rate ≥75 bpm, because in this group ivabradine conferred a survival benefit193 based on a retrospective subgroup analysis requested by the EMA.

Practical guidance on how to use ivabradine is given in Web Table 7.8.

7.3.4 Angiotensin II type 1 receptor blockers
ARBs are recommended only as an alternative in patients intolerant of an ACEI.182 Candesartan has been shown to reduce cardiovascular mortality.182 Valsartan showed an effect on hospitalization for HF (but not on all-cause hospitalizations) in patients with HFrEF receiving background ACEIs.194

The combination of ACEI/ARB for HFrEF was reviewed by the EMA, which suggested that benefits are thought to outweigh risks only in a select group of patients with HFrEF in whom other treatments are unsuitable. Therefore, ARBs are indicated for the treatment of HFrEF only in patients who cannot tolerate an ACEI because of serious side effects. The combination of ACEI/ARB should be restricted to symptomatic HFrEF patients receiving a beta-blocker who are unable to tolerate an MRA, and must be used under strict supervision.

7.3.5 Combination of hydralazine and isosorbide dinitrate
There is no clear evidence to suggest the use of this fixed-dose combination therapy in all patients with HFrEF. Evidence on the clinical utility of this combination is scanty and comes from one relatively small RCT conducted exclusively in men and before ACEIs or beta-blockers were used to treat HF.184 A subsequent RCT conducted in self-identified black patients (defined as being of African descent) showed that addition of the combination of hydralazine and isosorbide dinitrate to conventional therapy (ACEI, beta-blocker and MRA) reduced mortality and HF hospitalizations in patients with HFrEF and NYHA Classes III–IV.183 The results of this study are difficult to translate to patients of other racial or ethnic origins.

Additionally, a combination of hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither ACEI nor ARB (or they are contraindicated) to reduce mortality. However, this recommendation is based on the results of the Veterans Administration Cooperative Study, which recruited symptomatic HFrEF patients who received only digoxin and diuretics.184

7.4 Other treatments with less certain benefits in symptomatic patients with heart failure with reduced ejection fraction
This section describes treatments that have shown benefits in terms of symptomatic improvement, reduction in HF hospitalizations or both, and are useful additional treatments in patients with HFrEF.

7.4.1 Digoxin and other digitalis glycosides
Digoxin may be considered in patients in sinus rhythm with symptomatic HFrEF to reduce the risk of hospitalization (both all-cause and HF hospitalizations), although its effect on top of beta-blockers has never been tested. The effects of digoxin in patients with HFrEF and AF have not been studied in RCTs, and recent studies have suggested potentially higher risk of events (mortality and HF
hospitalization) in patients with AF receiving digoxin. However, this remains controversial, as another recent meta-analysis concluded on the basis of non-RCTs that digoxin has no deleterious effect on mortality in patients with AF and concomitant HF, most of whom had HFrEF.

In patients with symptomatic HF and AF, digoxin may be useful to slow a rapid ventricular rate, but it is only recommended for the treatment of patients with HFrEF and AF with rapid ventricular rate when other therapeutic options cannot be pursued. Of note, the optimal ventricular rate for patients with HF and AF has not been well established, but the prevailing evidence suggests that strict rate control might be deleterious. A resting ventricular rate in the range of 70–90 bpm is recommended based on current opinion, although one trial suggested that a resting ventricular rate of up to 110 bpm might still be acceptable. This should be tested and refined by further research.

Digitalis should always be prescribed under specialist supervision. Given its distribution and clearance, caution should be exerted in females, in the elderly and in patients with reduced renal function. In the latter patients, digitoxin should be preferred.

### 7.4.2 n-3 polyunsaturated fatty acids

n-3 polyunsaturated fatty acids (n-3 PUFAs) have shown a small treatment effect in a large RCT. n-3 PUFA preparations differ in composition and dose. Only preparations with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethyl esters of at least 85% (850 mg/g) have shown an effect on the cumulative endpoint of cardiovascular death and hospitalization. No effect of n-3 PUFA preparations containing 85% (850 mg/g) have shown an effect on the cumulative endpoint of cardiovascular death and hospitalization. No effect of n-3 PUFA preparations containing 850 mg/g has been shown in either HFrEF or post-myocardial infarction.

n-3 PUFA preparations containing 850–882 mg of EPA and DHA as ethyl esters in the average ratio of 1:1.2 may be considered as an adjunctive therapy in patients with symptomatic HFrEF who are already receiving optimized recommended therapy with an ACEI (or ARB), a beta-blocker and an MRA.

### 7.5 Treatments not recommended (unproven benefit) in symptomatic patients with heart failure with reduced ejection fraction

#### 7.5.1 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (‘statins’)

Although statins reduce mortality and morbidity in patients with atherosclerotic disease, statins are not effective in improving the prognosis in patients with HFrEF. Most statin trials excluded patients with HF (because it was uncertain that they would benefit). The two major trials that studied the effect of statin treatment in patients with chronic HF did not demonstrate any evidence of benefit. Therefore, evidence does not support the initiation of statins in most patients with chronic HF. However, in patients who already receive a statin because of underlying CAD or/and hyperlipidaemia, a continuation of this therapy should be considered.

#### 7.5.2 Oral anticoagulants and antiplatelet therapy

Other than in patients with AF (both HFrEF and HFpEF), there is no evidence that an oral anticoagulant reduces mortality/morbidity compared with placebo or aspirin. Studies testing the non-vitamin K antagonist oral anticoagulants (NOACs) in patients with HFrEF are currently ongoing. Patients with HFrEF receiving oral anticoagulation because of concurrent AF or risk of venous thromboembolism should continue anticoagulation. Detailed information is provided in Section 10.1.

Similarly, there is no evidence on the benefits of antiplatelet drugs (including acetylsalicylic acid) in patients with HF without accompanying CAD, whereas there is a substantial risk of gastrointestinal bleeding, particularly in elderly subjects, related with this treatment.

#### 7.5.3 Renin inhibitors

Aliskiren (direct renin inhibitor) failed to improve outcomes for patients hospitalized for HF at 6 months or 12 months in one study and is not presently recommended as an alternative to an ACEI or ARB.

### Treatments (or combinations of treatments) that may cause harm in patients with symptomatic (NYHA Class II–IV) heart failure with reduced ejection fraction

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.</td>
<td>III</td>
<td>A</td>
<td>209, 210</td>
</tr>
<tr>
<td>NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.</td>
<td>III</td>
<td>B</td>
<td>211–213</td>
</tr>
<tr>
<td>Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization.</td>
<td>III</td>
<td>C</td>
<td>214</td>
</tr>
</tbody>
</table>

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; COX-2 inhibitor = cyclooxygenase-2 inhibitor; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; NSAIDs = non-steroidal anti-inflammatory drugs.

1. Level of evidence.
2. Reference(s) supporting recommendations.
7.6 Treatments not recommended (believed to cause harm) in symptomatic patients with heart failure with reduced ejection fraction

### 7.6.1 Calcium-channel blockers

Non-dihydropyridine calcium-channel blockers (CCBs) are not indicated for the treatment of patients with HFrEF. Diltiazem and verapamil have been shown to be unsafe in patients with HFrEF. There is a variety of dihydropyridine CCBs; some are known to increase sympathetic tone and they may have a negative safety profile in HFrEF. There is only evidence on safety for amlodipine and felodipine in patients with HFrEF, and they can be used only if there is a compelling indication in patients with HFrEF.

8. Non-surgical device treatment of heart failure with reduced ejection fraction

This section provides recommendations on the use of ICDs and CRT. Currently, the evidence is considered insufficient to support specific guideline recommendations for other therapeutic technologies, including baroreflex activation therapy, vagal stimulation, diaphragmatic pacing and cardiac contractility modulation; further research is required. Implantable devices to monitor arrhythmias or haemodynamics are discussed elsewhere in these guidelines.

### 8.1 Implantable cardioverter-defibrillator

A high proportion of deaths among patients with HF, especially those with milder symptoms, occur suddenly and unexpectedly. Many of these are due to electrical disturbances, including ventricular arrhythmias, bradycardia and asystole, although some are due to coronary, cerebral or aortic vascular events. Treatments that improve or delay the progression of cardiovascular disease will reduce the annual rate of sudden death, but they may have little effect on lifetime risk and will not treat arrhythmic events when they occur. ICDs are effective in preventing bradyarrhythmia and correcting potentially lethal ventricular arrhythmias. Some antiarrhythmic drugs might reduce the rate of tachyarrhythmias and sudden death, but they do not reduce overall mortality and may increase it.

### Recommendations for implantable cardioverter-defibrillator in patients with heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secondary prevention</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for &gt;1 year with good functional status.</td>
<td>I</td>
<td>A</td>
<td>223–226</td>
</tr>
<tr>
<td><strong>Primary prevention</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II–III), and an LVEF ≤35% despite ≥3 months of OMT, provided they are expected to survive substantially longer than one year with good functional status, and they have:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• IHD (unless they have had an MI in the prior 40 days – see below).</td>
<td>I</td>
<td>A</td>
<td>149, 156, 227</td>
</tr>
<tr>
<td>• DCM.</td>
<td>I</td>
<td>B</td>
<td>156, 157, 227</td>
</tr>
<tr>
<td>ICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis.</td>
<td>III</td>
<td>A</td>
<td>158, 228</td>
</tr>
<tr>
<td>ICD therapy is not recommended in patients in NYHA Class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a ventricular assist device, or cardiac transplantation.</td>
<td>III</td>
<td>C</td>
<td>229–233</td>
</tr>
<tr>
<td>Patients should be carefully evaluated by an experienced cardiologist before generator replacement, because management goals and the patient's needs and clinical status may have changed.</td>
<td>IIa</td>
<td>B</td>
<td>234–238</td>
</tr>
<tr>
<td>A wearable ICD may be considered for patients with HF who are at risk of sudden cardiac death for a limited period or as a bridge to an implanted device.</td>
<td>IIb</td>
<td>C</td>
<td>239–241</td>
</tr>
</tbody>
</table>

**References**

CAD = coronary artery disease; CRT = cardiac resynchronization therapy; DCM = dilated cardiomyopathy; HF = heart failure; ICD = implantable cardioverter-defibrillator; IHD = ischaemic heart disease; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NYHA = New York Heart Association, OMT = optimal medical therapy.

*aClass of recommendation.

*bLevel of evidence.

*cReference(s) supporting recommendations.

**8.1.1 Secondary prevention of sudden cardiac death**

Compared with amiodarone treatment, ICDs reduce mortality in survivors of cardiac arrest and in patients who have experienced sustained symptomatic ventricular arrhythmias. An ICD is recommended in such patients when the intent is to increase survival; the decision to implant should take into account the patient’s view and their quality of life, the LVEF (survival benefit is uncertain when the LVEF is >35%) and the absence of other diseases likely to cause death within the following year.
8.1.2 Primary prevention of sudden cardiac death

Although amiodarone may have reduced mortality in older trials of HF,282,283 contemporary studies conducted since the widespread introduction of beta-blockers suggest that it does not reduce mortality in patients with HFrEF. Dronedarone246,247 and class I antiarrhythmic agents246,248 should not be used for prevention of arrhythmias in this population.

Some guideline-recommended therapies, including beta-blockers, MRAs, sacubitril/valsartan and pacemakers with CRT (CRT-Ps), reduce the risk of sudden death (see Section 7).

An ICD reduces the rate of sudden arrhythmic death in patients with HFrEF.249,250 In patients with moderate or severe HF, a reduction in sudden death may be partially or wholly offset by an increase in death due to worsening HF.227 In patients with mild HF (NYHA II), an ICD will prevent about two deaths per year for every 100 devices implanted.227 On average, patients with IHD are at greater risk of sudden death than patients with DCM and therefore, although the relative benefits are similar, the absolute benefit is greater in patients with IHD.249 Patients with longer QRS durations may also receive greater benefit from an ICD, but these patients should often receive a CRT device.227,251

Two RCTs showed no benefit in patients who had an ICD implanted within 40 days after a myocardial infarction. Although sudden arrhythmic deaths were reduced, this was balanced by an increase in non-arrhythmic deaths. Accordingly, an ICD is contraindicated in this time period. A wearable defibrillator may be considered if the patient is deemed to be at high risk of ventricular fibrillation, although evidence from randomized trials is lacking.239–241

ICD implantation is recommended only after a sufficient trial (minimum 3 months) of optimal medical therapy (OMT) has failed to increase the LVEF to >35%. However, one of the two landmark papers on which these recommendations are based included patients with an LVEF >30%. Fewer than 400 patients with an LVEF of 30–35% were included in the landmark studies, and although there was no statistical interaction between treatment effect and LVEF, the evidence of benefit is less robust in this group of patients.

Conservative programming with long delays between detection and the ICD delivering therapy dramatically reduces the risk of both inappropriate (due to artefacts or AF) and appropriate but unnecessary [due to self-terminating ventricular tachycardia (VT)] shocks.252–254

Patients with a QRS duration ≥130 ms should be considered for a defibrillator with CRT (CRT-D) rather than ICD. See the guideline on CRT for further details (Section 8.2).

ICD therapy is not recommended in patients in NYHA Class IV with severe symptoms refractory to pharmacological therapy who are not candidates for CRT, a ventricular assist device or cardiac transplantation, because such patients have a very limited life expectancy and are likely to die from pump failure.

Patients with serious co-morbidities who are unlikely to survive substantially more than 1 year are unlikely to obtain substantial benefit from an ICD.229–233

Patients should be counselled as to the purpose of an ICD, complications related to implantation and device activation (predominantly inappropriate shocks) and under what circumstances it might be deactivated (terminal disease) or explanted (infection, recovery of LV function).255

If HF deteriorates, deactivation of a patient’s ICD may be considered after appropriate discussion with the patient and caregiver(s).

If the ICD generator reaches its end of life or requires explantation, it should not automatically be replaced.234–238 Patients should be carefully evaluated by an experienced cardiologist before generator replacement. Treatment goals may have changed and the risk of fatal arrhythmia may be lower or the risk of non-arrhythmic death higher. It is a matter of some controversy whether patients whose LVEF has greatly improved and who have not required device therapy during the lifetime of the ICD should have another device implanted.234–238

Subcutaneous defibrillators may be as effective as conventional ICDs with a lower risk from the implantation procedure.256,257 They may be the preferred option for patients with difficult access or who require ICD explantation due to infection. Patients must be carefully selected, as they have limited capacity to treat serious bradyarrhythmia and can deliver neither antitachycardia pacing nor CRT. Substantial RCTs with these devices and more data on safety and efficacy are awaited.258,259

A wearable ICD (an external defibrillator with leads and electrode pads attached to a wearable vest) that is able to recognize and interrupt VT/Ventricular fibrillation may be considered for a limited period of time in selected patients with HF who are at high risk for sudden death but otherwise are not suitable for ICD implantation (e.g. those with poor LVEF after acute myocardial damage until LV function recovers, patients scheduled for heart transplantation).239–241,260 However, no prospective RCTs evaluating this device have been reported.

For detailed recommendations on the use/indications of ICD we refer the reader to the ESC/European Heart Rhythm Association (EHRA) guidelines on ventricular tachyarrhythmias and sudden cardiac death.260
8.2 Cardiac resynchronization therapy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration ≥ 130 msec and LBBB QRS morphology and with LVEF ≤ 35% despite OMT in order to improve symptoms and reduce morbidity and mortality.</td>
<td>I</td>
<td>A</td>
<td>261–272</td>
</tr>
<tr>
<td>CRT should be considered for symptomatic patients with HF in sinus rhythm with a QRS duration ≥ 150 msec and non-LBBB QRS morphology and with LVEF ≤ 35% despite OMT in order to improve symptoms and reduce morbidity and mortality.</td>
<td>IIa</td>
<td>B</td>
<td>261–272</td>
</tr>
<tr>
<td>CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and LBBB QRS morphology and with LVEF ≤ 35% despite OMT in order to improve symptoms and reduce morbidity and mortality.</td>
<td>I</td>
<td>B</td>
<td>266, 273</td>
</tr>
<tr>
<td>CRT may be considered for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and non-LBBB QRS morphology and with LVEF ≤ 35% despite OMT in order to improve symptoms and reduce morbidity and mortality.</td>
<td>IIb</td>
<td>B</td>
<td>266, 273</td>
</tr>
<tr>
<td>CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indication for ventricular pacing and high degree AV block in order to reduce morbidity. This includes patients with AF (see Section 10.1).</td>
<td>I A</td>
<td></td>
<td>274–277</td>
</tr>
<tr>
<td>CRT should be considered for patients with LVEF ≤ 35% in NYHA Class III–IV despite OMT in order to improve symptoms and reduce morbidity and mortality, if they are in AF and have a QRS duration ≥ 30 msec provided a strategy to ensure bi-ventricular capture is in place or the patient is expected to return to sinus rhythm.</td>
<td>IIa</td>
<td>B</td>
<td>275, 278–281</td>
</tr>
<tr>
<td>Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a high proportion of RV pacing may be considered for upgrade to CRT. This does not apply to patients with stable HF.</td>
<td>IIb</td>
<td>B</td>
<td>282</td>
</tr>
<tr>
<td>CRT is contra-indicated in patients with a QRS duration &lt; 130 msec.</td>
<td>III A</td>
<td></td>
<td>266, 283–285</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; AV = atrio-ventricular; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-defibrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OMT = optimal medical therapy; QRS = Q, R and S waves (combination of three of the graphical deflections); RV = right ventricular.

aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.

Use judgement for patients with end-stage HF who might be managed conservatively rather than with treatments to improve symptoms or prognosis.

CRT improves cardiac performance in appropriately selected patients and improves symptoms, and well-being and reduces morbidity and mortality. Of the improvement in quality-adjusted life-years (QALYs) with CRT among patients with moderate to severe HF, two-thirds may be attributed to improved quality of life and one-third to increased longevity.

Only the COMPANION and CARE-HF trials compared the effect of CRT to guideline-advised medical therapy. Most other trials have compared CRT-D to ICD, and a few have compared CRT-P to backup pacing. The prevention of lethal bradycardia might be an important mechanism of benefit shared by all pacing devices. In CARE-HF, at baseline, 25% of patients had a resting heart rate of ≤ 60 bpm and if prevention of bradycardia is important, the effect of CRT will appear greater in trials where there is no device in the control group.

Most studies of CRT have specified that the LVEF should be < 35%, but RAFT and MADIT-CRT specified an LVEF < 30%, while REVERSE and BLOCK-HF specified < 40% and < 50%. Relatively few patients with an LVEF of 35–40% have been randomized, but an individual participant data (IPD) meta-analysis suggests no diminution of the effect of CRT in this group.

Not all patients respond favourably to CRT. Several characteristics predict improvement in morbidity and mortality, and the extent of reverse remodelling is one of the most important mechanisms of action of CRT. Patients with ischaemic aetiology will have less improvement in LV function due to myocardial scar tissue, which is less likely to undergo favourable remodelling. Conversely, women may be more likely to respond than men, possibly due to smaller body and heart size. QRS width predicts CRT response and was the inclusion criterion in all randomized trials. But QRS morphology has also been related to a beneficial response to CRT. Several studies have shown that patients with left bundle branch block (LBBB) morphology are more likely to respond favourably to CRT, whereas there is less certainty about patients with non-LBBB morphology. However, patients with LBBB morphology often have wider QRS duration, and there is a current debate about whether QRS duration or QRS morphology is the main predictor of a beneficial response to CRT. Evidence from two IPD meta-analyses indicates that after accounting for QRS duration, there is little evidence to suggest that QRS morphology or aetiology of disease influence the effect of CRT on morbidity or mortality. In addition, none of the landmark trials selected patients for inclusion according to QRS morphology, sex or ischaemic aetiology, nor were they powered for subgroup analyses.

The Echo-CRT trial and an IPD meta-analysis suggest possible harm from CRT when QRS duration is < 130 ms, thus implantation of CRT is not recommended if QRS duration is < 130 ms.

If a patient is scheduled to receive an ICD and is in sinus rhythm with a QRS duration ≥ 130 ms, CRT-D should be considered if QRS is between 130 and 149 ms and is recommended if QRS is ≥ 150 ms. However, if the primary reason for implanting a CRT is for the relief of symptoms, then the clinician should choose CRT-P or CRT-D, whichever they consider appropriate. Clinical practice varies widely among countries. The only randomized trial to compare CRT-P and CRT-D failed to demonstrate a difference in morbidity or mortality between these technologies. If the primary reason for implanting CRT is to improve prognosis,
then the majority of evidence lies with CRT-D for patients in NYHA Class II and with CRT-P for patients in NYHA Classes III–IV. It is unclear whether CRT reduces the need for an ICD (by reducing the arrhythmia burden) or increases the benefit from an ICD (by reducing mortality rates from worsening HF, leading to longer exposure to the risk of arrhythmia).

When LVEF is reduced, RV pacing may exacerbate cardiac dysynchrony. This can be prevented by CRT, which might improve patient outcomes. However, a difference in outcome was not observed between CRT and RV pacing in a subgroup analysis of RAFT or in patients without HFrEF in BioPACE. On balance, CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indication for ventricular pacing in order to reduce morbidity, although no clear effect on mortality was observed. Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF with a high proportion of RV pacing, despite OMT, may be considered for upgrading to CRT.

Only two small trials have compared pharmacological therapy alone vs. CRT in patients with AF, with conflicting results. Several studies have indicated that CRT is superior to RV pacing in patients undergoing atrio-ventricular (AV) node ablation. However, CRT is not an indication to carry out AV node ablation except in rare cases when ventricular rate remains persistently high (>110 bpm) despite attempts at pharmacological rate control. A subgroup analysis of patients with AF from the RAFT study found no benefit from CRT-D compared with ICD, although less than half of patients had >90% biventricular capture. Observational studies report that when biventricular capture is <98%, the prognosis of patients with CRT declines. Whether this association reflects a loss of re-synchronization (which might be remedied by device programming), poor pacing of the LV lead (which might be avoided at implantation) or greater difficulty in pacing severely diseased myocardium (which might not be amenable to the above) is uncertain. This observation has not been confirmed in a randomized trial.

Imaging tests for dysynchrony have not yet been shown to be of value in selecting patients for CRT. Patients with extensive myocardial scar will have less improvement in LV function with CRT, but this is true of any treatment for HFrEF and does not reliably predict less clinical benefit. Pacing thresholds are higher in scarred myocardium and, if possible, lead placement should avoid such regions. Although patients with extensive scarring have an intrinsically worse prognosis, there is little evidence that they obtain less prognostic benefit from CRT.

The reader is directed to guidelines on pacing and CRT for recommendations on device implantation procedures. The value of trying to optimize AV or VV intervals after implantation using echo- or electrocardiographic criteria or blood pressure response is uncertain, but may be considered for patients who have had a disappointing response to CRT.

### 8.3 Other implantable electrical devices

For patients with HFrEF who remain symptomatic despite OMT and do not have an indication for CRT, new device therapies have been proposed and in some cases are approved for clinical use in several European Union (EU) countries but remain under trial evaluation.

Cardiac contractility modulation (CCM) is similar in its mode of insertion to CRT, but it involves non-excitatory electrical stimulation of the ventricle during the absolute refractory period to enhance contractile performance without activating extra systolic contractions. CCM has been evaluated in patients with HFrEF in NYHA Classes II–III with normal QRS duration (<120 ms). An individual patient data meta-analysis demonstrated an improvement in exercise tolerance (peak VO₂) and quality of life (Minnesota Living with Heart Failure questionnaire). Thus CCM may be considered in selected patients with HF. The effect of CCM on HF morbidity and mortality remains to be established.

Most other devices under evaluation involve some modification of the activity of the autonomic nervous system (ANS) by targeted electrical stimulation. These include vagal nerve stimulation, spinal cord stimulation, carotid body ablation and renal denervation, but so far none of the devices has improved symptoms or outcomes in RCTs.

Devices for remote monitoring are discussed in Section 14.

### 9. Treatment of heart failure with preserved ejection fraction

While there is clear agreement that the diagnosis of HFrEF requires an LVEF <40%, the exact definition of HFrEF is less clear. According to the definition provided in this document (see Section 3), the diagnosis of HFpEF requires an LVEF ≥50%, whereas patients with LVEF between 40 and 49% are considered to have HFrEF (for details, please refer to Section 3). Patients with HFrEF have generally been included in trials of HFpEF. Accordingly, the guidance in this section applies to patients with both HFrEF and HFpEF. As new data and analyses become available, it might be possible to make recommendations for each phenotype separately.

In clinical practice and clinical trials, compared with HFrEF patients, only slightly fewer patients with HFpEF and HFrEF currently appear to receive diuretics, beta-blockers, MRAs and ACEIs or ARBs. This may reflect treatment of cardiovascular co-morbidities, such as hypertension, CAD and AF, or extrapolation of results from trials conducted for these conditions showing a reduction in new-onset HF or failure to distinguish between guideline recommendations for HFrEF and HFmrEF/HFpEF or a belief that existing clinical trials provide some evidence of benefit with these agents.

A summary of phase II and III clinical trials of patients with HFpEF and HFrEF is presented in Web Table 9.1.

The pathophysiology underlying HFpEF and HFrEF is heterogeneous, and they are associated with different phenotypes including diverse concomitant cardiovascular diseases (e.g. AF, arterial hypertension, CAD, pulmonary hypertension) and non-cardiovascular diseases (diabetes, chronic kidney disease (CKD), anaemia, iron deficiency, COPD and obesity). Compared with HFrEF patients, hospitalizations and deaths in patients with HFmrEF/HFpEF are more likely to be non-cardiovascular. Therefore patients should be screened for cardiovascular and non-cardiovascular co-morbidities, which if present should be managed with interventions that have been shown to improve symptoms, well-being or outcome related to that co-morbidity and not to exacerbate HF (see Section 11).

No treatment has yet been shown, convincingly, to reduce morbidity or mortality in patients with HFpEF or HFrEF. However, since these patients are often elderly and highly symptomatic, and often have a poor quality of life, an important aim of therapy may be to alleviate symptoms and improve well-being.
9.1 Effect of treatment on symptoms in heart failure with preserved ejection fraction

Diuretics will usually improve congestion, if present, thereby improving symptoms and signs of HF. The evidence that diuretics improve symptoms is similar across the spectrum of LVEF.178,179

Evidence that beta-blockers and MRAs improve symptoms in these patients is lacking. There is inconsistent evidence for an improvement in symptoms in those treated with ARBs (only for candesartan was there an improvement in NYHA class)309,310 and ACEIs.311

9.2 Effect of treatment on hospitalization for heart failure in heart failure with preserved ejection fraction

For patients in sinus rhythm, there is some evidence that nebivolol,173,312,313 digoxin,128 spironolactone301 and candesartan310 might reduce HF hospitalizations. For patients in AF, beta-blockers do not appear to be effective and digoxin has not been studied. The evidence in support of either ARBs315 or ACEIs311 is inconclusive.

9.3 Effect of treatment on mortality in heart failure with preserved ejection fraction

Trials of ACEIs, ARBs, beta-blockers and MRAs have all failed to reduce mortality in patients with HFrEF or HFrEF. However, in older patients with HFrEF, HFrEF or HFrEF, nebivolol reduced the combined endpoint of death or cardiovascular hospitalization173,312 with no significant interaction between treatment effect and baseline LVEF.313

9.4 Other considerations

Patients in AF should receive an anticoagulant to reduce the risk of thromboembolic events (for details, see the ESC guidelines of AF176). Antiplatelet agents are ineffective for this purpose. Renal dysfunction, which is common in this population, may contraindicate or increase the risk of haemorrhage with NOACs.

The optimal ventricular rate in patients with HFrEF/HFrEF and AF is uncertain, and aggressive rate control might be deleterious. Whether digoxin, beta-blockers or rate-limiting CCBs, or a combination of these, should be preferred is unknown. Verapamil or diltiazem should not be combined with a beta-blocker. There are insufficient data to recommend ablation strategies (either pulmonary venous or AV node) for HFrEF and HFrEF.

Circumstantial evidence suggests that treating hypertension, often predominantly systolic, is important in HFrEF/HFrEF.127,317 Diuretics, ACEIs, ARBs and MRAs all appear appropriate agents, but beta-blockers may be less effective in reducing SBP. A recent study suggests that patients with hypertension and HFrEF or HFrEF should not receive an ARB (olmesartan) if they are receiving ACEIs and beta-blockers.318

The first-line oral hypoglycaemic drug for patients with HFrEF and HFrEF should be metformin317 (see also Section 11.6). Recently, a trial of empagliflozin showed a reduction in blood pressure and body weight, probably by inducing glycosuria and osmotic diuresis. Its use was associated with a reduction in hospitalization for HF and in cardiovascular mortality.130 However, aggressive management of dysglycaemia may be harmful.153,320

Myocardial ischaemia may contribute to symptoms, morbidity and mortality and should be considered when assessing patients. However, there is only anecdotal evidence that revascularization improves symptoms or outcome. Patients with angina should follow the same management route as patients with HFrEF.112

Patients with HFrEF and HFrEF have impaired exercise tolerance, commonly accompanied by an augmented blood pressure response to exercise and chronotropic incompetence. Combined endurance/resistance training appears safe for patients with HFrEF and HFrEF and improves exercise capacity (as reflected by an increase in peak oxygen consumption), physical functioning score and diastolic function.307,321

Recommendations for treatment of patients with heart failure with preserved ejection fraction and heart failure with mid-range ejection fraction

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diuretics are recommended in congested patients with HFrEF or HFrEF in order to alleviate symptoms and signs.</td>
<td>I</td>
<td>B</td>
<td>178, 179</td>
</tr>
</tbody>
</table>

HFmrEF = heart failure with mid-range ejection fraction; HFrEF = heart failure with preserved ejection fraction.
Class of recommendation.
Level of evidence.
Reference(s) supporting recommendations.

10. Arrhythmias and conductance disturbances

Ambulatory electrocardiographic monitoring can be used to investigate symptoms that may be due to arrhythmias,322-324 but evidence is lacking to support routine, systematic monitoring for all patients with HF to identify tachy- and bradyarrhythmias. There is no evidence that clinical decisions based on routine ambulatory electrocardiographic monitoring improve outcomes for patients with HF.

Ambulatory electrocardiographic recording detects premature ventricular complexes in virtually all patients with HF. Episodes of asymptomatic, non-sustained VT are common, increasing in frequency with the severity of HF and ventricular dysfunction and indicating a poor prognosis in patients with HF, but provide little discrimination between sudden death or death due to progressive HF.316,325 Bradycardia and pauses are also commonly observed, especially at night when sympathetic activity is often lower and parasympathetic activity higher; sleep apnoea may be a trigger.326-328 Pauses are associated with a poor prognosis in patients with CAD and left ventricular dysfunction.329 Bradyarrhythmias may make an important contribution to sudden death in HF.330
10.1 Atrial fibrillation

AF is the most common arrhythmia in HF irrespective of concomitant LVEF; it increases the risk of thromboembolic complications (particularly stroke) and may impair cardiac function, leading to worsening symptoms of HF. Incident HF precipitated by AF is associated with a more benign prognosis, but new-onset AF in a patient with established HF is associated with a worse outcome, probably because it is both a marker of a sicker patient and because it impairs cardiac function. Patients with chronic HF and permanent AF have a worse outcome than those in sinus rhythm, although this is largely explained by more advanced age and HF severity. Persistent ventricular rates > 150 bpm may cause HF exacerbations that resolve with rate control or rhythm correction (tachycardio-myopathy). AF should be classified and managed according to the current AF guidelines (i.e. first diagnosed episode, paroxysmal, persistent, long-standing persistent or permanent), recognizing the uncertainty about the actual duration of the episode and about previous undetected episodes.

The following issues need to be considered in patients with HF presenting with AF, irrespective of LVEF, especially with a first diagnosed episode of AF or paroxysmal AF:

- identification of potentially correctable causes (e.g. hypothyroidism or hyperthyroidism, electrolyte disorders, uncontrolled hypertension, mitral valve disease) and precipitating factors (e.g. recent surgery, chest infection or exacerbation of COPD/asthma, acute myocardial ischaemia, alcohol binge), as this may determine management strategy;
- assessment of stroke risk and need for anticoagulation;
- assessment of ventricular rate and need for rate control;
- evaluation of symptoms of HF and AF.

For details, the reader should refer to the 2016 ESC guidelines on AF.

10.1.1 Prevention of atrial fibrillation in patients with heart failure

Many treatments for HF, including ACEIs, ARBs, beta-blockers, and MRAs, will reduce the incidence of AF, but ivabradine may increase it. CRT has little effect on the incidence of AF.

Amiodarone will reduce the incidence of AF, induce pharmacological cardioversion, maintain more patients in sinus rhythm after cardioversion and may be used to control symptoms in patients with paroxysmal AF if beta-blockers fail to do so. Amiodarone should generally be restricted to short-term (< 6 months) use in patients with paroxysmal or persistent AF to help attain sinus rhythm and to reduce the high rate of recurrent AF immediately after cardioversion. Dronedarone is contraindicated in patients with HF and AF.

10.1.2 Management of new-onset, rapid atrial fibrillation in patients with heart failure

If the patient has no distressing symptoms of HF, then treatment with oral beta-blockers may be initiated to provide ventricular rate control. For patients with marked congestion who nonetheless have few symptoms at rest, initial treatment with oral or intravenous (i.v.) digoxin is preferred. For patients in haemodynamic instability, an i.v. bolus of digoxin or amiodarone should be administered into a peripheral vein with extreme care to avoid extravasation into tissues; where uncertainty exists about venous access, amiodarone must not be given. Longer-term infusion of amiodarone should be given only by central or long-line venous access to avoid peripheral vein phlebitis. In patients with haemodynamic collapse, emergency electrical cardioversion is recommended (see also Section 12).

Recommendations for initial management of a rapid ventricular rate in patients with heart failure and atrial fibrillation in the acute or chronic setting

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urgent electrical cardioversion is recommended if AF is thought to be contributing to the patient’s haemodynamic compromise in order to improve the patient clinical condition.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>For patients in NYHA Class IV, in addition to treatment for AHF, an intravenous bolus of amiodarone or, in digoxin-naive patients, an intravenous bolus of digoxin should be considered to reduce the ventricular rate.</td>
<td>Ila</td>
<td>B</td>
<td>348, 349</td>
</tr>
<tr>
<td>For patients in NYHA Class I–III, a beta-blocker, usually given orally, is safe and therefore is recommended as first-line treatment to control ventricular rate, provided the patient is euvaemic.</td>
<td>I</td>
<td>A</td>
<td>177</td>
</tr>
<tr>
<td>For patients in NYHA Class I–III, digoxin, should be considered when ventricular rate remains high despite beta-blockers or when beta-blockers are not tolerated or contra-indicated.</td>
<td>Ila</td>
<td>B</td>
<td>197</td>
</tr>
<tr>
<td>AV node catheter ablation may be considered to control heart rate and relieve symptoms in patients unresponsive or intolerant to intensive pharmacological rate and rhythm control therapy, accepting that these patients will become pacemaker dependent.</td>
<td>IIb</td>
<td>B</td>
<td>290</td>
</tr>
<tr>
<td>Treatment with dronedarone to improve ventricular rate control is not recommended due to safety concerns.</td>
<td>III</td>
<td>A</td>
<td>347</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; AHF = acute heart failure; AV = atrio-ventricular; bpm = beats per minute; HF = heart failure; NYHA = New York Heart Association. *Class of recommendation.

1. Level of evidence.

2. Reference(s) supporting recommendations.

3. The optimal ventricular rate for patients with HF and AF has not been established, but the prevailing evidence suggests that strict rate control might be deleterious. A resting ventricular rate in the range of 60–100 bpm may be considered based on the current opinion of this Task Force, although one trial suggested that a resting ventricular rate of up to 110 bpm might still be acceptable, and this is currently recommended by the ESC guidelines on AF. This should be tested and refined by further research.
ventricular rate to be assessed during rest, exercise and sleep, but the value of routine monitoring has not yet been established. Implanted devices such as pacemakers, CRT or ICDs can also be used to measure ventricular rate.

The optimal resting ventricular rate in patients with AF and HF is uncertain but may be between 60–100 bpm. One trial suggested that a resting ventricular rate of up to 110 bpm might still be acceptable. The 2016 ESC AF guidelines recommend this threshold as the target for rate control therapy. However, this Task Force believes that a lower rate for patients with HF may be preferable (60–100 bpm). Ventricular rates <70 bpm are associated with a worse outcome. This may explain why beta-blockers titrated to guideline-target doses failed to reduce morbidity or mortality in patients with HFrEF and AF. Beta-blockers reduce ventricular rate during periods of activity, while digoxin exerts a greater effect at night. Persistently high ventricular rates may indicate thyrotoxicosis or excessive sympathetic activity due to congestion, which might respond to diuretics. Although amiodarone and nondihydropyridine CCBs can reduce ventricular rate, they have more adverse effects and should generally be avoided in patients with HF. Beta-blockers reduce ventricular rate during periods of activity, while digoxin exerts a greater effect at night. Beta-blockers, digoxin and their combination may be used to control ventricular rate. 

It is uncertain which approach is optimal, but beta-blockers appear safe as the first-line agent even if it is not clear that they reduce morbidity and mortality in patients with AF. Beta-blockers reduce ventricular rate during periods of activity, while digoxin exerts a greater effect at night. Persistently high ventricular rates may indicate thyrotoxicosis or excessive sympathetic activity due to congestion, which might respond to diuretics. Although amiodarone and nondihydropyridine CCBs can reduce ventricular rate, they have more adverse effects and should generally be avoided in patients with HF. Beta-blockers reduce ventricular rate during periods of activity, while digoxin exerts a greater effect at night. Beta-blockers, digoxin and their combination may be used to control ventricular rate. 

10.1.4 Rhythm control

In patients with chronic HF, a rhythm control strategy (including pharmacological or electrical cardioversion) has not been shown to be superior to a rate control strategy in reducing mortality or morbidity. Urgent cardioversion is indicated only if the AF is life-threatening, otherwise both HF and ventricular rate should be controlled prior to cardioversion. A rhythm control strategy is probably best reserved for patients with a reversible secondary cause of AF (e.g., hyperthyroidism) or an obvious precipitant (e.g., recent pneumonia) and in patients with troublesome symptoms due to AF after optimization of rate control and HF therapy. The use of class I antiarrhythmic agents and dronedarone increases morbidity and mortality in patients with HF and AF and should be avoided. Amiodarone will cause some patients with chronic AF to revert to sinus rhythm, may reduce symptomatic paroxysms of AF and will help maintain patients in sinus rhythm after spontaneous or electrical cardioversion. When used, the need for continued administration of amiodarone should be regularly reviewed and justified.

The safety and efficacy of catheter ablation in the atria and pulmonary veins (PV) as a rhythm control strategy in HF is at present uncertain except for tachycardia induced cardiomyopathy. One small study suggested that AF ablation was superior to AV node ablation and CRT. Another study, including 203 patients with persistent AF, HF and an ICD or CRT device, showed that AF ablation was superior to amiodarone in correcting AF, and this was associated with fewer hospitalizations for HF and lower mortality. Two small studies of AF ablation compared with rate control met with mixed success in terms of procedural complications and success in improving symptoms. The most recent evidence from a meta-analysis that included 914 patients suggests an encouraging success rate of PV ablation of AF in patients with LV dysfunction, with improvements in LVEF and functional capacity. These results need to be confirmed in ongoing RCTs such as CASTLE AF, AMICA and CABANA.

### Recommendations for a rhythm control management strategy in patients with atrial fibrillation, symptomatic heart failure (NYHA II–IV) and left ventricular systolic dysfunction and no evidence of acute decompensation

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrical cardioversion or pharmacological cardioversion with amiodarone may be considered in patients with persisting symptoms and/or signs of HF, despite OMT and adequate control of ventricular rate, to improve clinical/symptomatic status.</td>
<td>IIb</td>
<td>B</td>
<td>344</td>
</tr>
<tr>
<td>AF ablation may be considered in order to restore sinus rhythm to improve symptoms in patients with persisting symptoms and/or signs of HF, despite OMT and adequate control of ventricular rate, to improve clinical/symptomatic status.</td>
<td>IIb</td>
<td>B</td>
<td>279, 363</td>
</tr>
<tr>
<td>Amiodarone may be considered prior to (and following) successful electrical cardioversion to maintain sinus rhythm.</td>
<td>IIb</td>
<td>B</td>
<td>342, 360</td>
</tr>
<tr>
<td>Dronedarone is not recommended because of an increased risk of hospital admissions for cardiovascular causes and an increased risk of premature death in NYHA Class III–IV patients.</td>
<td>III</td>
<td>A</td>
<td>247, 347</td>
</tr>
<tr>
<td>Class I antiarrhythmic agents are not recommended because of an increased risk of premature death.</td>
<td>III</td>
<td>A</td>
<td>248, 364, 365</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; HF = heart failure; NYHA = New York Heart Association, OMT = optimal medical therapy.

Patients should generally be anticoagulated for 6 weeks prior to electrical cardioversion.

*Class of recommendation.

*Level of evidence.

*Reference(s) supporting recommendations.
10.1.5 Thromboembolism prophylaxis

Patients with HF and AF should generally be anticoagulated and the balance of benefit and risk of bleeding (using CHA2DS2-VASc and HAS-BLED scores; for details, please see Web Tables 10.1 and 10.2) should be evaluated as recommended in the ESC guidelines for AF. A substantial proportion of patients with HF will have both benefit and risk scores ≥3, indicating that careful consideration should be given before prescribing an oral anticoagulant and that regular review is subsequently needed (and correctable risk factors for bleeding addressed) if an oral anticoagulant is given.

NOACs are preferred for patients with HF with non-valvular AF, as NOACs compared with vitamin K antagonists seem to be at least similarly effective and even safer (less intracranial haemorrhage) in NOACs compared with vitamin K antagonists seem to be at least similarly effective and even safer (less intracranial haemorrhage) in patients with HF than in subjects without HF, although concerns exist about their safety in older patients with HF and poor renal function.[316,366,367] However, in patients with symptomatic HF and paroxysmal or persistent/permanent AF as an alternative to an oral anticoagulant who is at high-risk both of thromboembolism and of bleeding in order to avoid the risk of haemorrhage due to anticoagulation risk.[381,382]

Recommendations for the prevention of thrombo-embolism in patients with symptomatic heart failure (NYHA Class II–IV) and paroxysmal or persistent/permanent atrial fibrillation

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class ¹</th>
<th>Level ²</th>
<th>Ref. ³</th>
</tr>
</thead>
<tbody>
<tr>
<td>The CHA2DS2-VASc and HAS-BLED scores are recommended tools in patients with HF for the estimation of the risk of thromboembolism and the risk of bleeding associated with oral anticoagulation, respectively.</td>
<td>I</td>
<td>B</td>
<td>376,377</td>
</tr>
<tr>
<td>An oral anticoagulant is recommended to prevent thrombo-embolism for all patients with paroxysmal or persistent/permanent AF and a CHA2DS2-VASc score ≥2, without contra-indications, and irrespective of whether a rate or rhythm management strategy is used (including after successful cardioversion).</td>
<td>I</td>
<td>A</td>
<td>372–375, 378,379</td>
</tr>
<tr>
<td>NOAC treatment is contra-indicated in patients with mechanical valves or at least moderate mitral stenosis.</td>
<td>III</td>
<td>B</td>
<td>380</td>
</tr>
<tr>
<td>In patients with AF of ≥48 h duration, or when the duration of AF is unknown, an oral anticoagulant is recommended at a therapeutic dose for ≥3 weeks prior to electrical or pharmacological cardioversion.</td>
<td>I</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td>Intravenous heparin or LMWH and TOE guided strategy is recommended for patients who have not been treated with an anticoagulant dose for ≥3 weeks and require urgent electrical or pharmacological cardioversion for a life threatening arrhythmia.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Combination of an oral anticoagulant and an antplatelet agent is not recommended in patients with chronic (&gt;12 months after an acute event) coronary or other arterial disease, because of a high-risk of serious bleeding. Single therapy with an oral anticoagulant is preferred after 12 months.</td>
<td>III</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>For patients with HF and non-valvular AF eligible for anticoagulation based on a CHA2DS2-VASc score, NOACs rather than warfarin should be considered for anticoagulation as NOACs are associated with a lower risk of stroke, intracranial haemorrhage and mortality, which outweigh the increased risk of gastrointestinal haemorrhage.</td>
<td>IIa</td>
<td>B</td>
<td>367</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; CHA2DS2-VASc = Congestive heart failure or left ventricular dysfunction, Hypertension, Age ≥ 75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female); HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly (1 point each); HF = heart failure; LMWH = low molecular weight heparin; NOAC = non-vitamin K antagonist oral anticoagulant; NYHA = New York Heart Association, TOE = transoesophageal echocardiography.

¹Class of recommendation.
²Level of evidence.
³Reference(s) supporting recommendations.

10.2 Ventricular arrhythmias

The initial management of asymptomatic ventricular arrhythmias is correction of electrolyte abnormalities, particularly low serum potassium and magnesium, withdrawal of agents that might provoke arrhythmias and, in patients with HFrEF, optimization of pharmacological therapy with ACEIs, beta-blockers and MRAs and sacubitril/valsartan, which all reduce the risk of sudden death.[174,177,383,384]

The clinical relevance of myocardial ischaemia for the provocation of ventricular arrhythmias is uncertain, although anecdotal cases of ischaemia-induced arrhythmias exist. Randomized trials of revascularization for patients with HFrEF have not reduced overall mortality,[107,385] even in subgroups of patients with angina or myocardial ischaemia,[115,386] but further analysis did suggest a reduction in sudden deaths.[387]

Amiodarone (often in combination with a beta-blocker) may be used to suppress symptomatic ventricular arrhythmias, but it may adversely affect prognosis, especially in patients with more severe HF.[227,246] Other antiarrhythmic drugs should be avoided.[247] Transcatheter radiofrequency modification of the arrhythmogenic substrate may reduce the number of appropriate ICD discharges and may be used to terminate arrhythmic storm in patients with...
HF and frequent, recurrent ventricular tachyarrhythmias and therefore should be considered in such patients. Seeking the advice of the members of the HF Team with expertise in electrophysiology is recommended in patients with recalcitrant ventricular arrhythmias. For further details we refer the reader to the ESC/EHRA guidelines on ventricular arrhythmias and sudden cardiac death.329

Recommendations for the management of ventricular tachyarrhythmias in heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potential aggravating/precipitating factors (e.g., low serum potassium/magnesium, ongoing ischemia) should be sought and corrected in patients with ventricular arrhythmias.</td>
<td>IIa</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Treatment with beta-blocker, MRA and sacubitril/valsartan reduces the risk of sudden death and is recommended for patients with HFrEF and ventricular arrhythmias (as for other patients)(see Section 7).</td>
<td>I</td>
<td>A</td>
<td>162, 170–175</td>
</tr>
<tr>
<td>Implantation of an ICD or CRT-D device is recommended for selected patients with HFrEF (see Section 8).</td>
<td>I</td>
<td>A</td>
<td>223–226, 388</td>
</tr>
<tr>
<td>Several strategies should be considered to reduce recurrent symptomatic arrhythmias in patients with an ICD (or in those who are not eligible for ICD), including attention to risk factors and optimal pharmacological treatment of HF; amiodarone, catheter ablation and CRT.</td>
<td>IIa</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Routine use of antiarrhythmic agents is not recommended in patients with HF and asymptomatic ventricular arrhythmias because of safety concerns (worsening HF, proarrhythmia, and death).</td>
<td>III</td>
<td>A</td>
<td>247, 248, 364, 365</td>
</tr>
</tbody>
</table>

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CRT = cardiac resynchronization therapy; CRT-D = defibrillator with cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter defibrillator; MRA = mineralocorticoid receptor antagonist.

Class of recommendation.
Level of evidence.
Reference(s) supporting recommendations.

AC= atrial fibrillation; AV = atrio-ventricular; bpm = beats per minute; CRT = cardiac resynchronization therapy; ECG = electrocardiogram; HFrEF = heart failure with reduced ejection fraction; RV = right ventricular.

Recommendations for the management of bradyarrhythmias in heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td>When pauses &gt;3 seconds are identified on the ECG, or if the bradyarrhythmia is symptomatic and the resting ventricular rate is &lt;50 bpm in sinus rhythm or &lt;60 bpm in AF, it should be considered whether there is need for any rate limiting medications prescribed; for patients in sinus rhythm beta-blockers should be reduced in dose or withdrawn only as a last resort.</td>
<td>IIa</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>For patients with symptomatic, prolonged or frequent pauses despite adjustment of rate limiting medication, either beta-blocker withdrawal or pacing may be considered as the next step.</td>
<td>IIb</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Pacing solely to permit initiation or titration of beta-blocker therapy in the absence of a conventional pacing indication is not recommended.</td>
<td>III</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>In patients with HFrEF who require pacing and who have high degree AV block, CRT rather than RV pacing is recommended.</td>
<td>I</td>
<td>A</td>
<td>274, 275, 290</td>
</tr>
<tr>
<td>In patients with HFrEF who require pacing who do not have high degree AV block, pacing modes that avoid inducing or exacerbating ventricular dyssynchrony should be considered.</td>
<td>IIa</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

10.3 Symptomatic bradycardia, pauses and atrio-ventricular block

The ESC Guidelines on Pacing and CRT recommended intervention when pauses exceed 6 s, even when this is not associated with symptoms.389 However, these recommendations were generated mainly for patients without obvious myocardial dysfunction, and shorter pauses might require intervention in patients with HFrEF.329 If pauses >3 s are identified on electrocardiographic monitoring, medications should be reviewed and the following agents stopped or reduced in dose, starting with rate-limiting CCBs then amiodarone, digoxin and ivabradine. For patients in AF, a reduction in the dose of beta-blockers allowing the daytime resting ventricular rate to rise to 70–90 bpm may be considered, since evidence that beta-blockers improve outcome in patients with AF is lacking.327 For patients with pauses but in sinus rhythm, a reduction in the dose of beta-blockers should be avoided unless the pauses are symptomatic, prolonged or frequent, in which case the relative merits of dose reduction, beta-blocker withdrawal and (biventricular) pacing may be considered. However, evidence is lacking to support a strategy of pacing solely to permit initiation or titration of beta-blocker therapy in the absence of a conventional pacing indication; this strategy is not recommended. For patients with HFrEF and high-degree AV block, CRT is preferred over RV pacing (Section 8.2). When the cause of bradycardia or pauses is sinus node disease with intact AV conduction, then therapeutic strategies that avoid inducing ventricular dysynchrony are preferred, although clinical trial evidence to support this expert opinion for patients with HF is sparse. For other pacing indications, please consult the ESC Guidelines on Pacing and CRT.389
11. Co-morbidities

11.1. Heart failure and co-morbidities

Co-morbidities are of great importance in HF (Table 11.1) and may affect the use of treatments for HF (e.g. it may not be possible to use renin–angiotensin system inhibitors in some patients with severe renal dysfunction) (see Section 7). The drugs used to treat co-morbidities may cause worsening of HF (e.g. NSAIDs given for arthritis, some anti-cancer drugs) (see Section 7). Management of co-morbidities is a key component of the holistic care of patients with HF (see Section 14). Many co-morbidities are actively managed by specialists in the field of the co-morbidity, and these physicians will follow their own specialist guidelines. The current guidelines will identify where the presence of HF should change the way a co-morbidity would normally be treated. This may be because either safety or efficacy may be different in the presence of HF (or may simply be unknown) or because of evidence of particular effects in an HF population, either beneficial or detrimental. HFrEF has an even higher prevalence of co-morbidities compared with HFrEF, and many of these may be instrumental in the progression of this syndrome. 218

11.2 Angina and coronary artery disease

11.2.1 Pharmacological management

Beta-blockers, and in selected patients ivabradine, 180 are effective agents for angina control, as well as an essential component of HFrEF therapy. In HFrEF patients, they may also be used for angina relief, although this has never been formally tested. 399

Trimetazidine has been shown to exert some beneficial effect as an add-on to beta-blockers in patients with HF and angina. 100–406 There are data suggesting that it may improve NYHA functional capacity, exercise duration and LV function in patients with HFrEF. 402–406 Certain other effective anti-anginal drugs have been studied in sizeable numbers of HFrEF/LV dysfunction patients and shown to be safe [e.g. amiodipine, 215,407 nicorandil, 408 and nitrates 183,184,409]. The safety of other anti-anginal agents in HFrEF, such as ranolazine, is uncertain, while other drugs, specifically dilatiazem and verapamil, are thought to be unsafe in patients with HFrEF (although they may be used in HFrEF). 216 Dihydropyridine CCBs may all increase sympathetic tone, and their safety in HFrEF [except amiodipine 215 and felodipine 214] and HFrEF is uncertain.

11.2.2 Myocardial revascularization

For indications for invasive coronary angiography in patients with HF, please refer to Section 5.8.

Percutaneous and surgical revascularization are complementary approaches for symptomatic relief of angina in HFrEF, but whether these interventions improve outcomes is not entirely clear. Recent ESC guidelines on myocardial revascularization recommended coronary artery bypass grafting (CABG) for patients with significant left main stenosis and left main equivalent (proximal stenosis of both the left anterior descending and left circumflex arteries) to improve prognosis. 112,113 However, one needs to be aware of a lack of studies including patients who have well-defined HF, therefore this recommendation is solely based on expert opinion. On the basis of the results of the STICH trial [which excluded patients with left main disease and Canadian Cardiovascular Society (CCS) angina classes III–IV], CABG is also recommended in patients with HFrEF, significant CAD (left anterior descending artery or multivessel disease) and LVEF ≤35% to reduce death and hospitalization for cardiovascular causes. 185 Patients with >10% dysfunctional but viable LV myocardium may be more likely to benefit from myocardial revascularization (and those with <10% are less likely to benefit), although this approach to patient selection for revascularization is unproven. In the STICH trial, neither the presence of viability nor the severity of LV remodelling identified those who benefited from CABG in terms of a reduction in mortality. 118 For the assessment of techniques to assess myocardial viability, please refer to Section 5. Post hoc analyses from the STICH trial revealed that the presence of inducible myocardial ischaemia (either on radionuclide stress test or dobutamine stress echocardiogram) or angina does not identify those with worse prognosis and greater benefit from CABG over OMT. 115,386 However, CABG does improve angina to a greater extent than medical therapy alone.

The choice between CABG and PCI should be made by the Heart Team after careful evaluation of the patient’s clinical status and coronary anatomy, expected completeness of revascularization, coexisting valvular disease and co-morbidities.

**Table 11.1 Importance of co-morbidities in patients with heart failure**

| 1. interfere with the diagnostic process of HF (e.g. COPD as a potentially confounding cause of dyspnoea). 202–204 |
| 2. aggravate HF symptoms and further impair quality of life. 211,212 |
| 3. contribute to the burden of hospitalizations and mortality, 235 as the main cause of readmissions at 1 and 3 months. 216 |
| 4. may affect the use of treatments for HF (e.g. renin–angiotensin system inhibitors contra-indicated in some patients with severe renal dysfunction or beta-blockers relatively contra-indicated in asthma). 215,216 |
| 5. evidence base for HF treatment is more limited as co-morbidities were mostly an exclusion criterion in trials; efficacy and safety of interventions is therefore often lacking in the presence of co-morbidities. |
| 6. drugs used to treat co-morbidities may cause worsening HF (e.g. NSAIDs given for arthritis, some anti-cancer drugs). 235,236 |
| 7. interaction between drugs used to treat HF and those used to treat co-morbidities, resulting in lower efficacy, poorer safety, and the occurrence of side effects (e.g. beta-blockers for HFrEF and beta-agonists for COPD and asthma). 235,236 |

HF = heart failure; COPD = chronic obstructive pulmonary disease; HFrEF = heart failure with reduced ejection fraction; NSAIDs = non-steroidal anti-inflammatory drugs.
11.3 Cachexia and sarcopenia (for frailty, please refer to Section 14)

Cachexia is a generalized wasting process affecting all body compartments [i.e. lean tissue (skeletal muscle), fat tissue (energy reserves) and bone tissue (osteoporosis)]. It may occur in 5–15% of patients with HF, especially those with HFrEF, and more advanced disease status. 414–416 This serious complication is associated with more severe symptoms and reduced functional capacity, more frequent hospitalization and decreased survival. Cachexia in HF can be diagnosed and defined as involuntary non-oedematous weight loss ≥6% of total body weight within the previous 6–12 months. 414–417

The causes are multifactorial, and in individual patients they are difficult to determine. These may include pro-inflammatory immune activation, neurohormonal derangements, poor nutrition and malabsorption, impaired calorie and protein balance, anabolic hormone resistance, reduced anabolic drive, prolonged immobilization and physical deconditioning, together characterized by catabolic/anabolic imbalance. 418 Skeletal muscle wasting, when associated with impaired mobility and symptoms (termed sarcopenia or myopenia), occurs in 30–50% of patients with HFrEF. 419 In its most severe form it is associated with frailty and poor morbidity and mortality. 420

Potential treatments may include appetite stimulants, exercise training 421 and anabolic agents, including testosterone, in combination with the application of nutritional supplements and anti-catabolic interventions, although none is of proven benefit and their safety is unknown. 421

11.4 Cancer

Certain chemotherapeutic agents can cause (or aggravate) LV systolic dysfunction and HF. The best recognized of these are the
anthracyclines (e.g. doxorubicin), trastuzumab and tyrosine kinase inhibitors. A recent Cochrane review found that dexrazoxane may confer some cardioprotection in patients receiving anthracyclines. Pre- and post-evaluation of LVEF, if available with myocardial strain imaging, is essential in patients receiving cardiotoxic chemotherapy, as detailed elsewhere. A risk score for identifying women with breast cancer at risk of developing HF during trastuzumab therapy has been developed based on age, chemotherapy details, baseline cardiovascular status and other co-morbidities, and may be helpful. Chemotherapy should be discontinued and HFrEF therapy commenced in patients developing moderate to severe LV systolic dysfunction. If LV function improves, the risks and benefits of further chemotherapy need to be reconsidered. Mediastinal irradiation can also lead to a variety of long-term cardiac complications. Cardiac biomarkers (NPs and troponins) can be used to identify patients at higher risk of cardiotoxicity and may be helpful in monitoring the use and dosing of cardiotoxic cytotoxics.

11.5 Central nervous system (including depression, stroke and autonomic dysfunction)

Stroke and HF commonly coexist because of an overlap of shared risk factors. Both contribute to a worse prognosis. Stroke may make self-care more difficult for the HF patient. Management of high-risk stroke patients may require balancing the risk of anticoagulant and antiplatelet therapies. Autonomic dysfunction is common in HFrEF, especially when severe. Combined with low blood pressure, it can make fainting and injuries more likely and can interfere with optimal dosing of beta-blockers, ACEIs, ARBs and MRAs. Diuretic dosage may be reduced to reduce the severity of postural hypotension.

Depression is common and is associated with worse clinical status and a poor prognosis in HF. It may also contribute to poor adherence and social isolation. A high index of suspicion is needed to make the diagnosis, especially in the elderly. Routine screening using a validated questionnaire is good practice. Until now, the Beck Depression Inventory (BDI) and Cardiac Depression Questionnaire have been formally validated as reliable tools for the assessment of depressive mood in patients with HF, but other questionnaires have been broadly used in this group of patients (e.g. Geriatric Depression Scale, Hamilton Depression Scale, Hospital Anxiety and Depression Scale).

Psychosocial intervention and pharmacological treatment are helpful, as well as exercise training, in patients with HFrEF and depression. Cognitive behavioural therapy delivered in patients with HF and major depression beyond standard care and a structured education programme were able to reduce depression severity, anxiety and fatigue symptoms, as well as improve social functioning and mental and HF-related quality of life. Selective serotonin reuptake inhibitors are thought to be safe, although the Sertraline Antidepressant Heart Attack Randomized Trial did not confirm that sertraline provides a greater reduction in depressive symptoms or improvement in cardiovascular status compared with placebo in HFrEF patients, but this trial was not powered enough to prove the latter. Similarly, escitalopram had no effect on either depression or clinical outcomes during the 24-month follow-up as compared with placebo in patients with HFrEF and depression. Importantly, tricyclic antidepressants should be avoided, because they may cause hypotension, worsening HF and arrhythmias.

11.6 Diabetes

Dysglycaemia and diabetes are very common in HF, and diabetes is associated with poorer functional status and worse prognosis. In patients with HFrEF, interventions that reduce morbidity and mortality confer similar benefit in the presence or absence of diabetes. For instance, beta-blockers improve outcome similarly, whether or not the patient has diabetes, although different beta-blockers may vary in their effects on glycaemic indices.

Whether strict glycaemic control alters the risk of cardiovascular events in patients with HF is uncertain. Among patients with HF who have not been treated for diabetes, higher HbA1c is associated with greater risk of cardiovascular events, but this may not be the case once treatment for diabetes has been commenced.

In patients with diabetes and HF, glycaemic control should be implemented gradually and moderately, giving preference to those drugs, such as metformin, that have been shown to be safe and effective. In contrast to what was previously believed, metformin is safe to use in patients with HFrEF, and it should be the treatment of choice in patients with HF but is contraindicated in patients with severe renal or hepatic impairment, because of the risk of lactic acidosis.

Insulin is required for patients with type 1 diabetes and to treat symptomatic hyperglycaemia in patients with type 2 diabetes and pancreatic islet cell exhaustion. However, insulin is a powerful sodium-retaining hormone, and when combined with a reduction in glycosuria, may exacerbate fluid retention, leading to HF worsening. Sulphonylurea derivatives have also been associated with an increased risk of worsening HF and should be used with caution.

Thiazolidinediones (glitazones) cause sodium and water retention and increased risk of worsening HF and hospitalization and are not recommended in patients with HF. Dipeptidylpeptidase-4 inhibitors (DPP4is; gliptins), which increase incretin secretion, thereby stimulating insulin release, and long-acting glucagon-like peptide 1 (GLP-1) receptor agonists, which act as incretin mimetics, improve glycaemic indices but do not reduce and may increase the risk of cardiovascular events and worsening HF. Importantly, there are no data on the safety of gliptins and GLP-1 analogues in patients with HF.

Recently, empagliflozin, an inhibitor of sodium-glucose co-transporter 2, reduced hospitalization for HF and mortality, but not myocardial infarction or stroke, in patients with diabetes at high cardiovascular risk, some of whom had HF. In the absence of other studies with drugs from this group, the results obtained with empagliflozin cannot be considered as a proof of a class effect.

ESC Guidelines
As glycaemic derangement progresses, the judgement on glycaemic control should be made according to cardiac conditions, and if the new anti-diabetic drugs are to be prescribed, they have to be closely monitored by an HF team.

11.7 Erectile dysfunction
Erectile dysfunction is a common and important component of quality of life in men with HF. Its treatment should include optimal therapies for underlying cardiovascular diseases and other interfering co-morbidities (e.g. diabetes) and amelioration of anxiety and depressive symptoms. Some drugs applied for HF therapy (e.g. thiazide diuretics, spironolactone and beta-blockers) may augment erectile dysfunction. Phosphodiesterase type 5 inhibitors (PDE5Is) have been shown to have favourable haemodynamic and anti-remodelling effects and to improve exercise capacity and quality of life in patients with HFrEF, but they are contraindicated in patients taking nitrates.

11.8 Gout and arthritis
Hyperuricaemia and gout are common in HF and may be caused or aggravated by diuretic treatment. Hyperuricaemia is associated with a worse prognosis in HFrEF. The current European League Against Rheumatism (EULAR) guideline for the management of gout recommends that urate-lowering therapy (ULT) is indicated in patients with recurrent acute flares, arthropathy, tophi or radiographic changes of gout, aiming to maintain a serum urate level below the saturation point for monosodium urate. Xanthine oxidase inhibitors (allopurinol, oxypurinol) may be used to prevent gout, although their safety in HFrEF is uncertain. Gout attacks are better treated with colchicine rather than with NSAIDs (although colchicine should not be used in patients with very severe renal dysfunction and may cause diarrhoea). Intra-articular corticosteroids are an alternative for monoarticular gout, but systemic corticosteroids cause sodium and water retention.

Arthritis is a common co-morbidity and is a common cause of both self-taken and prescribed drugs that can worsen renal function and HF, especially NSAIDs. Rheumatoid arthritis is associated with an increased risk of HFrEF. The safety of disease-modifying drugs commonly given to patients with rheumatoid arthritis has not been established in HF.

11.9 Hypokalaemia and hyperkalaemia
Both hypokalaemia and hyperkalaemia are associated with HF and with many drugs used for HF treatment. Both can aggravate ventricular arrhythmias. Loop and thiazide diuretics reduce serum potassium, while ACEIs, ARBs and MRAs can all increase serum potassium. Amiloride and triamterene are sometimes used as adjunct diuretics in resistant oedema and to assist in preventing hypokalaemia. The treatment of hypokalaemia can involve recommending high potassium foods or prescribing potassium supplements.

The management of acute hyperkalaemia (>6.0 mmol/L) may require a short-term cessation of potassium-retaining agents and RAAS inhibitors, but this should be minimized and RAAS inhibitors should be carefully reintroduced as soon as possible while monitoring potassium levels. A Cochrane review found no trial evidence of major outcome benefits for any emergency therapy regimen for hyperkalaemia. Two new potassium binders (patiromer and sodium zirconium cyclosilicate) are currently under consideration for regulatory approval. Initial results from patients with HF are available and confirm the efficacy of these therapies in reducing serum potassium and preventing recurrent hyperkalaemia in patients with HF and CKD in the context of treatment with RAAS inhibitors.

11.10 Hyperlipidaemia
Elevated low-density lipoprotein cholesterol is uncommon in HFrEF; patients with advanced HFrEF often have low concentrations of low-density lipoprotein, which is associated with a worse prognosis. Rosuvastatin did not reduce the primary composite mortality/morbidity endpoints in two large RCTs in patients with HF with or without IHD, but it also did not increase risk, and may have reduced, hospitalizations. Therefore there is no evidence to recommend the initiation of statins in most patients with HF. However, in patients who are already receiving a statin for CAD, a continuation of this therapy may be considered.

11.11 Hypertension
Hypertension is associated with an increased risk of developing HF; antihypertensive therapy markedly reduces the incidence of HF (with an exception of α-adrenoceptor blockers, which are less effective than other antihypertensives in preventing HF). A recent prospective cohort study documented that in a population with incident HF, higher baseline systolic, diastolic and pulse pressure levels were associated with a higher rate of adverse events, which further supports the importance for optimized blood pressure control in this population. Blood pressure control is an element of the holistic management of patients with HF.

Negatively inotropic CCBs (i.e. diltiazem and verapamil) should not be used to treat hypertension in patients with HFrEF (but are believed to be safe in HfPEF), and moxonidine should also be avoided in patients with HFrEF, as it increased mortality in patients in one RCT. If blood pressure is not controlled with an ACEI (or an ARB), a beta-blocker, an MRA and a diuretic, then hydralazine and amlodipine [or felodipine] are additional blood pressure lowering agents that have been shown to be safe in systolic HF. The blood pressure targets recommended in hypertension guidelines are applicable to HF. Uncontrolled hypertension in patients with HFrEF is very rare, provided they are optimally treated for HF. In contrast, treatment of hypertension is an important issue in patients with HfPEF. In patients with AHF, i.e. nitrates (or sodium nitroprusside) are recommended to lower blood pressure (see Section 12).
11.12 Iron deficiency and anaemia

Iron deficiency is common in HF, as it is with other chronic illnesses, and it can lead to anaemia and/or skeletal muscle dysfunction without anaemia. Within an HF population, iron deficiency is associated with a worse prognosis. Intravenous iron has been specifically studied in two RCTs in patients with HF and iron deficiency (serum ferritin < 100 µg/L or ferritin between 100 and 299 µg/L and transferrin saturation < 20%) both with and without anaemia. Intravenous ferric carboxymaltose (FCM) has been shown to improve self-reported patient global assessment, quality of life and NYHA class (over 6 months) in the FAIR-HF trial both in anaemic and non-anaemic patients with HF, and in the CONFIRM-HF trial, exercise capacity improved over 24 weeks. In the analysis of secondary endpoints in the CONFIRM-HF trial, i.v. iron reduced the risk of HF hospitalizations in iron-deficient patients with HFrEF. A meta-analysis of i.v. iron therapy in HFrEF patients with iron deficiency over up to 52 weeks showed reduced hospitalization rates and improved HF symptoms, exercise capacity and quality of life. Treatment with FCM may therefore result in sustainable improvement in functional capacity, symptoms and quality of life. Treatment was also associated with a significant reduction in hospitalizations for worsening HF. The number of deaths and the incidence of adverse events were similar. Neither i.v. iron trial was powered to test for an effect on major outcomes or to evaluate separately the effects in anaemic and non-anaemic patients. The effect of treating iron deficiency in HFpEF/HFmrEF and the long-term safety of iron therapy in either HFrEF, HFmrEF or HFpEF is unknown.

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; HF = heart failure; HFrEF = heart failure with mid-range ejection fraction; HFrEF = heart failure with reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; NYHA = New York Heart Association.

Class of recommendation.

Level of evidence.

Reference(s) supporting recommendations.

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE-I (or ARB), a beta-blocker or an MRA (or a combination) is recommended to</td>
<td>I</td>
<td>A</td>
<td>2, 164, 165, 167, 168, 171–174, 182, 461–463</td>
</tr>
<tr>
<td>reduce blood pressure as first-, second- and third-line therapy, respectively</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>because of their associated benefits in HFrEF (reducing the risk of death and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF hospitalization). They are also safe in HFpEF.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Step 2</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A thiazide diuretic (or if the patient is being treated with a thiazide</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>diuretic, switching to a loop diuretic) is recommended to reduce blood pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>when hypertension persists despite treatment with a combination of an ACE-I (or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>alternatively ARB but NOT together with ACE-I), a beta-blocker and an MRA.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Step 3</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amlodipine or hydralazine is recommended to reduce blood pressure when</td>
<td>I</td>
<td>A</td>
<td>183, 184, 215, 409</td>
</tr>
<tr>
<td>hypertension persists despite treatment with a combination of an ACE-I (or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>alternatively ARB but NOT together with ACE-I), a beta-blocker, an MRA and a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>diuretic.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Felodipine should be considered to reduce blood pressure when hypertension</td>
<td>IIa</td>
<td>B</td>
<td>216</td>
</tr>
<tr>
<td>persists despite treatment with a combination of an ACE-I (or alternatively ARB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>but NOT together with ACE-I), a beta-blocker, an MRA and a diuretic.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moxonidine is not recommended to reduce blood pressure because of safety</td>
<td>III</td>
<td>B</td>
<td>460</td>
</tr>
<tr>
<td>concerns in HFrEF patients (increased mortality).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alpha-adrenoceptor antagonists are not recommended to reduce blood pressure</td>
<td>III</td>
<td>A</td>
<td>458, 464, 465</td>
</tr>
<tr>
<td>because of safety concerns in HFrEF patients (neurohormonal activation, fluid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>retention, worsening HF).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diltiazem and verapamil are not recommended to reduce blood pressure in patients</td>
<td>III</td>
<td>C</td>
<td>214</td>
</tr>
<tr>
<td>with HFrEF because of their negative inotropic action and risk of worsening HF.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

11.12 Iron deficiency and anaemia

Iron deficiency is common in HF, as it is with other chronic illnesses, and it can lead to anaemia and/or skeletal muscle dysfunction without anaemia. Within an HF population, iron deficiency is associated with a worse prognosis. Intravenous iron has been specifically studied in two RCTs in patients with HF and iron deficiency (serum ferritin < 100 µg/L or ferritin between 100 and 299 µg/L and transferrin saturation < 20%) both with and without anaemia. Intravenous ferric carboxymaltose (FCM) has been shown to improve self-reported patient global assessment, quality of life and NYHA class (over 6 months) in the FAIR-HF trial both in anaemic and non-anaemic patients with HF, and in the CONFIRM-HF trial, exercise capacity improved over 24 weeks. In the analysis of secondary endpoints in the CONFIRM-HF trial, i.v. iron reduced the risk of HF hospitalizations in iron-deficient patients with HFrEF. A meta-analysis of i.v. iron therapy in HFrEF patients with iron deficiency over up to 52 weeks showed reduced hospitalization rates and improved HF symptoms, exercise capacity and quality of life. Treatment with FCM may therefore result in sustainable improvement in functional capacity, symptoms and quality of life. Treatment was also associated with a significant reduction in hospitalizations for worsening HF. The number of deaths and the incidence of adverse events were similar. Neither i.v. iron trial was powered to test for an effect on major outcomes or to evaluate separately the effects in anaemic and non-anaemic patients. The effect of treating iron deficiency in HFpEF/HFmrEF and the long-term safety of iron therapy in either HFrEF, HFmrEF or HFpEF is unknown. The safety of i.v. iron is unknown in patients with HF and haemoglobin > 15 g/dL. Patients with iron deficiency need to be screened for any potentially treatable/reversible causes (e.g. gastrointestinal sources of bleeding).
Anaemia (defined as a haemoglobin concentration < 13.0 g/dL in men and < 12.0 g/dL in women) is common in HF, particularly in hospitalized patients. It is more common in women, the elderly, and in patients with renal impairment and is associated with advanced myocardial remodelling, inflammation and volume overload. Anaemia is associated with advanced symptoms, worse functional status, greater risk of HF hospitalization and reduced survival. A diagnostic workup to seek a cause for any finding of anaemia is indicated (e.g. occult blood loss, iron deficiency, B12/folate deficiency, blood dyscrasias), although in many patients no specific cause is found. The erythropoietin-stimulating agent darbepoetin alfa did not improve clinical outcomes in HFrEF patients with mild to moderate anaemia, but led to an excess of thromboembolic events and is therefore not recommended.375

11.13 Kidney dysfunction (including chronic kidney disease, acute kidney injury, cardio-renal syndrome and prostatic obstruction)

HF and CKD frequently coexist, share many risk factors (diabetes, hypertension, hyperlipidaemia) and interact to worsen prognosis.376,477 CKD is generally defined as an eGFR < 60 mL/min/1.73 m² and/or the presence of albuminuria (high 30–300 or very high > 300 mg albumin/1 g of urine creatinine). Patients with severe renal dysfunction (eGFR < 30 mL/min/1.73m²) have systematically been excluded from randomized clinical trials and therefore there is lack of evidence-based therapies in these patients.

A further deterioration in renal function, termed worsening renal function (WRF), is used to indicate an increase in serum creatinine, usually by > 26.5 µmol/L (0.3 mg/dL) and/or a 25% increase or a 20% drop in GFR. The importance of these apparently small changes is that they are frequent, they promote the development and progression of CKD378 and, as a consequence, can worsen the prognosis of HF. Increases in creatinine during an AHF hospitalization are not always clinically relevant, especially when they are accompanied by appropriate decongestion, diuresis and haemoconcentration.479

Large increases in serum creatinine, termed acute kidney injury (AKI), are relatively rare in HF and are probably associated with the combination of diuretic therapy with other potentially nephrotoxic drugs such as some antibiotics (gentamicin and trimethoprim), contrast media, ACEIs, ARBs, NSAIDs, etc. Of relevance, some of these drugs may accumulate if they are renally excreted. In HF, WRF is relatively common, especially during initiation and up-titration of RAAS inhibitor therapy. Despite the fact that RAAS blockers can frequently cause a decrease in GFR in patients with HF, this reduction is usually small and should not lead to treatment discontinuation unless there is a marked decrease, as the treatment benefit in these patients is probably largely maintained.480 When large increases in serum creatinine occur, care should be taken to evaluate the patient thoroughly and should include assessment of a possible renal artery stenosis, excessive hyper- or hypovolaemia, concomitant medication and hyperkalaemia, which frequently coincides with WRF.

Diuretics, especially thiazides, but also loop diuretics, may be less effective in patients with a very low GFR, and if used, should be dosed appropriately (higher doses to achieve similar effects). Renally excreted drugs (e.g. digoxin, insulin and low molecular weight heparin) may accumulate in patients with renal impairment and may need dose adjustment if renal function deteriorates. Patients with HF and coronary or peripheral vascular disease are at risk of acute renal dysfunction when they undergo contrast media enhanced angiography [contrast-induced acute
kidney injury (CI-AKI). Renal dysfunction and worsening renal function is further discussed in the section about AHF (see Section 12).

Prostatic obstruction is common in older men and can interfere with renal function; it should therefore be ruled out in men with HF with deteriorating renal function. Alpha-adrenoceptor blockers cause hypotension and sodium and water retention, and may not be safe in HFrEF. For these reasons, 5-alpha-reductase inhibitors are generally preferred in the medical treatment of prostatic obstruction in patients with HF.

11.14 Lung disease (including asthma and chronic obstructive pulmonary disease)
The diagnosis of COPD and asthma may be difficult in patients with HF, due to overlap in symptoms and signs, but also problems in the interpretation of spirometry, especially in HFrEF. COPD (and asthma) in patients with HF may be overdiagnosed. Spirometry should be performed when patients have been stable and euolemic for at least 3 months, to avoid the confounding effect of pulmonary congestion causing external obstruction of alveoli and bronchioles. Both correctly and incorrectly labelled COPD are associated with worse functional status and a worse prognosis in HFrEF.

Beta-blockers are only relatively contraindicated in asthma, but not in COPD, although a more selective beta-adrenoceptor antagonist (i.e. bisoprolol, metoprolol succinate, or nebivolol) is preferred. The contraindication to beta-blockers in asthma, as mentioned on pharmacy leaflets, is based on small case series published in the 1980s and late 1990s with very high initial dosages in young patients with severe asthma. In clinical practice, starting with low doses of cardioselective beta-blockers combined with close monitoring for signs of airway obstruction (wheezeing, shortness of breath with lengthening of the expiration) may allow the use of profoundly effective beta-blockers in HFrEF, especially in older people where true severe asthma is uncommon. Therefore, according to the 2015 GINA global strategy report, asthma is not an absolute contraindication, but these medications should only be used under close medical supervision by a specialist, with consideration of the risks for and against their use. The long-term safety of cardioactive inhaled pulmonary drugs is uncertain and the need for their use should be reconsidered in patients with HFrEF, especially as their benefit in asthma and COPD may be symptomatic only without a clear effect on mortality. Oral corticosteroids can cause sodium and water retention, potentially leading to worsening of HF, but this is not believed to be a problem with inhaled corticosteroids. Pulmonary hypertension can complicate severe long-standing COPD, which, as a result, makes right-sided HF and congestion more likely. Non-invasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary oedema.

11.15 Obesity
Obesity is a risk factor for HF and complicates its diagnosis, because it can cause dyspnoea, exercise intolerance and ankle swelling and may result in poor-quality echocardiographic images. Obese individuals also have reduced NP levels. Obesity is more common in HFrEF than in HFrEF, although it is possible that misdiagnosis may explain at least some of this difference in prevalence. Although obesity is an independent risk factor for developing HF, once HF is diagnosed, it is well established that obesity is associated with lower mortality across a wide range of body mass indexes (BMIs) (see also cachexia in Section 11.3)—the so-called obesity paradox also seen in other chronic illnesses. Obesity should be managed as recommended in the ESC guidelines on cardiovascular disease prevention, if the aim is to prevent future development of HF. However, these guidelines do not refer to the HF patient in whom higher BMI is not adverse, and, although often recommended for symptom benefit and risk factor control, weight loss as an intervention has never been prospectively shown to be either beneficial or safe in HFrEF. When weight loss is occurring in HF, it is associated with high mortality and morbidity, worse symptom status and poor quality of life. In patients with HF with moderate degrees of obesity (BMI <35 kg/m²), weight loss cannot be recommended. In more advanced obesity (BMI 35–45 kg/m²), weight loss may be considered to manage symptoms and exercise capacity.

11.16 Sleep disturbance and sleep-disordered breathing
Sleep-disordered breathing (SDB) occurs in more than one-third of patients with HF, being even more prevalent in patients with AHF. The most common types are: central sleep apnoea (CSA, similar to Cheyne Stokes respiration, CSR), obstructive sleep apnoea (OSA), and a mixed pattern of the two. Other causes of sleep disturbance include anxiety, depression, decubitus or paroxysmal pulmonary congestion (orthopnoea and paroxysmal nocturnal dyspnoea) and diuretic therapy causing nocturnal diuresis. Reviewing sleep history (including asking a partner) is part of the holistic care of patients with HF (see Section 14). CSA and OSA have been shown to be associated with a worse prognosis in HF. OA is associated with an increased risk of incident HF in men. CSA is the most common form of SDB in HFrEF, and HFrEF is the most common cause of CSA, so they are closely linked. Screening for, and the diagnosis and treatment of, sleep apnoea is discussed in detail elsewhere. Diagnosis used to require overnight polysomnography, although advanced home testing equipment which can distinguish the type of sleep apnoea has been developed.

Nocturnal oxygen supplementation, continuous positive airway pressure (CPAP), bi-level positive airway pressure (BiPAP), and adaptive servo-ventilation (ASV) may be considered to treat nocturnal hypoxaemia in OSA as recommended in other guidelines. An apnoea/hypopnoea index (AHI) of above 30 per hour can be treated using any of CPAP, BiPAP, ASV and nocturnal oxygen supplementation, which have all been shown to be effective in this regard. It should be noted, however, that none of these interventions has been prospectively shown to be beneficial on major outcomes in HFrEF. CPAP in HF related CSA has been shown to reduce the frequency of episodes of apnoea and hypopnoea, and improve LVEF and 6 minute walk test distance, but did not improve prognosis or the rate of HF related hospitalizations.

The recently published SERVE-HF trial has shown that ASV used in patients with HFrEF and a predominantly CSA was neutral regarding the composite primary endpoint (all-cause death, lifesaving cardiovascular intervention, i.e. cardiac transplantation, implantation of a ventricular assist device, resuscitation after sudden cardiac arrest, or appropriate lifesaving shock, or unplanned hospitalization for HF worsening), but more importantly led to an increase in both all-cause and cardiovascular mortality. Therefore ASV is not recommended in patients with HFrEF and predominantly CSA.
The safety and efficacy of alternative approaches to treating CSA in HFrEF patients, such as implantable phrenic nerve stimulation, are presently undergoing clinical investigation and may require additional long term study.

11.17. Valvular heart disease

Valvular heart disease may cause or aggravate HF. This section briefly addresses problems particularly relevant to HF, and the reader is referred to the recent guidelines on valvular disease for more information.

Patients with HF and concomitant valvular heart disease constitute a high-risk population. Thus, the whole process of decision-making should be based on a multidisciplinary approach with the involvement of specialists, anaesthetists and, if needed, general practitioners, geriatricians, or intensive care specialists. This may be particularly beneficial in patients with HF being considered for surgery, transcatheter aortic valve implantation or transcatheter mitral valve intervention.

All patients should receive OMT. In those with HFrEF pharmacological therapy should be planned according to a previously described algorithm (see Section 7 for details). Care must be taken using vasodilators (ACEI, ARBs, CCBs, hydralazine, and nitrates) in patients with severe aortic stenosis in order not to cause hypotension.

11.17.1. Aortic stenosis

The main concern in patients with severe aortic stenosis and reduced LVEF is the entity of ‘low-flow, low-gradient’ aortic stenosis (valve area < 1 cm², LVEF < 40%, mean pressure gradient < 40 mmHg). In such individuals, low-dose dobutamine stress echocardiography should be considered to differentiate between patients with moderate aortic stenosis, and those with severe stenosis and low flow across the valve due to low stroke volume, and to evaluate for contractile or flow reserve.

If the mean gradient is > 40 mmHg, there is theoretically no lower LVEF limit for aortic valve replacement in symptomatic patients with severe aortic stenosis.

Transcatheter valve implantation (TAVI) is recommended in patients with severe aortic stenosis who are not suitable for surgery as assessed by a ‘heart team’ and have predicted post-TAVI survival > 1 year. TAVI should be also considered in high-risk patients with severe aortic stenosis who may still be suitable for surgery, but in whom TAVI is favoured by a ‘heart team’ based on the individual risk profile and anatomic suitability.

In a recent trial in patients with severe aortic stenosis, TAVI with a self-expanding transcatheter aortic valve bioprosthesis was associated with a significantly higher rate of survival at 1 year which was sustained at 2 years.

11.17.2. Aortic regurgitation

In patients with severe aortic regurgitation, aortic valve repair or replacement is recommended in all symptomatic patients and in asymptomatic patients with resting LVEF ≤ 50%, who are otherwise fit for surgery.

11.17.3. Mitral regurgitation

This section refers to chronic settings while acute settings are discussed in Section 12.

Primary (organic) mitral regurgitation

Surgery is indicated in symptomatic patients with severe organic mitral regurgitation with no contra-indications to surgery. The decision of whether to replace or repair depends mostly on valve anatomy, surgical expertise available, and the patient’s condition.

When the LVEF is < 30%, a durable surgical repair may improve symptoms, although its effect on survival is unknown. In this situation, the decision to operate should take account of response to medical therapy, co-morbidities, and the likelihood that the valve can be repaired (rather than replaced).

Secondary mitral regurgitation

This occurs because LV enlargement and remodelling lead to reduced leaflet closing. Effective medical therapy (including CRT in suitable patients) leading to reverse remodelling of the LV may reduce functional mitral regurgitation, and every effort should be made to optimize medical treatment in these patients.

Combined valve and coronary surgery should be considered in symptomatic patients with LV systolic dysfunction (LVEF < 30%), coronary arteries suitable for revascularization, and evidence of viability. Surgery is also recommended in patients with severe mitral regurgitation undergoing CABG with LVEF > 30%.

However, a recent study in patients with moderate, secondary ischaemic mitral regurgitation did not prove that the addition of mitral valve repair to CABG would lead to a higher degree of LV reverse remodelling. Also, there is no evidence favouring mitral valve repair over replacement in the context of better outcomes and magnitude of LV remodelling. In the presence of AF, atrial ablation and LA appendage closure may be considered at the time of mitral valve surgery.

The role of isolated mitral valve surgery in patients with severe functional mitral regurgitation and severe LV systolic dysfunction (LVEF < 30%) who cannot be revascularized or have non-ischaemic cardiomyopathy is questionable, and in most patients conventional medical and device therapy are preferred. In selected cases, repair may be considered in order to avoid or postpone transplantation. The decision should be based on comprehensive evaluation (including strain echocardiography or magnetic resonance imaging) and discussed within the ‘heart team’.

In patients with HF with moderate-severe, secondary mitral regurgitation who are judged inoperable or at high surgical risk, percutaneous mitral valve intervention (percutaneous edge-to-edge repair) may be considered in order to improve symptoms and quality of life, although no RCT evidence of improvement has been published, only registry studies.

11.17.4. Tricuspid regurgitation

Secondary (functional) tricuspid regurgitation (TR) frequently complicates the natural course of HF, due to annular dilatation and increased tricuspid leaflet tethering in relation to RV pressure and/or volume overload. Severe TR causes/deteriorates symptoms and signs of right HF, thus diuretics are used to reduce peripheral oedema. As hepatic congestion is often present in these patients (additionally contributing to hyperaldosteronism), an addition of an MRA (in higher natriuretic doses) may improve decongestion.

Management of HF which underlies secondary TR should be optimized as TR may diminish, following the treatment of its cause. Indications for surgical correction of secondary TR complicating HF are not clearly established. The need for correction of TR is usually considered at the time of surgical correction of left-sided valve disease.
valve lesions. A recent first report indicated that catheter-based interventions may be possible for TR.

12. Acute heart failure

12.1 Definition and classification

AHF refers to rapid onset or worsening of symptoms and/or signs of HF. It is a life-threatening medical condition requiring urgent evaluation and treatment, typically leading to urgent hospital admission.

AHF may present as a first occurrence (de novo) or, more frequently, as a consequence of acute decompensation of chronic HF, and may be caused by primary cardiac dysfunction or precipitated by extrinsic factors, often in patients with chronic HF. Acute myocardial dysfunction (ischaemic, inflammatory or toxic), acute valve insufficiency or pericardial tamponade are among the most frequent acute primary cardiac causes of AHF. Decompensation of chronic HF can occur without known precipitant factors, but more often with one or more factors, such as infection, uncontrolled hypertension, rhythm disturbances or non-adherence with drugs/diet (Table 12.1).

A large number of overlapping classifications of AHF based on different criteria have been proposed. In practice the most useful classifications are those based on clinical presentation at admission, allowing clinicians to identify patients at high risk of complications and to direct management at specific targets, which creates a pathway for personalized care in the AHF setting. In most cases, patients with AHF present with either preserved (90–140 mmHg) or elevated (>140 mmHg; hypertensive AHF) systolic blood pressure (SBP). Only 5–8% of all patients present with low SBP (i.e. <90 mmHg; hypotensive AHF), which is associated with poor prognosis, particularly when hypoperfusion is also present.

Another approach is to classify patients according to the presence of the following precipitants/causes leading to decompensation, which need to be treated/corrected urgently (see Section 12.3.1): ACS, hypertensive emergency, rapid arrhythmias or severe
bradycardia/conduction disturbance, acute mechanical cause underlying AHF or acute pulmonary embolism.

Clinical classification can be based on bedside physical examination in order to detect the presence of clinical symptoms/signs of congestion (‘wet’ vs. ‘dry’ if present vs. absent) and/or peripheral hypoperfusion (‘cold’ vs. ‘warm’ if present vs. absent) (Figure 12.1). The combination of these options identifies four groups: warm and wet (well perfused and congested) — most commonly present; cold and wet (hypoperfused and congested); cold and dry (hypoperfused without congestion); and warm and dry (compensated, well perfused without congestion). This classification may be helpful to guide therapy in the initial phase and carries prognostic information.

Patients with HF complicating AMI can be classified according to Killip and Kimball into class I, no clinical signs of HF; class II, HF with rales and S3 gallop; class III, with frank acute pulmonary oedema; class IV, cardiogenic shock, hypotension (SBP < 90 mmHg) and evidence of peripheral vasoconstriction such as oliguria, cyanosis and diaphoresis.

Definitions of the terms used in this section related to clinical presentation of patients with AHF are provided in Table 12.2.

12.2 Diagnosis and initial prognostic evaluation

The diagnostic workup needs to be started in the pre-hospital setting and continued in the emergency department (ED) in order to establish the diagnosis in a timely manner and initiate appropriate management. The greater benefit of early treatment is well established in ACS and now needs to be considered in the setting of...
In parallel, coexisting life-threatening clinical conditions and/or precipitants that require urgent treatment/correction need to be immediately identified and managed (Figure 12.2). Typically, an initial step in the diagnostic workup of AHF is to rule out alternative causes for the patient’s symptoms and signs (i.e. pulmonary infection, severe anaemia, acute renal failure).

When AHF is confirmed clinical evaluation is mandatory to select further management.

It is recommended that initial diagnosis of AHF should be based on a thorough history assessing symptoms, prior cardiovascular history and potential cardiac and non-cardiac precipitants, as well as on the assessment of signs/symptoms of congestion and/or hypoperfusion by physical examination and further confirmed by appropriate additional investigations such as ECG, chest X-ray, laboratory assessment (with specific biomarkers) and echocardiography.

In patients presenting with AHF, early initiation of appropriate therapy (along with relevant investigations) is of key importance.516–518

Typically, symptoms and signs of AHF reflect fluid overload (pulmonary congestion and/or peripheral oedema) or, less often, reduced cardiac output with peripheral hypoperfusion (Table 12.2).

Since the sensitivity and specificity of symptoms and signs are often not satisfactory, careful clinical evaluation needs to be followed by these additional investigations:

- Chest X-ray can be a useful test for the diagnosis of AHF. Pulmonary venous congestion, pleural effusion, interstitial or alveolar oedema and cardiomegaly are the most specific findings for AHF, although in up to 20% of patients with AHF, chest X-ray is nearly normal.519 Supine chest radiographs are of limited value in AHF. Chest X-ray is also useful to identify alternative non-cardiac diseases that may cause or contribute to the patient’s symptoms (i.e. pneumonia, non-consolidative pulmonary infections).
- ECG is rarely normal in AHF (high negative predictive value).520 It is also helpful in identifying underlying cardiac disease and potential precipitants (rapid AF, acute myocardial ischaemia).
- Immediate echocardiography is mandatory only in patients with haemodynamic instability (particularly in cardiogenic shock) and in patients suspected of acute life-threatening structural or functional cardiac abnormalities (mechanical complications, acute valvular regurgitation, aortic dissection). Early echocardiography should be considered in all patients with de novo AHF and in those with unknown cardiac function; however, the optimal timing is unknown (preferably within 48 h from admission, if the expertise is available). Pocket-size echocardiography may be used as an extension of the clinical examination in the first instance where available. Repeated echocardiography is usually not needed unless there is relevant deterioration in clinical status. Bedside thoracic ultrasound for signs of interstitial oedema and

**Table 12.2 Definitions of the terms used in Section 12 on acute heart failure**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms/signs of congestion (left-sided)</td>
<td>Orthopnoea, paroxysmal nocturnal dyspnoea, pulmonary rales (bilateral), peripheral oedema (bilateral).</td>
</tr>
<tr>
<td>Symptoms/signs of congestion (right-sided)</td>
<td>Jugular venous dilatation, peripheral oedema (bilateral), congested hepatomegaly, hepatojugular reflux, ascites, symptoms of gut congestion.</td>
</tr>
<tr>
<td>Symptoms/signs of hypoperfusion</td>
<td>Clinical cold sweated extremities, oliguria, mental confusion, dizziness, narrow pulse pressure. Laboratory measures: metabolic acidosis, elevated serum lactate, elevated serum creatinine. Hypoperfusion is not synonymous with hypotension, but often hypoperfusion is accompanied by hypotension.</td>
</tr>
<tr>
<td>Hypotension</td>
<td>Systolic BP &lt;90 mmHg</td>
</tr>
<tr>
<td>Bradycardia</td>
<td>Heart rate &lt;40 bpm</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>Heart rate &gt;120 bpm</td>
</tr>
<tr>
<td>Abnormal respiratory effort</td>
<td>Respiratory rate &gt;25 breaths/min with use of accessory muscles for breathing, or respiratory rate &lt;8 breaths/min despite dyspnoea.</td>
</tr>
<tr>
<td>Low O2 saturation</td>
<td>O2 saturation (SaO2) &lt;90% in pulse oximetry Normal SaO2 neither excludes hypoxaemia (low PaO2) nor tissue hypoxia.</td>
</tr>
<tr>
<td>Hypoxaemia</td>
<td>O2 partial pressure (PaO2) in arterial blood &lt;80 mmHg (&lt;10,67 kPa) (blood gas analysis).</td>
</tr>
<tr>
<td>Hypoxaemic respiratory failure (type I)</td>
<td>PaO2 &lt;60 mmHg (&lt;3 kPa)</td>
</tr>
<tr>
<td>Hypercapnia</td>
<td>CO2 partial pressure (PaCO2) in arterial blood &gt;45 mmHg (&gt;6 kPa) (blood gas analysis).</td>
</tr>
<tr>
<td>Hypercapnic respiratory failure (type II)</td>
<td>PaCO2 &gt;50 mmHg (&gt;6,65 kPa).</td>
</tr>
<tr>
<td>Acidosis</td>
<td>pH &lt;7.35</td>
</tr>
<tr>
<td>Elevated blood lactate</td>
<td>&gt;2 mmol/L</td>
</tr>
<tr>
<td>Oliguria</td>
<td>Urine output &lt;0.5 mL/kg/h</td>
</tr>
</tbody>
</table>

*BP = blood pressure; bpm = beats per minute; PaCO2 = partial pressure of carbon dioxide in arterial blood; PaO2 = partial pressure of oxygen in arterial blood; SaO2 = oxygen saturation.*

**ESC Guidelines**

2173

Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/27/2129/1748921 by guest on 10 April 2018
Figure 12.2 Initial management of a patient with acute heart failure. *Acute mechanical cause: myocardial rupture complicating acute coronary syndrome (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis, see above.
Table 12.3  Causes of elevated concentrations of natriuretic peptides

<table>
<thead>
<tr>
<th>Cardiac</th>
<th>Non-cardiac</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure</td>
<td>Advanced age</td>
</tr>
<tr>
<td>Acute coronary syndromes</td>
<td>Ischaemic stroke</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>Subarachnoid haemorrhage</td>
</tr>
<tr>
<td>Myocarditis</td>
<td>Renal dysfunction</td>
</tr>
<tr>
<td>Left ventricular hypertrophy</td>
<td>Liver dysfunction (mainly liver cirrhosis with ascites)</td>
</tr>
<tr>
<td>Hypertrophic or restrictive cardiomyopathy</td>
<td>Paraneoplastic syndrome</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>Congenital heart disease</td>
<td>Severe infections (including pneumonia and sepsis)</td>
</tr>
<tr>
<td>Atrial and ventricular tachyarrhythmias</td>
<td>Severe burns</td>
</tr>
<tr>
<td>Heart contusion</td>
<td>Anaemia</td>
</tr>
<tr>
<td>Cardioversion, ICD shock</td>
<td>Severe metabolic and hormone abnormalities</td>
</tr>
<tr>
<td>Surgical procedures involving the heart</td>
<td>(e.g. thyrotoxicosis, diabetic ketoacidosis)</td>
</tr>
</tbody>
</table>

HFrEF = heart failure with preserved ejection fraction; HfPeF = heart failure with reduced ejection fraction; ICD = implantable cardioverter defibrillator.

pleural effusion may be useful in detecting AHF if the expertise is available.

- Laboratory tests:
  - Natriuretic peptides.
  - Upon presentation to the ED or CCU/ICU, a plasma NP level (BNP, NT-proBNP or MR-proANP) should be measured in all patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnoea. NPs have high sensitivity, and normal levels in patients with suspected AHF makes the diagnosis unlikely (thresholds: BNP < 100 pg/mL, NT-proBNP < 300 pg/mL, MR-proANP < 120 pg/mL). However, elevated levels of NPs do not automatically confirm the diagnosis of AHF, as they may also be associated with a wide variety of cardiac and non-cardiac causes (Table 12.3). Unexpectedly low levels of NPs can be detected in some patients with decompensated end-stage HF, flash pulmonary oedema or right sided AHF.

Other laboratory tests at presentation.

- The following laboratory assessments should be performed at admission on the blood of all patients with AHF: cardiac troponin, blood urea nitrogen (BUN) (or urea), creatinine, electrolytes (sodium, potassium), liver function tests, thyroid-stimulating hormone (TSH), glucose and complete blood count; D-dimer is indicated in patients with a suspicion of acute pulmonary embolism.

- Routine arterial blood gas is not needed and should be restricted to patients in whom oxygenation cannot be readily assessed by pulse oximetry. However, arterial blood gas may be useful when a precise measurement of O2 and CO2 partial pressures is needed. A venous sample might acceptably indicate pH and CO2.

- Of note, measurement of cardiac troponins is useful for detection of ACS as the underlying cause of AHF. However, elevated concentrations of circulating cardiac troponins are detected in the vast majority of patients with AHF, often without obvious myocardial ischaemia or an acute coronary event, suggesting ongoing myocyte injury or necrosis in these patients. Also in patients with acute pulmonary embolism as the underlying cause of acute decompensation, elevated troponins are useful for risk stratification and decision-making.

- It is recommended to measure creatinine, BUN and electrolytes every 1–2 days while in the hospital and before discharge from the hospital. Of note, more frequent testing might be justified according to the severity of the case. Pre-discharge assessment of NPs may be considered for prognostic evaluation.

- Assessment of procalcitonin levels may be considered in patients with AHF with suspected coexisting infection, particularly for the differential diagnosis of pneumonia and to guide antibiotic therapy.

- Liver function tests are often impaired in patients with AHF due to haemodynamic derangements (both reduced output and increased venous congestion). Abnormal liver function tests identify patients at risk of poor prognosis and may be useful for optimal management.

- Since both hypothyroidism and hyperthyroidism may precipitate AHF, TSH should be assessed in newly diagnosed AHF.

- Multiple other biomarkers, including those reflecting inflammation, oxidative stress, neurohormonal disarray and myocardial and matrix remodelling, have been investigated for their diagnostic and prognostic value in AHF; however, none has reached the stage of being recommended for routine clinical use.

- Routine invasive haemodynamic evaluation with a pulmonary artery catheter is not indicated for the diagnosis of AHF. It may be helpful in selected cases of haemodynamically unstable patients with an unknown mechanism of deterioration. Also, routine use of an arterial line or central venous line for diagnostic purposes is not indicated.

Numerous clinical and laboratory variables are independent predictors of in-hospital complications and longer-term outcomes in AHF syndromes, but their impact on management has not been adequately established.
**Recommendations regarding applied diagnostic measurements**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upon presentation a measurement of plasma natriuretic peptide level (BNP, NT-proBNP or MR-proANP) is recommended in all patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnoea.</td>
<td>I</td>
<td>A</td>
<td>531–534</td>
</tr>
<tr>
<td>At admission in all patients presenting with suspected AHF, the following diagnostic tests are recommended:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. 12-lead ECG;</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>b. chest X-ray to assess signs of pulmonary congestion and detect other cardiac or non-cardiac diseases that may cause or contribute to the patient’s symptoms;</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>c. the following laboratory assessments in the blood: cardiac troponins, BUN (or urea), creatinine, electrolytes (sodium, potassium), glucose, complete blood count, liver function tests and TSH.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Echocardiography is recommended immediately in haemodynamically unstable AHF patients and within 48 hours when cardiac structure and function are either not known or may have changed since previous studies.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

AHF = acute heart failure; BNP = B-type natriuretic peptide; BUN = blood urea nitrogen; ECG = electrocardiogram; MR-proANP = mid-regional pro A-type natriuretic peptide; NT-proBNP = N-terminal pro-B type natriuretic peptide; TSH = thyroid-stimulating hormone

*a*Class of recommendation.

*b*Level of evidence.

*b*Reference(s) supporting recommendations.

### 12.3 Management

AHF is a life-threatening medical condition, thus rapid transfer to the nearest hospital should be pursued, preferably to a site with a cardiology department and/or a coronary care/intensive care unit (CCU/ICU).

Early diagnosis is important in AHF. Therefore, all patients with suspected AHF should have a diagnostic workup and appropriate pharmacological and non-pharmacological treatment should be started promptly and in parallel.

Initial evaluation and continued non-invasive monitoring of the patient’s vital cardiorespiratory functions, including pulse oximetry, blood pressure, respiratory rate and a continuous ECG instituted within minutes, is essential to evaluate whether ventilation, peripheral perfusion, oxygenation, heart rate and blood pressure are adequate. Urine output should also be monitored, although routine urinary catheterization is not recommended.

Patients with respiratory distress/failure or haemodynamic compromise should be triaged to a location where immediate respiratory and cardiovascular support can be provided (Figure 12.2).

#### 12.3.1 Identification of precipitants/causes leading to decompensation that needs urgent management

The next step should comprise the identification of major precipitants/causes leading to decompensation, which should be managed urgently to avoid further deterioration (Figure 12.2). These include the following:

- **Acute coronary syndrome.** Patients presenting with ACS should be managed according to the ESC guidelines on non-ST elevation ACS (NSTEMI) and STEMI. Coexistence of these two clinical conditions (ACS and AHF) always identifies a very-high-risk group where an immediate (i.e. <2 h from hospital admission in patients with NSTEMI, analogous to STEMI management) invasive strategy with intent to perform revascularization is recommended, irrespective of ECG or biomarker findings.

  See below for patients presenting with persistent haemodynamic instability due to mechanical ACS complication.

- **Hypertensive emergency.** AHF precipitated by rapid and excessive increase in arterial blood pressure typically manifests as acute pulmonary oedema. A prompt reduction in blood pressure should be considered as a primary therapeutic target and initiated as soon as possible. Aggressive blood pressure reduction (in the range of 25% during the first few hours and cautiously thereafter) with i.v. vasodilators in combination with loop diuretics is recommended.

  - **Rapid arrhythmias or severe bradycardia/conduction disturbance.** Severe rhythm disturbances in patients with AHF and unstable conditions should be corrected urgently with medical therapy, electrical cardioversion or temporary pacing (see also Section 10.1 for AF management).

  Electrical cardioversion is recommended if an atrial or ventricular arrhythmia is thought to be contributing to the patient’s haemodynamic compromise in order to restore sinus rhythm and improve the patient’s clinical condition.

  Patients with AHF and incessant ventricular arrhythmias present a challenging scenario, as arrhythmias and haemodynamic instability operate in a vicious circle, perpetuating each other. In selected cases, immediate angiography (with resultant revascularization, if needed) and electrophysiological testing with radiofrequency ablation may be considered.

- **Acute mechanical cause underlying AHF.** This may present as a mechanical complication of ACS (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, or as acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis and comprise rare causes of obstruction (e.g. cardiac tumours). Echocardiography is essential for diagnosis, and treatment typically requires circulatory support with surgical or percutaneous intervention.

  - **Acute pulmonary embolism.** When acute pulmonary embolism is confirmed as the cause of shock or hypotension, immediate specific treatment is recommended with primary reperfusion either with thrombolysis, catheter-based approach or surgical embolectomy. Patients presenting with acute pulmonary embolism should be managed according to the appropriate guidelines.
Identification of acute aetiologies/precipitants with subsequent initiation of specific treatments should be done within the immediate phase of AHF management (initial 60–120 min) (Figure 12.2).

### 12.3.2 Criteria for hospitalization in ward vs. intensive care/ coronary care unit

- Patients with persistent, significant dyspnoea or haemodynamic instability should be triaged to a location where immediate resuscitative support can be provided if needed.
- For high-risk patients (i.e. with persistent, significant dyspnoea, haemodynamic instability, recurrent arrhythmias, AHF and associated ACS), initial care should be provided in a high-dependency setting (ICU/CCU). Clinical risk algorithms developed to predict in-hospital mortality of patients with AHF can assist in determining which patients in the ED need the highest level of inpatient care.538,539
- The criteria for ICU/CCU admission include any of the following:— need for intubation (or already intubated)

### 12.3.3 Management of the early phase

#### Oxygen therapy and/or ventilatory support

**Recommendations for the management of patients with acute heart failure: oxygen therapy and ventilatory support**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring of transcutaneous arterial oxygen saturation (SpO2) is recommended.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Measurement of blood pH and carbon dioxide tension (possibly including lactate) should be considered, especially in patients with acute pulmonary oedema or previous history of COPD using venous blood. In patients with cardiogenic shock arterial blood is preferable.</td>
<td>Ii a</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Oxygen therapy is recommended in patients with AHF and SpO2 &lt;90% or PaO2 &lt;60 mmHg (8.0 kPa) to correct hypoxaemia.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Non-invasive positive pressure ventilation (CPAP, BiPAP) should be considered in patients with respiratory distress (respiratory rate &gt;25 breaths/min, SpO2 &lt;90%) and started as soon as possible in order to decrease respiratory distress and reduce the rate of mechanical endotracheal intubation. Non-invasive positive pressure ventilation can reduce blood pressure and should be used with caution in hypotensive patients. Blood pressure should be monitored regularly when this treatment is used.</td>
<td>Ii a</td>
<td>B</td>
<td>541–545</td>
</tr>
<tr>
<td>Intubation is recommended, if respiratory failure, leading to hypoxaemia (PaO2 &lt;60 mmHg (8.0 kPa)), hypercapnia (PaCO2 &gt;50 mmHg (6.65 kPa)) and acidosis (pH &lt;7.35), cannot be managed non-invasively.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

AHF = acute heart failure; BiPAP = bilevel positive airway pressure; COPD = chronic obstructive pulmonary disease; CPAP = continuous positive airway pressure; PaCO2 = partial pressure of carbon dioxide in arterial blood; PaO2 = partial pressure of oxygen in arterial blood; SpO2 = transcutaneous oxygen saturation.

aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.

In AHF, oxygen should not be used routinely in non-hypoxaemic patients, as it causes vasoconstriction and a reduction in cardiac output.546,547 In COPD, hyperoxegenation may increase ventilation-perfusion mismatch, suppressing ventilation and leading to hypercapnia. During oxygen therapy, acid-base balance and transcutaneous SpO2 should be monitored.

Non-invasive positive pressure ventilation includes both CPAP and bi-level positive pressure ventilation (PPV). Bi-level PPV also allows inspiratory pressure support that improves minute ventilation and is especially useful in patients with hypercapnia, most typically COPD patients.

Congestion affects lung function and increases intrapulmonary shunting, resulting in hypoxaemia. The fraction of inspired oxygen (FiO2) should be increased up to 100% if necessary, according to SpO2, unless contraindicated. Hyperoxia, however, should be avoided.546,547 Non-invasive positive pressure ventilation reduces respiratory distress541–545 and may decrease intubation and mortality rates,543 although data regarding mortality are less conclusive. CPAP is a feasible technique in the pre-hospital setting, because it is simpler than pressure support positive end-expiratory pressure (PS-PEEP) and requires minimal training and equipment. On hospital arrival, patients who still show signs of respiratory distress should continue with non-invasive ventilation, preferably PS-PEEP, in case of acidosis and hypercapnia, particularly in those with a previous history of COPD or signs of fatigue.540

Caution should be exercised with regard to side effects of anaesthetic drugs, among which propofol can induce hypotension and have cardiodepressive side effects. In contrast, midazolam may have fewer cardiac side effects and thus is preferred in patients with AHF or cardiogenic shock.

A management algorithm for patients with AHF based on the clinical profile during an early phase is presented in Figure 12.3.
Figure 12.3  Management of patients with acute heart failure based on clinical profile during an early phase
Symptoms/signs of congestion: orthopnoea, paroxysmal nocturnal dyspnoea, breathlessness, bi-basilar rales, an abnormal blood pressure response to the Valsalva maneuver (left-sided); symptoms of gut congestion, jugular venous distension, hepatojugular reflux, hepatomegaly, ascites, and peripheral oedema (right-sided).
# Pharmacological therapy

## Recommendations for the management of patients with acute heart failure: pharmacotherapy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diuretics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of fluid overload to improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of i.v. diuretics.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose should be 20–40 mg i.v. furosemide (or equivalent); for those on chronic diuretic therapy, initial i.v. dose should be at least equivalent to oral dose.</td>
<td>I</td>
<td>B</td>
<td>540, 548</td>
</tr>
<tr>
<td>It is recommended to give diuretics either as intermittent boluses or as a continuous infusion, and the dose and duration should be adjusted according to patients' symptoms and clinical status.</td>
<td>I</td>
<td>B</td>
<td>548</td>
</tr>
<tr>
<td>Combination of loop diuretic with either thiazide-type diuretic or spironolactone may be considered in patients with resistant oedema or insufficient symptomatic response.</td>
<td>IIb</td>
<td>C</td>
<td>549</td>
</tr>
<tr>
<td><strong>Vasodilators</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>i.v. vasodilators should be considered for symptomatic relief in AHF with SBP &gt;90 mmHg (and without symptomatic hypotension). Symptoms and blood pressure should be monitored frequently during administration of i.v. vasodilators.</td>
<td>IIa</td>
<td>B</td>
<td>537, 550–555</td>
</tr>
<tr>
<td>In patients with hypertensive AHF, i.v. vasodilators should be considered as initial therapy to improve symptoms and reduce congestion.</td>
<td>IIa</td>
<td>B</td>
<td>537, 551–554</td>
</tr>
<tr>
<td><strong>Inotropic agents – dobutamine, dopamine, levosimendan, phosphodiesterase III (PDE III) inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short-term, i.v. infusion of inotropic agents may be considered in patients with hypotension (SBP &lt;90 mmHg) and/or signs/symptoms of hypoperfusion despite adequate filling status, to increase cardiac output, increase blood pressure, improve peripheral perfusion and maintain end-organ function.</td>
<td>IIb</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>An intravenous infusion of levosimendan or a PDE III inhibitor may be considered to reverse the effect of beta-blockade if beta-blockade is thought to be contributing to hypotension with subsequent hypoperfusion.</td>
<td>IIb</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern.</td>
<td>III</td>
<td>A</td>
<td>556, 557</td>
</tr>
<tr>
<td><strong>Vasopressors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A vasopressor (norepinephrine preferably) may be considered in patients who have cardiogenic shock, despite treatment with another inotrope, to increase blood pressure and vital organ perfusion.</td>
<td>IIb</td>
<td>B</td>
<td>558</td>
</tr>
<tr>
<td>It is recommended to monitor ECG and blood pressure when using inotropic agents and vasopressors, as they can cause arrhythmia, myocardial ischaemia, and in the case of levosimendan and PDE III inhibitors also hypotension. In such cases intra-arterial blood pressure measurement may be considered.</td>
<td>I</td>
<td>C</td>
<td>540, 559–563</td>
</tr>
<tr>
<td><strong>Thrombo-embolism prophylaxis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombo-embolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no contra-indication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism.</td>
<td>I</td>
<td>B</td>
<td>564</td>
</tr>
<tr>
<td><strong>Other drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| For acute control of the ventricular rate in patients with atrial fibrillation:  
  a. digoxin and/or beta-blockers should be considered as the first-line therapy.  
  b. amiodarone may be considered. | IIa | C | 565–567 |
| Opiates may be considered for cautious use to relieve dyspnoea and anxiety in patients with severe dyspnoea but nausea and hypopnea may occur. | IIb | B | 568, 569 |

AHF = acute heart failure; ECG = electrocardiogram; HF = heart failure; i.v. = intravenous; LMWH = low molecular weight heparin; SBP = systolic blood pressure.

*aClass of recommendation.

*bLevel of evidence.

*cReference(s) supporting recommendations.

*Beta-blockers should be used cautiously, if the patient is hypotensive.
Diuretics
Diuretics are a cornerstone in the treatment of patients with AHF and signs of fluid overload and congestion. Diuretics increase renal salt and water excretion and have some vasodilatory effect. In patients with AHF and signs of hypoperfusion, diuretics should be avoided before adequate perfusion is attained.

The initial approach to congestion management involves i.v. diuretics with the addition of vasodilators for dyspnoea relief if blood pressure allows. To enhance diuresis or overcome diuretic resistance, options include dual nephron blockade by loop diuretics (i.e. furosemide or torasemide) with thiazide diuretics or natriuretic doses of MRAs. However, this combination requires careful monitoring to avoid hypokalaemia, renal dysfunction and hypovolaemia.

Data defining optimal dosing, timing and method of delivery are incomplete. In the ‘high-dose’ arm of the DOSE study, administration of furosemide at 2.5 times the previous oral dose resulted in greater improvement in dyspnoea, larger weight change and fluid loss at the cost of transient worsening in renal function. In AHF, i.v. furosemide is the most commonly used first-line diuretic. The dose should be limited to the smallest amount to provide adequate clinical effect and modified according to previous renal function and previous dose of diuretics. The initial i.v. dose should be at least equal to the pre-existing oral dose used at home. Consequently, patients with new-onset AHF or those with chronic HF without a history of renal failure and previous use of diuretics may respond to i.v. boluses of 20–40 mg, whereas those with previous use of diuretics usually require higher doses. A bolus of 10–20 mg i.v. torasemide may be considered as an alternative.

Vasodilators
Intravenous vasodilators (Table 12.4) are the second most often used agents in AHF for symptomatic relief; however, there is no robust evidence confirming their beneficial effects.

They have dual benefit by decreasing venous tone (to optimize preload) and arterial tone (decrease afterload). Consequently, they may also increase stroke volume. Vasodilators are especially useful in patients with hypertensive AHF, whereas in those with SBP <90 mmHg (or with symptomatic hypotension) they should be avoided. Dosing should be carefully controlled to avoid excessive decreases in blood pressure, which is related to poor outcome. Vasodilators should be used with caution in patients with significant mitral or aortic stenosis.

Use of an inotrope (Table 12.5) should be reserved for patients with a severe reduction in cardiac output resulting in compromised vital organ perfusion, which occurs most often in hypotensive AHF. Inotropic agents are not recommended in cases of hypotensive AHF where the underlying cause is hypovolaemia or other potentially correctable factors before elimination of these causes. Levosimendan is preferable over dobutamine to reverse the effect of beta-blockade if beta-blockade is thought to be contributing to hypoperfusion. However, levosimendan is a vasodilator, thus it is not suitable for treatment of patients with hypotension (SBP <85 mmHg) or cardiogenic shock unless in combination with other inotropes or vasopressors. Inotropes, especially those with adrenergic mechanisms, can cause sinus tachycardia and may induce myocardial ischaemia and arrhythmias, thus ECG monitoring is required. There is long-standing concern that they may increase mortality, which

### Table 12.5 Positive inotropes and/or vasopressors used to treat acute heart failure

<table>
<thead>
<tr>
<th>Vasodilator</th>
<th>Bolus</th>
<th>Infusion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobutamine*</td>
<td>No</td>
<td>2–20 µg/kg/min (beta+)</td>
</tr>
<tr>
<td>Dopamine</td>
<td>No</td>
<td>3–5 µg/kg/min; inotropic (beta+)</td>
</tr>
<tr>
<td>Milrinone&lt;sup&gt;c&lt;/sup&gt;</td>
<td>25–75 µg/kg over 10–20 min</td>
<td>0.375–0.75 µg/kg/min</td>
</tr>
<tr>
<td>Enoximone&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.5–1.0 mg/kg over 5–10 min</td>
<td>5–20 µg/kg/min</td>
</tr>
<tr>
<td>Levosimendan&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12 µg/kg over 10 min (optional)</td>
<td>0.1 µg/kg/min, which can be decreased to 0.05 or increased to 0.2 µg/kg/min</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>No</td>
<td>0.2–1.0 µg/kg/min</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>Bolus: 1 mg can be given i.v. during resuscitation; repeated every 3–5 min</td>
<td>0.05–0.5 µg/kg/min</td>
</tr>
</tbody>
</table>

<sup>a</sup>Not available in many European countries.
<sup>b</sup>Also a vasodilator.
<sup>c</sup>Not recommended in acutely worsened ischaemic heart failure.
<sup>d</sup>Bolus not recommended in hypotensive patients.

### Table 12.4 Intravenous vasodilators used to treat acute heart failure

<table>
<thead>
<tr>
<th>Vasodilator</th>
<th>Dosing</th>
<th>Main side effects</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitroglycerine</td>
<td>Start with 10–20 µg/min, increase up to 200 µg/min</td>
<td>Hypotension, headache</td>
<td>Tolerance on continuous use</td>
</tr>
<tr>
<td>Isosorbide dinitrate</td>
<td>Start with 1 mg/h, increase up to 10 mg/h</td>
<td>Hypotension, headache</td>
<td>Tolerance on continuous use</td>
</tr>
<tr>
<td>Nitroprusside</td>
<td>Start with 0.3 µg/kg/min and increase up to 5 µg/kg/min</td>
<td>Hypotension, isocyanate toxicity</td>
<td>Light sensitive</td>
</tr>
<tr>
<td>Nesiritide&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Bolus 2 µg/kg + infusion 0.01 µg/kg/min</td>
<td>Hypotension</td>
<td></td>
</tr>
</tbody>
</table>

<sup>*</sup>Not available in many European countries.
Vasopressors

Drugs with prominent peripheral arterial vasoconstrictor action such as norepinephrine or dopamine in higher doses (≥5 μg/kg/min) are given to patients with marked hypotension. These agents are given to raise blood pressure and redistribute blood to the vital organs. However, this is at the expense of an increase in LV afterload.

Dopamine was compared with norepinephrine in the treatment of various shock patients. A subgroup analysis suggested that nor-epinephrine would have fewer side effects and lower mortality. Epinephrine (adrenaline) should be restricted to patients with persistent hypotension despite adequate cardiac filling pressures and the use of other vasoactive agents, as well as for resuscitation protocols.

Thromboembolism prophylaxis

Thromboembolism prophylaxis with heparin or another anticoagulant is recommended unless contraindicated or unnecessary (because of existing treatment with oral anticoagulants).

Digoxin

Digoxin is mostly indicated in patients with AF and rapid ventricular rate (>110 bpm) and given in boluses of 0.25–0.5 mg i.v. if not used previously (0.0625–0.125 mg may be an adequate dose in patients with moderate to severe renal dysfunction). However, in patients with co-morbidities or other factors affecting digoxin metabolism (including other drugs) and/or the elderly, the maintenance dose may be difficult to estimate theoretically, and in this situation it should be established empirically, based on the measurements of digoxin concentration in peripheral blood.

Vasopressin antagonists

Vasopressin antagonists such as tolvaptan block the action of arginine vasopressin (AVP) at the V2 receptor in renal tubules and promote aquaresis. Tolvaptan may be used to treat patients with refractory hyponatraemia (thirst and dehydration, termed aquaresis). Tolvaptan may be used to treat patients with volume overload and resistant hyponatraemia. Tolvaptan may be used to treat patients with refractory hyponatraemia (thirst and dehydration, termed aquaresis).

Opiates

Opiates relieve dyspnoea and anxiety. In AHF, routine use of opiates is not recommended and they may only be cautiously considered in patients with severe dyspnoea, mostly with pulmonary oedema. Dose-dependent side effects include nausea, hypotension, bradycardia and respiratory depression (potentially increasing the need for invasive ventilation). There are controversies regarding the potentially elevated mortality risk in patients receiving morphine.

Anxiolytics and sedatives

Anxiolytics or sedatives may be needed in a patient with agitation or delirium. Cautious use of benzodiazepines (diazepam or lorazepam) may be the safest approach.

Device therapy

Recommendations regarding renal replacement therapy in patients with acute heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultrafiltration may be considered for patients with refractory congestion, who failed to respond to diuretic-based strategies.</td>
<td>I Ib</td>
<td>B</td>
<td>578–580</td>
</tr>
<tr>
<td>Renal replacement therapy should be considered in patients with refractory volume overload and acute kidney injury.</td>
<td>I Ia</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

*Class of recommendation.  
Level of evidence.  
Reference(s) supporting recommendations.

Renal replacement therapy

Ultrafiltration involves the removal of plasma water across a semipermeable membrane in response to a transmembrane pressure gradient. There is no evidence favouring ultrafiltration over loop diuretics as first-line therapy in patients with AHF. At the present time, routine use of ultrafiltration is not recommended and should be confined to patients who fail to respond to diuretic-based strategies.

The following criteria may indicate the need for initiation of renal replacement therapy in patients with refractory volume overload: oliguria unresponsive to fluid resuscitation measures, severe hyperkalaemia (K⁺ > 6.5 mmol/L), severe acidemia (pH < 7.2), serum urea level >25 mmol/L (150 mg/dL) and serum creatinine >300 μmol/L (>3.4 mg/dL).

Mechanical assist devices

Intra-aortic balloon pump

The conventional indications for an intra-aortic balloon pump (IABP) are to support the circulation before surgical correction of specific acute mechanical problems (e.g. interventricular septal rupture and acute mitral regurgitation), during severe acute myocarditis and in selected patients with acute myocardial ischaemia or infarction before, during and after percutaneous or surgical revascularization. There is no good evidence that an IABP is of benefit in other causes of cardiogenic shock (for details see below).

Ventricular assist devices

Ventricular assist devices and other forms of mechanical circulatory support (MCS) may be used as a ‘bridge to decision’ or longer term in selected patients (see Section 13).  

Other interventions

In patients with AHF and pleural effusion, pleurocentesis with fluid evacuation may be considered if feasible in order to alleviate dyspnoea. In patients with ascites, ascitic paracentesis with fluid evacuation may be considered in order to alleviate symptoms. This procedure, through reduction in intra-abdominal pressure, may also partially normalize the transrenal pressure gradient, thus improving renal filtration.
12.4 Management of patients with cardiogenic shock

Cardiogenic shock is defined as hypotension (SBP < 90 mmHg) despite adequate filling status with signs of hypoperfusion (Table 12.2). The pathogenetic scenarios of cardiogenic shock range from low-output advanced end-stage chronic HF to acute-onset de novo cardiogenic shock most often caused by STEMI, but also by various aetiologies other than ACS. A patient in cardiogenic shock should undergo immediate comprehensive assessment. ECG and echocardiography are required immediately in all patients with suspected cardiogenic shock. In patients with cardiogenic shock complicating ACS, an immediate coronary angiography is recommended (within 2 h from hospital admission) with an intent to perform coronary revascularization.114,535 Invasive monitoring with an arterial line should be also considered.

There is no agreement on the optimal method of haemodynamic monitoring in assessing and treating patients in cardiogenic shock, including pulmonary artery catheterization.

Pharmacologic therapy aims to improve organ perfusion by increasing cardiac output and blood pressure. After fluid challenge, pharmacologic management consists of an inotropic agent and a vasopressor as needed. Treatment is guided by the continuous monitoring of organ perfusion and haemodynamics. Pulmonary artery catheterization may be considered. As a vasopressor, norepinephrine is recommended when mean arterial pressure needs pharmacologic support. Dobutamine is the most commonly used adrenergic inotrope. Levosimendan may also be used in combination with a vasopressor.582,583 Levosimendan infusion in cardiogenic shock following AMI on top of dobutamine and norepinephrine improved cardiovascular haemodynamics without leading to hypotension.582,583 PDE3 inhibitors may be another option, especially in non-ischaemic patients.561,584

However, rather than combining several inotropes, device therapy has to be considered when there is an inadequate response. Recently the IABP-SHOCK II trial showed that the use of an IABP did not improve outcomes in patients suffering from AMI and cardiogenic shock.585,586 Therefore, routine use of an IABP cannot be recommended.

12.4 Management of evidence-based oral therapies

Recommendations regarding oral evidence-based disease-modifying therapies in patients with acute heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>In case of worsening of chronic HFrEF, every attempt should be made to continue evidence-based, disease-modifying therapies, in the absence of haemodynamic instability or contraindications.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>In the case of de novo HFrEF, every attempt should be made to initiate these therapies after haemodynamic stabilization.</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

AHF = acute heart failure; HFrEF = heart failure with reduced ejection fraction.

Oral disease-modifying HF therapy should be continued on admission with AHF, except in the presence of haemodynamic instability (symptomatic hypotension, hypoperfusion, bradycardia), hyperkalaemia or severely impaired renal function. In these cases, the daily dosage of oral therapy may be reduced or stopped temporarily until the patient is stabilized. In particular, beta-blockers can be safely continued during AHF presentations except in cardiogenic shock. A recent meta-analysis demonstrated that discontinuation of beta-blockers in patients hospitalized with AHF was associated with significantly increased in-hospital mortality, short-term mortality and the combined endpoint of short-term rehospitalization or mortality.587
12.5 Monitoring of clinical status of patients hospitalized due to acute heart failure

Recommendations regarding monitoring of clinical status of patients hospitalized due to acute heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard non-invasive monitoring of heart rate, rhythm, respiratory rate, oxygen saturation and blood pressure is recommended.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended that patients should be weighed daily and have an accurate fluid balance chart completed.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to evaluate signs and symptoms relevant to HF (e.g. dyspnoea, pulmonary rales, peripheral oedema, weight) daily to assess correction of fluid overload.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Intra-arterial line should be considered in patients with hypotension and persistent symptoms despite treatment.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Pulmonary artery catheter may be considered in patients who, despite pharmacological treatment present refractory symptoms (particularly with hypotension and hypoperfusion).</td>
<td>IIb</td>
<td>C</td>
</tr>
</tbody>
</table>

HF = heart failure; i.v. = intravenous.

Class of recommendation.

Level of evidence.

Patients should be weighed daily and an accurate fluid balance chart should be maintained. Renal function should preferably be monitored with daily measurement of BUN/urea, creatinine and electrolytes. Routine use of a urinary catheter is not recommended. Renal function is commonly impaired at admission, but may improve or deteriorate with diuresis. Routine monitoring of pulse, respiratory rate and blood pressure should continue. There is no study showing the usefulness of invasive haemodynamic monitoring in patients with AHF excluding those with cardiogenic shock. There is evidence that measuring NPs during the hospital admission may help with discharge planning. Patients whose NP concentrations fall during admission have lower cardiovascular mortality and readmission rates at 6 months.588–590

12.6 Criteria for discharge from hospital and follow-up in high-risk period

Patients admitted with AHF are medically fit for discharge552

- when haemodynamically stable, euvolaemic, established on evidence-based oral medication and with stable renal function for at least 24 hours before discharge;
- once provided with tailored education and advice about self-care.

Patients should preferably be

- enrolled in a disease management programme; follow-up plans must be in place prior to discharge and clearly communicated to the primary care team;
- reviewed by their general practitioner within 1 week of discharge;
- seen by the hospital cardiology team within 2 weeks of discharge if feasible.

Patients with chronic HF should be followed up within a multiprofessional HF service. Pre- and post-discharge management should follow the standards of care of the HFA.540,591,592

12.7 Goals of treatment during the different stages of management of acute heart failure

During the treatment of patients with AHF, one can distinguish subsequent stages that require different therapeutic approaches (described in the previous sections of this chapter). Importantly, the goals of treatment during the different stages of management of patients with AHF also differ, and are summarized in Table 12.6.

**Table 12.6 Goals of treatment in acute heart failure**

<table>
<thead>
<tr>
<th>Immediate (ED/ICU/CCU)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improve haemodynamics and organ perfusion.</td>
</tr>
<tr>
<td>Restore oxygenation.</td>
</tr>
<tr>
<td>Alleviate symptoms.</td>
</tr>
<tr>
<td>Limit cardiac and renal damage.</td>
</tr>
<tr>
<td>Prevent thrombo-embolism.</td>
</tr>
<tr>
<td>Minimize ICU length of stay.</td>
</tr>
<tr>
<td>Intermediate (in hospital)</td>
</tr>
<tr>
<td>Identify etiology and relevant co-morbidities.</td>
</tr>
<tr>
<td>Titrate therapy to control symptoms and congestion and optimize blood pressure.</td>
</tr>
<tr>
<td>Initiate and up-titrated disease-modifying pharmacological therapy.</td>
</tr>
<tr>
<td>Consider device therapy in appropriate patients.</td>
</tr>
<tr>
<td>Pre-discharge and long-term management</td>
</tr>
<tr>
<td>Develop a careplan that provides:</td>
</tr>
<tr>
<td>o A schedule for up-titration and monitoring of pharmacological therapy.</td>
</tr>
<tr>
<td>o Need and timing for review for device therapy.</td>
</tr>
<tr>
<td>o Who will see the patient for follow-up and when.</td>
</tr>
<tr>
<td>Enrol in disease management programme, educate, and initiate appropriate lifestyle adjustments.</td>
</tr>
<tr>
<td>Prevent early readmission.</td>
</tr>
<tr>
<td>Improve symptoms, quality of life, and survival.</td>
</tr>
</tbody>
</table>

CCU = coronary care unit; ED = emergency department; ICU = intensive care unit.
13. Mechanical circulatory support and heart transplantation

13.1 Mechanical circulatory support

For patients with either chronic or acute HF who cannot be stabilized with medical therapy, MCS systems can be used to unload the failing ventricle and maintain sufficient end-organ perfusion. Patients in acute cardiogenic shock are initially treated with short-term assistance using extracorporeal, non-durable life support systems so that more definitive therapy may be planned. Patients with chronic, refractory HF despite medical therapy can be treated with a permanent implantable left ventricular assist device (LVAD). Table 13.1 lists the current indications for the use of mechanical circulatory assist devices.593

13.1.1 Mechanical circulatory support in acute heart failure

To manage patients with AHF or cardiogenic shock (INTERMACS level 1), short-term mechanical support systems, including percutaneous cardiac support devices, extracorporeal life support (ECLS) and extracorporeal membrane oxygenation (ECMO) may be used to support patients with left or biventricular failure until cardiac and other organ function have recovered. Typically the use of these devices is restricted to a few days to weeks. The Survival After Veno-arterial ECMO (SAVE) score can help to predict survival for patients receiving ECMO for refractory cardiogenic shock (online calculator at http://www.save-score.com).594

In addition, MCS systems, particularly ECLS and ECMO, can be used as a ‘bridge to decision’ (BTD) in patients with acute and rapidly deteriorating HF or cardiogenic shock to stabilize haemodynamics, recover end-organ function and allow for a full clinical evaluation for the possibility of either heart transplant or a more durable MCS device.595

Evidence regarding the benefits of temporary percutaneous MCS in patients not responding to standard therapy, including inotropes, is limited. In a meta-analysis of three randomized clinical trials comparing a percutaneous MCS vs. IABP in a total of 100 patients in cardiogenic shock, percutaneous MCS appeared safe and demonstrated better haemodynamics, but did not improve 30-day mortality and was associated with more bleeding complications.596 In a randomized trial on high-risk PCI in patients with impaired LV function (PROTECT II trial), the 30-day incidence of major adverse events was not different for patients with IABP or a haemodynamic support device.597 Based on these results, temporary percutaneous MCS cannot be recommended as a proven or efficacious treatment for acute cardiogenic shock. In selected patients it may serve as a bridge to definite therapy. A difficult decision to withdraw MCS may need to be made when the patient has no potential for cardiac recovery and is not eligible for longer-term MCS support or heart transplant.

13.1.2 Mechanical circulatory support in end-stage chronic heart failure

Heart transplantation has always been a limited therapeutic option for patients with end-stage chronic HF. The increasing number of patients with refractory, chronic HF and the declining willingness for organ donation have resulted in expanded waiting lists and prolonged waiting times for patients listed for heart transplantation (median 16 months in the region covered by Eurotransplant).598 More than 60% of patients are transplanted in high-urgency status, leaving little chance for patients listed for less urgent transplantation. Three times more patients are listed for heart transplantation annually than are actually transplanted, and the mortality rate on the Eurotransplant waiting list in 2013 was 21.7%.598

More recent data suggest that patients with ongoing LVAD support may have an improved survival on the transplant waiting list.599 Accordingly, MCS devices, particularly continuous-flow LVADs, are increasingly seen as an alternative to heart transplantation. Initially LVADs were developed for use as a short-term BTT approach (Table 13.1),600 but they are now being used for months to years in patients who will either face a long-term wait on the transplant list (currently only 10% of patients with an MCS device implanted with a BTT indication will receive an organ within 1 year of listing) or in patients who are not eligible for transplantation as permanent therapy or destination therapy. The number of patients with a permanent LVAD who are considered neither too old nor ineligible for transplantation is constantly growing. For a majority of these patients, lifelong LVAD therapy, despite eligibility for transplantation, has become a clinical reality. Current 2–3-year survival rates in carefully selected patients receiving the latest continuous flow devices are excellent, and comparable to early survival after heart transplantation.595 However, fewer data are available

Table 13.1 | Terms describing various indications for mechanical circulatory support

<table>
<thead>
<tr>
<th>Indication</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bridge to decision (BTD)</td>
<td>Use of short-term MCS (e.g. ECLS or ECMO) in patients with cardiogenic shock until haemodynamics and end-organ perfusion are stabilized, contra-indications for long-term MCS are excluded (brain damage after resuscitation) and additional therapeutic options including long-term VAD therapy or heart transplant can be evaluated.</td>
</tr>
<tr>
<td>Bridge to candidacy (BTC)</td>
<td>Use of MCS (usually LVAD) to improve end-organ function in order to make an ineligible patient eligible for heart transplantation.</td>
</tr>
<tr>
<td>Bridge to transplantation (BTT)</td>
<td>Use of MCS (LVAD or BiVAD) to keep patient alive who is otherwise at high risk of death before transplantation until a donor organ becomes available.</td>
</tr>
<tr>
<td>Bridge to recovery (BTR)</td>
<td>Use of MCS (typically LVAD) to keep patient alive until cardiac function recovers sufficiently to remove MCS.</td>
</tr>
<tr>
<td>Destination therapy (DT)</td>
<td>Long-term use of MCS (LVAD) as an alternative to transplantation in patients with end-stage HF ineligible for transplantation or long-term waiting for heart transplantation.</td>
</tr>
</tbody>
</table>

BiVAD = biventricular assist device; BBT = bridge to bridge; BTC = bridge to candidacy; BTD = bridge to decision; BTR = bridge to recovery; BTT = bridge to transplantation; DT = destination therapy; ECLS = extracorporeal life support; ECMO = extracorporeal membrane oxygenation; HF = heart failure; LVAD = left ventricular assist device; MCS = mechanical circulatory support; VAD = ventricular assist device.
Discuss LVAD on 10 April 2018

LVADs may also be used as a ‘bridge to candidacy’ (BTC) in order to permit recovery of surgery (BTR). This outcome is more likely in younger patients with diabetes or peripartum cardiomyopathy. LVADs may also be used during on medical therapy. The INTERMACS registry like LVAD therapy in transplant-eligible patients. ECLS, ECMO, percutaneous support devices

<table>
<thead>
<tr>
<th>INTERMACS level</th>
<th>NYHA Class</th>
<th>Description</th>
<th>Device</th>
<th>1y survival with LVAD therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cardiogenic shock “Crash and burn”</td>
<td>IV</td>
<td>Haemodynamic instability in spite of increasing doses of catecholamines and/or mechanical circulatory support with critical hypoperfusion of target organs (severe cardiogenic shock).</td>
<td>ECLS, ECMO, LVAD</td>
<td>52.6±5.6%</td>
</tr>
<tr>
<td>2. Progressive decline despite inotropic support “Sliding on inotropes”</td>
<td>IV</td>
<td>Intravenous inotropic support with acceptable blood pressure but rapid deterioration of renal function, nutritional state, or signs of congestion.</td>
<td>ECLS, ECMO, LVAD</td>
<td>63.1±3.1%</td>
</tr>
<tr>
<td>3. Stable but inotrope dependent “Dependent stability”</td>
<td>IV</td>
<td>Haemodynamic stability with low or intermediate doses of inotropics, but necessary due to hypotension, worsening of symptoms, or progressive renal failure.</td>
<td>LVAD</td>
<td>78.4±2.5%</td>
</tr>
<tr>
<td>4. Resting symptoms “Frequent flyer”</td>
<td>IV ambulatory</td>
<td>Temporary cessation of inotropic treatment is possible, but patient presents with frequent symptom recurrences and typically with fluid overload.</td>
<td>LVAD</td>
<td>78.7±3.0%</td>
</tr>
<tr>
<td>5. Exertion intolerant “Housebound”</td>
<td>IV ambulatory</td>
<td>Complete cessation of physical activity, stable at rest, but frequently with moderate fluid retention and some level of renal dysfunction.</td>
<td>LVAD</td>
<td>93.0±3.9%</td>
</tr>
<tr>
<td>6. Exertion limited “Walking wounded”</td>
<td>III</td>
<td>Minor limitation on physical activity and absence of congestion while at rest. Easily fatigued by light activity.</td>
<td>LVAD / Discuss LVAD as option</td>
<td>-</td>
</tr>
<tr>
<td>7. “Placeholder”</td>
<td>III</td>
<td>Patient in NYHA Class III with no current or recent unstable fluid balance.</td>
<td>Discuss LVAD as option</td>
<td>-</td>
</tr>
</tbody>
</table>

ECLS = extracorporeal life support; ECMO = extracorporeal membrane oxygenation; INTERMACS = Interagency Registry for Mechanically Assisted Circulatory Support; LVAD = left ventricular assist device; NYHA = New York Heart Association.

For patients with chronic biventricular failure or a high risk for perioperative mortality and reduces survival to, and after, transplantation. There are, however, multiple approaches to assessment of the RV (see Section 5.2.3). If RV failure is expected to be potentially reversible, temporary (days to weeks) extracorporeal right ventricular assist device (RVAD) support using a centrifugal pump in addition to LVAD implantation may be considered. For patients with chronic biventricular failure or a high risk for persisting RV failure after LVAD implantation, implantation of a biventricular assist device (BiVAD) may be necessary. Patients requiring long-term BiVAD support must be transplant-eligible, as BiVAD therapy is not suitable for destination therapy. The outcomes of BiVAD therapy are inferior to those for LVAD therapy and therefore the indication for VAD therapy should be discussed before RV function deteriorates. The implantation of a total artificial heart with removal of the native heart should be restricted to selected patients who cannot be treated with an LVAD (unrepairable ventricular septal defect, cardiac rupture).
Patients with active infection, severe renal, pulmonary or hepatic dysfunction or uncertain neurological status after cardiac arrest or due to cardiogenic shock are not usually candidates for BTT or DT but may be candidates for BTC (Table 13.3).

Table 13.3 Patients potentially eligible for implantation of a left ventricular assist device

<table>
<thead>
<tr>
<th>Patients with &gt;2 months of severe symptoms despite optimal medical and device therapy and more than one of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEF &lt;25% and, if measured, peak VO₂ &lt;12 mL/kg/min.</td>
</tr>
<tr>
<td>≥3 HF hospitalizations in previous 12 months without an obvious precipitating cause.</td>
</tr>
<tr>
<td>Dependence on i.v. inotropic therapy.</td>
</tr>
<tr>
<td>Progressive end-organ dysfunction (worsening renal and/or hepatic function) due to reduced perfusion and not to inadequate ventricular filling pressure (PCWP ≥20 mmHg and SBP ≤80–90 mmHg or CI ≤2 L/min/m²).</td>
</tr>
<tr>
<td>Absence of severe right ventricular dysfunction together with severe tricuspid regurgitation.</td>
</tr>
</tbody>
</table>

CI = cardiac index; HF = heart failure; i.v. = intravenous; LVEF = left ventricular ejection fraction; PCWP = pulmonary capillary wedge pressure; SBP = systolic blood pressure; VO₂ = oxygen consumption.

Recommendations for implantation of mechanical circulatory support in patients with refractory heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class a</th>
<th>Level b</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td>An LVAD should be considered in patients who have end-stage HF/EF despite optimal medical and device therapy and who are eligible for heart transplantation in order to improve symptoms, reduce the risk of HF hospitalization and the risk of premature death (Bridge to transplant indication).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIA</td>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>An LVAD should be considered in patients who have end-stage HF/EF despite optimal medical and device therapy and who are not eligible for heart transplantation to, reduce the risk of premature death.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIA</td>
<td>B</td>
<td>605, 612, 613</td>
<td></td>
</tr>
</tbody>
</table>

HF = heart failure; HF/EF = heart failure with reduced ejection fraction; LVAD = left ventricular assist device.

aClass of recommendation.

bLevel of evidence.

cReference(s) supporting levels of evidence.

13.2 Heart transplantation

Heart transplantation is an accepted treatment for end-stage HF. Although controlled trials have never been conducted, there is a consensus that transplantation—provided that proper selection criteria are applied—significantly increases survival, exercise capacity, quality of life and return to work compared with conventional treatment.

Apart from the shortage of donor hearts, the main challenges in transplantation are the consequences of the limited effectiveness and complications of immunosuppressive therapy in the long term (i.e. antibody-mediated rejection, infection, hypertension, renal failure, malignancy and coronary artery vasculopathy). The indications for and contraindications to heart transplantation have recently been updated and are summarized in Table 13.4. It needs to be considered that some contraindications are transient and treatable. While an active infection remains a relative contraindication to heart transplantation, patients with HIV, hepatitis, Chagas disease and tuberculosis can be considered as suitable candidates provided certain strict management principles are adhered to by the teams. In patients with cancer requiring heart transplantation, a close collaboration with oncology specialists should occur to stratify each patient as to their risk of tumour recurrence.
The use of mechanical circulatory support, particularly LVAD, should be considered for patients with potentially reversible or treatable co-morbidities, such as cancer, obesity, renal failure, tobacco use and pharmacologically irreversible pulmonary hypertension, with a subsequent re-evaluation to establish candidacy.

14. Multidisciplinary team management

Non-pharmacological non-device/surgical interventions used in the management of HF (both HFrEF and HFrEF) are summarized in Tables 14.1 and 14.2 and detailed practical recommendations on their use have been published by the HFA of the ESC.591,592 There is no evidence that these on their own improve mortality, morbidity or quality of life. For this reason, these interventions have not been given a recommendation with an evidence level. The exceptions are implementation of care in a multidisciplinary framework, monitoring and exercise training (see recommendations table), all of which are discussed below.

---

Table 14.1 Characteristics and components of management programmes for patients with heart failure

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Should employ a multidisciplinary approach (cardiologists, primary care physicians, nurses, pharmacists, physiotherapists, dieticians, social workers, surgeons, psychologists, etc.).</td>
<td>Optimized medical and device management.</td>
</tr>
<tr>
<td>Should target high-risk symptomatic patients.</td>
<td>Adequate patient education, with special emphasis on adherence and self-care.</td>
</tr>
<tr>
<td>Should include competent and professionally educated staff.</td>
<td>Patient involvement in symptom monitoring and flexible diuretic use.</td>
</tr>
<tr>
<td></td>
<td>Follow-up after discharge (regular clinic and/or home-based visits; possibly telephone support or remote monitoring).</td>
</tr>
<tr>
<td></td>
<td>Increased access to healthcare (through in-person follow-up and by telephone contact; possibly through remote monitoring).</td>
</tr>
<tr>
<td></td>
<td>Facilitated access to care during episodes of decompensation.</td>
</tr>
<tr>
<td></td>
<td>Assessment of (and appropriate intervention in response to) an unexplained change in weight, nutritional status, functional status, quality of life, or laboratory findings.</td>
</tr>
<tr>
<td></td>
<td>Access to advanced treatment options.</td>
</tr>
<tr>
<td></td>
<td>Provision of psychosocial support to patients and family and/or caregivers.</td>
</tr>
</tbody>
</table>

The use of mechanical circulatory support, particularly LVAD, should be considered for patients with potentially reversible or treatable co-morbidities, such as cancer, obesity, renal failure, tobacco use and pharmacologically irreversible pulmonary hypertension, with a subsequent re-evaluation to establish candidacy.

14.1 Organization of care

The goal of management of HF is to provide a ‘seamless’ system of care that embraces both the community and hospital throughout the health care journey. The standards of care that patients with HF should expect have been published by the ESC HFA.591 To achieve this goal, other services, such as cardiac rehabilitation and palliative care, must be integrated into the overall provision for patients with HF. Fundamental to the delivery of this complete package of care are multidisciplinary management programmes designed to improve outcomes through structured follow-up with patient education, optimization of medical treatment, psychosocial support and improved access to care (Table 14.1). Such strategies reduce HF hospitalization and mortality in patients discharged from the hospital.622–625

Key to the success of these programmes is coordination of care along the continuum of HF and throughout the chain of care.
Table 14.2  Key topics and self-care skills to include in patient education and the professional behaviours to optimize learning and facilitate shared decision making

<table>
<thead>
<tr>
<th>Education topic</th>
<th>Patient skills</th>
<th>Professional behaviours</th>
</tr>
</thead>
</table>
| Definition, aetiology and trajectory of HF (including prognosis). | • Understand the cause of HF, symptoms and disease trajectory.  
• Make realistic decisions including decisions about treatment at end-of-life. | • Provide oral and written information that takes account of educational grade and health literacy.  
• Recognize HF disease barriers to communication and provide information at regular time intervals.  
• Sensitively communicate information on prognosis at time of diagnosis, during decision making about treatment options, when there is a change in the clinical condition and whenever the patient requests. |
| Symptom monitoring and self-care.            | • Monitor and recognize change in signs and symptoms.  
• Know how and when to contact a healthcare professional.  
• In line with professional advice, know when to self-manage diuretic therapy and fluid intake. | • Provide individualized information to support self-management such as:  
→ In the case of increasing dyspnoea or oedema or a sudden unexpected weight gain of >2 kg in 3 days, patients may increase their diuretic dose and/or alert their healthcare team.  
→ Use of flexible diuretic regime.  
→ Self-care support aids such as dosette box when appropriate. |
| Pharmacological treatment.                   | • Understand the indications, dosing and side effects of drugs.  
• Recognize the common side effects and know when to notify a healthcare professional.  
• Recognize the benefits of taking medication as prescribed. | • Provide written and oral information on dosing effects and side effects (see web tables 7.4–7.8 – practical guidance on use of pharmacological agents).  
• Provide written and oral information on benefits and side effects.  
• Provide written and oral information on regular control of device functioning, along with documentation of regular check-up. |
| Implanted devices and percutaneous/surgical interventions. | • Understand the indications and aims of procedures/implanted devices.  
• Recognize the common complications and know when to notify a healthcare professional.  
• Recognize the importance and benefits of procedures/implanted devices. | • Provide written and oral information on benefits and side effects.  
• Provide written and oral information on regular control of device functioning, along with documentation of regular check-up. |
| Immunization                                 | • Receive immunization against influenza and pneumococcal disease. | • Advise on local guidance and immunization practice. |
| Diet and alcohol                             | • Avoid excessive fluid intake.  
• Recognize need for altered fluid intake such as:  
→ Increase intake during periods of high heat and humidity, nausea/vomiting  
→ Fluid restriction of 1.5–2 L/day may be considered in patients with severe HF to relieve symptoms and congestion.  
• Monitor body weight and prevent malnutrition.  
• Eat healthily, avoid excessive salt intake (>6 g/day) and maintain a healthy body weight.  
• Abstain from or avoid excessive alcohol intake, especially for alcohol induced cardiomyopathy. | • Individualize information on fluid intake to take into account body weight and periods of high heat and humidity. Adjust advice during periods of acute decompensation and consider altering these restrictions towards end-of-life.  
• Tailor alcohol advice to aetiology of HF; e.g. abstinence in alcoholic cardiomyopathy.  
• Normal alcohol guidelines apply (2 units per day in men or 1 unit per day in women). 1 unit is 10 mL of pure alcohol (e.g. 1 glass of wine, 1/2 pint of beer, 1 measure of spirit).  
• For management of obesity (see Section 11.15). |
| Smoking and recreational substance use.      | • Stop smoking and taking recreational substances. | • Refer for specialist advice for smoking cessation and drug withdrawal and replacement therapy.  
• Consider referral for cognitive behavioural theory and psychological support if patient wishes support to stop smoking.  
• Referral to exercise programme when appropriate. |
| Exercise                                     | • Undertake regular exercise sufficient to provoke mild or moderate breathlessness. | • Advice on exercise that recognizes physical and functional limitations, such as frailty, comorbidities.  
• Referral to exercise programme when appropriate. |
| Travel and leisure                           | • Prepare travel and leisure activities according to physical capacity.  
• Monitor and adapt fluid intake according to humidity (flights and humid climates).  
• Be aware of adverse reactions to sun exposure with certain medication (such as amiodarone).  
• Consider effect of high altitude on oxygenation.  
• Compute medicine in cabin luggage in the plane, have a list with you of treatments and the dosage with the generic name. | • Refer to local country specific driving regulations regarding ICD.  
• Provide advice regarding flight security devices in presence of ICD. |
| Sleep and breathing (see co-morbidities Section 11.16.) | • Recognize problems with sleeping, their relationship with HF and how to optimize sleep. | • Provide advice such as timing of diuretics, environment for sleep, device support.  
• In presence of sleep-disordered breathing provide advice on weight reduction/control. |
| Sexual activity (see co-morbidities Section 11.7.) | • Be reassured about engaging in sex, provided sexual activity does not provoke undue symptoms.  
• Recognize problems with sexual activity, their relationship with HF and applied treatment and how to treat erectile dysfunction. | • Provide advice on eliminating factors predisposing to erectile dysfunction and available pharmacological treatment of erectile dysfunction.  
• Refer to specialist for sexual counselling when necessary. |
delivered by the various services within the health care system. This necessitates close collaboration between HF practitioners (primarily cardiologists, HF nurses and general practitioners) and other experts, including pharmacists, dieticians, physiotherapists, psychologists, palliative care providers and social workers. The content and structure of HF management programmes may vary in different countries and health care settings. The components shown in Table 14.1 are recommended. HF services should be easily accessible to the patient and his/her family and care providers. A telephone helpline may facilitate access to professional advice.

The website http://www.heartfailurematters.org is an option for professional information for those patients and families with Internet access.

### 14.2 Discharge planning

Early readmission after hospital discharge is common and may be addressed through coordinated discharge planning. The standards of care that patients should expect have been published by the HFA and the Acute Cardiac Care Association.540,631 Discharge planning should commence as soon as the patient’s condition is stable. During hospital admission, providing patients with information and education for self-care improves outcome. Discharge should be arranged for when the patient is euvaemic and any precipitants of the admission have been treated. Hospitals with early physician follow-up after discharge show reduced 30-day readmission, and those that initiated programmes to discharge patients with an outpatient follow-up appointment already scheduled experienced a greater reduction in readmissions than those not taking up this strategy.632

### 14.3 Lifestyle advice

There is little evidence that specific lifestyle advice improves quality of life or prognosis; however, providing this information has become a key component of education for self-care. Patients should be provided with sufficient up-to-date information to make decisions on lifestyle adjustment and self-care. Ideally for those patients admitted to the hospital, lifestyle advice should begin prior to discharge. Information should be individually tailored to need and take into account relevant co-morbidities that may influence retention of information (such as cognitive impairment and depression). Practical recommendations have been published by the HFA.591 Key topics to include are recommended in Table 14.2.

### 14.4 Exercise training

Several systematic reviews and meta-analyses of small studies have shown that physical conditioning by exercise training improves exercise tolerance, health-related quality of life and HF hospitalization rates in patients with HF. A single large RCT618 showed a modest and non-significant reduction in the primary composite outcome of all-cause mortality or all-cause hospitalization. There was no reduction in mortality and no safety concerns were raised.618,633 The most recent Cochrane review of exercise training 619 included 33 trials with 4740 patients with HF (predominantly HFrEF). There was a trend towards a reduction in mortality with exercise in trials with >1 year of follow-up. Compared with the control group, exercise training reduced the rate of overall and HF-specific hospitalization and improved quality of life. Practical recommendations on exercise training have been published by the HFA.120

There is evidence that in patients with HFpEF, exercise training has several benefits, including improvements in exercise capacity, as measured objectively using peak oxygen consumption, quality of life and diastolic function, assessed by echocardiography.621,620,621,634

Patients with HF, regardless of LVEF, are recommended to perform properly designed exercise training (see the recommendations table).

### 14.5 Follow-up and monitoring

Patients with HF benefit from regular follow-up and monitoring of biomedical parameters to ensure the safety and optimal dosing of medicines and detect the development of complications or disease progression that may require a change in management (e.g. the onset of AF or development of anaemia). Monitoring may be undertaken by the patients themselves during home visits, in community or hospital clinics, by remote monitoring with or without implanted devices or by structured telephone support (STS). The optimal method of monitoring will depend on local organizations and resources and will vary among patients. For example, more frequent monitoring will be required during periods of instability or optimization of medication. Older adults may also benefit from more frequent monitoring. Some patients will be keen and able to participate in self-monitoring. High circulating NPs predict unfavourable outcomes in patients with HF, and a decrease in NP levels during recovery from circulatory decompensation is associated with a better prognosis.588–590

Although it is plausible to monitor clinical status and tailor treatment based on changes in circulating NPs in patients with HF, published studies have provided differing results.635–638 This does not enable us to recommend a broad application of such an approach.

Telemedicine in HF, which is also termed remote patient management, has variable clinical trial results.637 Several meta-analyses suggest clinical benefits, but numerous prospectively initiated clinical trials including >3700 patients have not confirmed this. These clinical trials include Tele-HF,640 TIM-HF,641 INH,643 WISH43 and...
TEHAF. It is clear that there is not just one type of telemedicine, and each approach needs to be assessed on its individual merit.

Recently, two individual approaches were shown to be successful in improving clinical outcome when used in patients with HFrEF or HFrEF. These approaches include the CardioMEMS system (tested in 550 patients with both HFrEF and HFrEF) and the IN-TIME approach (tested in 664 HFrEF patients), which may be considered for use in selected patients with HF (see the recommendations table).

### 14.6 The older adult, frailty and cognitive impairment

HF management and self-care behaviour are complicated by ageing, co-morbid conditions, cognitive impairment, frailty and limited social support. HF is also a leading cause of hospital admission in the older adult, where it is associated with increased hospital length of stay and risk of mortality. Frailty is common in older adults with HF, with a recent study suggesting it may be present in >70% of patients with HF and >80 years of age. Frailty scoring systems provide an objective assessment and identify the presence of or change in the level of frailty. Patients with a high frailty score will benefit from closer contact with the HF specialist team, more frequent follow-up and monitoring and individualized self-care support. Frailty scores include walking speed (gait speed test), timed up-and-go test, PRISMA 7 questionnaire, Fried Score, and Short Physical Performance Battery (SPPB).

Cognitive impairment and HF frequently coexist. Acute delirium is also associated with decompensated HF and may be present on hospital admission. Cognitive function can be assessed using the Mini-Mental State Examination or the Montreal cognitive assessment. The presence of delirium and HF is found more commonly in older adults and is associated with increased mortality and poorer self-care ability and increases any hospital length of stay. There is currently no clinical evidence that HF medication worsens or improves cognitive function. However, its effect on HF outcome is currently under investigation. The presence of delirium and HF is found more commonly in older adults and is associated with increased mortality and poorer self-care ability and increases any hospital length of stay. There is currently no clinical evidence that HF medication worsens or improves cognitive function. However, its effect on HF outcome is currently under investigation.

### 14.7 Palliative and end-of-life care

Palliative care approaches include a focus on symptom management, emotional support and communication between the patient and his/her family. Ideally this should be introduced early in the disease trajectory and increased as the disease progresses. A decision to alter the focus of care from modifying disease progression to optimising quality of life should be made in discussion with the patient, cardiologist, nurse and general practitioner. The patient’s family should be involved in such discussions if requested by the patient. Key components of a palliative care service are recommended in Table 14.5. Palliative care has been discussed in detail in a position paper from the ESC HFA.

Liaison between the specialist palliative care services and the HF team and/or the primary care physician, using a shared care approach, is required in order to address and optimally coordinate the patient’s care. Recent pilot studies have suggested an improvement in symptom burden and quality of life, but these data are too limited to provide a recommendation. Specific therapies and actions may provide palliation of symptoms and improve quality of life but have a limited evidence base:

- Morphine (with an antiemetic when high doses are needed) can be used to reduce breathlessness, pain and anxiety.

---

**Table 14.3 Specific recommendations regarding monitoring and follow-up of the older adult with heart failure**

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitor frailty and seek and address reversible causes (cardiovascular and non-cardiovascular) of deterioration in frailty score.</td>
</tr>
<tr>
<td>Medication review: optimize doses of heart failure medication slowly and with frequent monitoring of clinical status. Reduce polypharmacy; number, doses and complexity of regime. Consider stopping medication without an immediate effect on symptom relief or quality of life (such as statin). Review the timing and dose of diuretic therapy to reduce risk of incontinence.</td>
</tr>
<tr>
<td>Consider need to refer to specialist care of the elderly team and to general practitioner and social worker etc. for follow-up and support for the patient and his/her family.</td>
</tr>
</tbody>
</table>

**Table 14.4 Patients with heart failure in whom end of life care should be considered**

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progressive functional decline (physical and mental) and dependence in most activities of daily living.</td>
</tr>
<tr>
<td>Severe heart failure symptoms with poor quality of life despite optimal pharmacological and non-pharmacological therapies.</td>
</tr>
<tr>
<td>Frequent admissions to hospital or other serious episodes of decompensation despite optimal treatment.</td>
</tr>
<tr>
<td>Heart transplantation and mechanical circulatory support ruled out.</td>
</tr>
<tr>
<td>Cardiac cachexia.</td>
</tr>
<tr>
<td>Clinically judged to be close to end of life.</td>
</tr>
</tbody>
</table>

**Table 14.5 Key components of palliative care service in patients with heart failure**

<table>
<thead>
<tr>
<th>Component</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focus on improving or maintaining the quality of life of a patient and his/her family as well as possible until he/she dies.</td>
</tr>
<tr>
<td>Frequent assessment of symptoms (including dyspnoea and pain) resulting from advanced heart failure and other co-morbidities and focus on symptom relief.</td>
</tr>
<tr>
<td>Access for the patient and his/her family to psychological support and spiritual care according to need.</td>
</tr>
<tr>
<td>Advanced care planning, taking account of preferences for place of death and resuscitation (which may include deactivating devices, such as pacemaker and/or implantable cardioverter defibrillator).</td>
</tr>
</tbody>
</table>
15. Gaps in evidence

Clinicians responsible for managing patients with HF must frequently make treatment decisions without adequate evidence or a consensus of expert opinion. The following is a short list of selected, common issues that deserve to be addressed in future clinical research.

1. Definition, diagnosis, epidemiology
   - For HFmrEF/HFpEF, research into the underlying characteristics, pathophysiology and diagnosis (with new modalities)
   - Updated epidemiology on HF incidence and prevalence including patients from all continents
   - For imaging and biomarkers, studies on effects of specific imaging modalities and biomarkers to improve clinical outcome (e.g. biomarker-guided therapies, detection of CAD/myocardial ischaemia, late-gadolinium enhancement CMR, echocardiographic strain measurements, stress echocardiography, etc.)
   - Increasing awareness of HF in the medical community, lay public and among policy makers.

2. Strategies aimed at prevention and screening of HF
   - Evaluate the comparative clinical effectiveness and cost-effectiveness of different strategies to screen for HF.

3. Pharmacological therapy
   - Identification of non-responders to current guideline-advised medical treatment

4. Devices and interventions
   - Indications for ICDs in specific subgroups (e.g. ARVC and HFmrEF/HFpEF) and optimal selection of ICD candidates
   - QRS morphology or duration as a predictor of response to CRT
   - CRT in patients with AF
   - Efficacy of PV ablation as a rhythm-control strategy in patients with AF
   - Interventional approach to recurrent, life-threatening ventricular tachyarrhythmias
   - The role of remote monitoring strategies in HF
   - Non-surgical (percutaneous) correction of functional mitral and tricuspid regurgitations
   - Identification of indications for coronary angiography/vascularization in patients with HF and chronic stable CAD
   - Effects of novel LVADs as destination therapy and bridge to transplantation

5. Co-morbidities
   - A better understanding of pathophysiology and potential treatments in specific HF populations, including the young patients, very elderly, diabetic patients, cardiotoxic chemotherapy-induced HF, muscular dystrophies, cachexia and depression.
   - Therapies for HF-related sleep-disordered breathing in HFrEF/HFpEF/HFmrEF.

6. Acute heart failure
   - Prospective evaluation of the ‘time-to-treatment’ concept in AHF
   - Evaluation of whether inadequate phenotyping is responsible for the failure of treatments to improve outcome in AHF
   - Better definition and treatment of diuretic resistance
   - Role of nitrates in the management of AHF
   - Treatments improving mortality and morbidity
   - Strategies and therapies to prevent early rehospitalization after discharge for a hospital admission for AHF.

7. Other/remaining aspects
   - Treatment algorithms for patients with HF excluded by pivotal clinical trials
   - Palliative and end-of-life care management and assessment of outcome
   - Optimal integration of multidisciplinary care, self-management of patients and their adherence.
16. To do and not to do messages from the Guidelines

### Recommendations for cardiac imaging in patients with suspected or established heart failure

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTE is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish a diagnosis of either HFrEF, HFmrEF or HFpEF.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>TTE is recommended for the assessment of LVEF in order to identify patients with HF who would be suitable for evidence-based pharmacological and device (ICD, CRT) treatment recommended for HFrEF.</td>
<td>I</td>
<td>C</td>
</tr>
</tbody>
</table>

### Recommendations aiming to prevent or delay the development of overt heart failure or prevent death before the onset of symptoms

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>ACE-I is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction in order to prevent or delay the onset of HF and prolong life.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>Beta-blocker is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction, in order to prevent or delay the onset of HF and prolong life.</td>
<td>I</td>
<td>B</td>
</tr>
</tbody>
</table>

### Pharmacological treatments indicated in patients with symptomatic heart failure with reduced ejection fraction

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>An ACE-I is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>A beta-blocker is recommended, in addition to an ACE-I, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>An MRA is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE-I and a beta-blocker, to reduce the risk of HF hospitalization and death.</td>
<td>I</td>
<td>A</td>
</tr>
</tbody>
</table>

### Other pharmacological treatments recommended in selected patients with symptomatic heart failure with reduced ejection fraction

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Sacubitril/valsartan is recommended as a replacement for an ACE-I to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE-I, a beta-blocker and an MRA.</td>
<td>I</td>
<td>B</td>
</tr>
</tbody>
</table>

### Treatments (or combinations of treatments) that may cause harm in patients with symptomatic Heart Failure Association Class II–IV heart failure with reduced ejection fraction

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization.</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td>The addition of an ARB (or a renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with HF, because of the increased risk of renal dysfunction and hyperkalaemia.</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

### Recommendations for implantable cardioverter-defibrillator in patients with heart failure

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary prevention</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for &gt;1 year with good functional status.</td>
<td>I</td>
<td>A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary prevention</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II–III), and an LVEF ≤35% despite ≥3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status, and they have:</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>• IHD (unless they have had an MI in the prior 40 days)</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>• DCM</td>
<td>I</td>
<td>B</td>
</tr>
</tbody>
</table>

| ICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis. | III | A |

### Recommendations for cardiac resynchronization therapy implantation in patients with heart failure

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration ≥150 msec and LBBB QRS morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and LBBB QRS morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA Class who have an indication for ventricular pacing and high degree AV block in order to reduce morbidity. This includes patients with atrial fibrillation (see Section 10.1).</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>CRT is contra-indicated in patients with a QRS duration &lt;130 msec.</td>
<td>III</td>
<td>A</td>
</tr>
</tbody>
</table>

continued
To do and not to do messages from the Guidelines (continued)

<table>
<thead>
<tr>
<th>Not-recommended treatments of co-morbidities in patients with heart failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adaptive servo-ventilation is not recommended in patients with HFrEF and a predominant central sleep apnoea because of an increased all-cause and cardiovascular mortality.</td>
</tr>
<tr>
<td>Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.</td>
</tr>
<tr>
<td>NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations regarding diagnostic measurements in patients with suspected acute heart failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upon presentation a measurement of plasma natriuretic peptide level (BNP, NT-proBNP or MR-proANP) is recommended in all patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnoea.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations for the management of patients with acute heart failure – pharmacotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of fluid overload to improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of i.v. diuretics.</td>
</tr>
<tr>
<td>In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose should be 20–40 mg i.v. furosemide (or equivalent); for those on chronic diuretic therapy, initial i.v. dose should be at least equivalent to oral dose.</td>
</tr>
<tr>
<td>It is recommended to give diuretics either as intermittent boluses or a continuous infusion, and the dose and duration should be adjusted according to the patients’ symptoms and clinical status.</td>
</tr>
<tr>
<td>Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations regarding management of patients with cardiogenic shock</th>
</tr>
</thead>
<tbody>
<tr>
<td>In all patients with suspected cardiogenic shock, immediate ECG and echocardiography are recommended.</td>
</tr>
<tr>
<td>All patients with cardiogenic shock should be rapidly transferred to a tertiary care centre which has a 24/7 service of cardiac catheterization, and a dedicated ICU/CCU with availability of short-term mechanical circulatory support.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations regarding oral evidence-based disease-modifying therapies in patients with acute heart failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>In case of worsening of chronic HFrEF, every attempt should be made to continue evidence-based, disease-modifying therapies, in the absence of haemodynamic instability or contra-indications.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations for exercise, multidisciplinary management, and monitoring of patients with heart failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended that regular aerobic exercise is encouraged in patients with HF to improve functional capacity and symptoms.</td>
</tr>
<tr>
<td>It is recommended that regular aerobic exercise is encouraged in stable patients with HFrEF to reduce the risk of HF hospitalization.</td>
</tr>
<tr>
<td>It is recommended that patients with HF are enrolled in a multidisciplinary care management programme to reduce the risk of HF hospitalization and mortality.</td>
</tr>
</tbody>
</table>

ACE-I = angiotensin-converting enzyme inhibitor; AHF = acute heart failure; ARB = angiotensin receptor-blocker; AST = aspartate aminotransferase; AV = atrio-ventricular; BNP = B-type natriuretic peptide; CCU = coronary care unit; COX-2 = cyclooxygenase 2; CRT = cardiac resynchronization therapy; CT = computed tomography; DCM = dilated cardiomyopathy; ECG = electrocardiogram; HF = heart failure; HFrEF = heart failure with preserved ejection fraction; HfP EF = heart failure with mid-range ejection fraction; HfPEF = heart failure with preserved ejection fraction; ICD = implantable cardioverter-defibrillator; ICU = intensive care unit; i.v. = intravenous; LBBB = left bundle branch block; LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; MRA = mineralocorticoid receptor antagonist; MR-proANP = mid-regional pro A-type natriuretic peptide; NSAIDs = non-steroidal anti-inflammatory drugs; NT-proBNP = N-terminal pro-B type natriuretic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; QRS = Q, R, and S waves (combination of three of the graphical deflections); RV = right ventricular; TTE = transthoracic echocardiography.

*Class of recommendation.

*Level of evidence

*Or ARB if ACEI is not tolerated/contra-indicated.

17. Web Addenda

All Web figures and Web tables are available in the Web addenda, available at European Heart Journal online and also via the ESC website.
18. Appendix

ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Lina Badimont (Spain), Gonzalo Barón-Esquivias (Spain), Helmut Baumgartner (Germany), Jeroen J. Bax (The Netherlands), Héctor Bueno (Spain), Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey), Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Paulus Kirchhof (UK/Germany), Philippe Kolb (Belgium), Patrizio Lancellotti (Belgium), Gregory Y. H. Lip (UK), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marco Roffi (Switzerland), Adam Torbicki (Poland), António Vaz Carneiro (Portugal), Stephan Windecker (Switzerland).

ESC National Cardiac Societies actively involved in the review process of the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Armenia: Armenian Cardiologists Association, Hamayak S. Sisakian; Azerbaijan: Azerbaijani Society of Cardiology, Elnur Isayev; Belarus: Belorussian Scientific Society of Cardiologists, Alena Kurielskaya; Belgium: Belgian Society of Cardiology, Wilfried Mullens; Bulgaria: Bulgarian Society of Cardiology, Mariya Tolmakova; Cyprus: Cyprus Society of Cardiology, Petros Agathangelou; Czech Republic: Czech Society of Cardiology, Vojtech Melenovsky; Denmark: Danish Society of Cardiology, Henrik Wiggers; Egypt: Egyptian Society of Cardiology, Mahmoud Hassanein; Estonia: Estonian Society of Cardiology, Tiina Uuetoa; Finland: Finnish Cardiac Society, Jyri Lommel; Former Yugoslav Republic of Macedonia: Macedonian FYR Society of Cardiology, Elizabeta Srbinovska Kostovska; France: French Society of Cardiology, Yves Junliere; Georgia: Georgian Society of Cardiology, Alexander Aladashvili; Germany: German Cardiac Society, Andreas Luchner; Greece: Hellenic Cardiological Society, Christina Chrysouhou; Hungary: Hungarian Society of Cardiology, Noémi Nylóczas; Iceland: Icelandic Society of Cardiology, Gestur Thorgerisson; Israel: Israel Heart Society, Jean Marc Weinstein; Italy: Italian Federation of Cardiology, Andrea Di Lenarda; Kazakhstan: Association of Cardiologists of Kazakhstan, Nazipa Aidargaliyeva; Kosovo: Kosovo Society of Cardiology, Gani Bajraktari; Kyrgyzstan: Kyrgyz Society of Cardiology, Medet Beishenkulov; Latvia: Latvian Society of Cardiology, Ginta Kamzola; Lebanon: Lebanese Society of Cardiology, Tony Abdel-Massih; Lithuania: Lithuanian Society of Cardiology, Jelena Ėlutiškienė; Luxembourg: Luxembourg Society of Cardiology, Stéphane Noppe; Malta: Maltese Cardiac Society, Andrew Cassar; Moldova: Moldavian Society of Cardiology, Eleonora Vata-man; Morocco: Moroccan Society of Cardiology, Saadia Abir-Khalil; The Netherlands: Netherlands Society of Cardiology, Petra van Pol; Norway: Norwegian Society of Cardiology, Rune Mo; Poland: Polish Cardiac Society, Ewa Straburzyńska-Mijag; Portugal: Portuguese Society of Cardiology, Cândida Fonseca; Romania: Romanian Society of Cardiology, Ovidiu Chioncel; Russian Federation: Russian Society of Cardiology, Evgeny Shlyakhto; San Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology Society of Serbia, Petar Otasevic; Slovakia: Slovak Society of Cardiology, Eva Goncalvesova; Slovenia: Slovenian Society of Cardiology, Mitja Lainscak; Spain: Spanish Society of Cardiology, Beatriz Díaz Molina; Sweden: Swedish Society of Cardiology, Maria Schaufelberger; Switzerland: Swiss Society of Cardiology, Thomas Suter; Turkey: Turkish Society of Cardiology, Mehmet Birhan Yilmaz; Ukraine: Ukrainian Association of Cardiology, Leonid Voronkov; United Kingdom: British Cardiovascular Society, Ceri Davies.

19. References


Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Eur J Heart Fail 2014;16:803–869.


13. Van Riet EES, Hoes AW, Limburg A, Landman MAJ, van der Hoeven H, Rutten FH. Epi-Prevalence of heart failure and systolic ventricular dysfunction in older Austra-


74. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR, Sutherland GR, McMurray JJV. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996;312:222.


11. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cercequira MD. Genetic mutations and mechanisms in hypertrophic cardiomyopathy: ad


meta-analysis of mortality effects of implantable cardiac devices.

ESC Guidelines

336. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. Trandolapril reduces the in-

322. Katritsis DG, Siontis GCM, Camm AJ. Prognostic significance of ambulatory ECG

324. Turakhia MP, Ullal AJ, Hoang DD, Than CT, Miller JD, Friday KJ, Perez M V,

327. Gilat H, Vinker S, Buda I, Soudry E, Shani M, Bachar G. Obstructive sleep apnea

326. Cintra FD, Leite RP, Storti LJ, Bittencourt LA, Poyares D, Castro L de S, Tufik S,

328. Vizzardi E, Sciatti E, Bonadei I, D’Aloia A, Curnis A, Metra M. Obstructive sleep

332. Swedberg K, Olsson LG, Charlesworth A, Cleland JF, Hanrath P, Komajda M,

333. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JGF, Freemantle N,

ventricular dysfunction.

cidence of atrial fibrillation after acute myocardial infarction in patients with left

diacardioversion (RACE) study.

Atrial fibrillation and cardiovascular comorbidities: a large epidemiologic study. Medicine (Baltimore)

and cardiovascular comorbidities: a large epidemiologic study. Medicine (Baltimore)

of chronic atrial fibrillation and heart failure: (CAFE-II Study).

Heart failure associated with ivabradine treatment: meta-analysis of randomised

One of the best available options for atrial fibrillation is


Effects of a high dose

Gestational heart rate in patients with atrial fibrillation accompanied by severe con-


Dependency on ivabradine use and outcomes among patients in a contempor-

Factors associated with increased mortality among patients with atrial fibrillation:

Affirm Investigators. Does intensity of rate-control

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RACE Control versus Electrical cardioversion (RACE) study. Am Heart J 2005;150:1106–1111.

Van Gelder IC, Hagena VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Sada SA,


Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagena VE,

358. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JGF. Carvedilol
ESC Guidelines
374. Granger CB, Alexander JH, McMurray JJ V, Lopes RD, Hylek EM, Hanna M, 
361. Ganesan AN, Nandal S, Lüker J, Pathak RK, Mahajan R, Twomey D, Lau DH, 
362. Marrouche NF, Brachmann J. Catheter ablation versus standard conventional
365. A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecaïne,
367. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-vitamin K antagonist 
oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and
368. Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implan-
table cardioverter-defibrillator trials: antiarrhythmics versus implantable defibril-
ators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac 
369. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, 
Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, 
370. Khan MN, Pijls NHJ, Pieters WCJ, Hoes AW, Kostense PJ, van der Wall EE, 
Marchand CB, Arbustini E, Blomstrom-Lundqvist C, Drexler H, Ferrari R, Filippatos G, 
Gandjbakhche H, Gregoratos G, Grines C, Hansson L-O, Helderman JH, Herrmann L, 
Hohnloser SH, Kappenberger L, Kastrati A, Lackner K, Langendorf A, Lip GYH, 
Marchetti P, Nava A, Mühlhauser I, Nezafat R, Ongini E, Pappone C, Pogue J, 
Poulter R, Quinlan D, Podrid PJ, Rizzoli L, Thiele H, Tchou PJ, Torbicki A, 
Turina M, Uriel S, Wijns W, Zareba W. ACCF/AHA/ESC 2013 guidelines for the 
management of patients with atrial fibrillation: a report of the American College of 
Cardiology/American Heart Association Task Force and the European Society of 
371. Ganzes AN, Nandall S, Luker J, Pathak RK, Mahajan R, Twomey D, Lau DH, 
P Sanders. Catheter ablation of atrial fibrillation in patients with concomitant left 
ventricular impairment: a systematic review of efficacy and effect on ejection 
372. Marroncchi NF, Brachmann J. Catheter ablation versus standard conventional 
ablation and antiarrhythmic drug therapy as first- or second-line therapy in the 
management of atrial fibrillation: systematic review and meta-analysis. Circ Arrhythm 
maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Data-
base Syst Rev 2012;5.CD005049.
375. A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecaïne, 
and propafenone in patients with cardiac disease and complex ventricular arrhyth-
miabase Syst Rev 2012;5.CD005049.
376. Lip GYH, Nieuwlaat R, Pisters R, Lane DA. Refining clinical risk stratification for 
377. Pisters R, Lane DA, Nieuwlaat R. A novel user-friendly score (HAS-BLED) to assess 
year-risk of major bleeding in patients with atrial fibrillation. Chest 2010;138: 
1093–1100.
prognostic markers in the RE-LY randomised trial. Eur J Heart Fail 2010;12: 
1875–1876.
379. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent 
stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 
146:857–867.
380. Elkeboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack 
Pl, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Knder Y, Lombeyre MT, 
Holmes DR, Doshi SK, Kar S, Price MJ, Sanchez MJ, Sievert H, Valderrabano M, 
Reddy VY. Left atrial appendage closure as an alternative to warfarin for stroke 
Huber KC, Holmes DR. Bleeding outcomes after left atrial appendage closure 
compared with long-term warfarin: a pooled, patient-level analysis from the 
382. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or elec-
383. Desai AS, McMurray JJ V, Packer M, Swedberg K, Rourke J, Chen F, Garg J, 
Rzikala AR, Brabham A, Claggett B, Finn P, Hartley L, Liu J, Leitweg M, 
Shi V, Zia MR, Solomon SD. Effect of the angiotensin-receptor-neprilysin inhibi-
tor LCZ696 compared with enalapril on mode of death in heart failure patients. 
Gradsic N, Abraham WT, Yip M, Prabhakaran D, Saeed H, Ferruzza P, Petric MC, 
O’Connor CM, Paschavinnin F, She L, Bonow RO, Rankin GR, Jones RH, 
385. Panza JA, Holly TA, Asch FM, She L, Pelikika A, Velazquez EJ, Lee KL, 
Borges-Neto S, Forsyke PS, Jones RH, Berman DS, Bonow RO. Inducible myocar-
dial ischemia and outcomes in patients with coronary artery disease and left 
386. Cansan P, Wenthemier M, Miller A, O’Connor CM, Pina IL, Selman C, Sueta C, 
She L, Greene D, Lee KL, Jones RH, Velazquez EJ. The STICH trial (Surgical Treat-
ment for Ischemic Heart Failure): mode-of-death results. JACC Heart Fail 2013: 
400–408.
387. Oseroff O, Retyk E, Bochoyer A. Subanalyses of secondary prevention implan-
table cardioverter-defibrillator trials: antiarrhythmics versus implantable defibril-
ators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac 
Breithardt O-A, Cleland J, Deharo J-C, Delgado V, Elliott PM, Gorenek B, 
Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vadars P, 
Zamorano J, Achenbach S, Baumgartner H, Bax J, Bueno H, Dean V, 
Knust M, Kolb P, Lancetti P, Linhart A, Nihoyannopoulos P, Pfelder MF, 
Pieske B, Poposka L, Ruschitzka F, Van Gelder IC, Wilson CM. 2013 ESC Guide-
lines on cardiac pace and cardiac resynchronization therapy: the Task Force on 
cardiac pacing and resynchronization therapy of the European Society of Cardi-
ology (ESC). Developed in collaboration with the European Heart Rhythm Asso-
ic and prognostic value of brain natriuretic peptide (BNP) concentrations in very 
elderly heart disease patients: specific geriatric cut-off and impacts of age, gender, 
390. Health/min U.S. Viswanath T, Caceres C. Heart failure and chronic obstructive pulmonary 
disease: the challenges facing physicians and health services. Eur Heart J 2013;34: 
2795–2807.
396. Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GMC. Ef-
399. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
400. randomised, double-blind, placebo-controlled trial.
401. coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a
405. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
406. randomised, double-blind, placebo-controlled trial.
407. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
408. randomised, double-blind, placebo-controlled trial.
409. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
410. randomised, double-blind, placebo-controlled trial.
411. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
412. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
413. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
414. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
415. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
416. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
417. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
418. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
419. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
420. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
421. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
422. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
423. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
424. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
425. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
426. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
427. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
428. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
429. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
430. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
431. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
432. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
433. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
434. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
435. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
436. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
437. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
438. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
439. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
440. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
441. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
442. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
443. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
444. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
445. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
446. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
447. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
448. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
449. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
450. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
451. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
452. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
453. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
454. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
455. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
456. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
457. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
458. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
459. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
460. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
461. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
462. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
463. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
464. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
465. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
466. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
467. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
468. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
469. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
470. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
471. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
472. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
473. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
474. Wijeysundera HC, Hansen MS, Stanton E, Cropp a. S, Hall C, Dhalla NS, Ghali J,
sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56:692–699.


Dentàl F, Doukatsis JD, Gianni P, Lim W, Crowther M. A meta-analysis: anticoagu-

lant prophylaxis to prevent symptomatic venous thromboembolism in hospital-


Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woolsey RL. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regi-


Cox DL, Lenihan DJ. Loop diuretic resistance in heart failure: resistance etiology-


Pathak A, Lebrin M, Vaccaro A, Senard JM, Despres P. Pharmacology of levosimi-


2200l


